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Recombinant bovine somatotropin (rbST) is a proteohormone, which can be used to 
increase milk production in dairy cows. While its use in food production is approved in 
several countries, such as the United States (US), it is banned in the European Union (EU). 
Therefore, appropriate monitoring methods are required to control for its abuse. In this 
thesis, biomarker-based screening methods have been developed to detect rbST abuse 
in serum and milk of dairy cows. The general introduction shall give an insight into the 
history of rbST development and the corresponding regulatory mechanisms in different 
countries. The molecular structure and physiology of the hormone are described and 
the effects of rbST onto the cow’s metabolism are outlined. From this follows a view on 
the controversial public debate about rbST use in food production. Different analytical 
detection strategies for monitoring rbST abuse that were followed so far are described. 
Finally, the immunoassay detection methods for biomarker-based screening used in this 
thesis are shortly outlined.
1 History and legislation of rbST
In 1937 it was described that an extract from bovine pituitaries can increase the milk 
yield after it was injected into lactating cows [1]. Because of the general food shortage 
during the Second World War, British scientists investigated the effects of pituitary 
extracts on milk yield and milk composition. But since the supply of somatotropin (ST), 
also called growth hormone (GH), was limited to that extracted from bovine pituitaries, 
no general beneficial effect on milk supply was seen [2]. In 1949 ST was found to be 
responsible for this galactopoietic effect [3] and in the 1970s, the primary structure of the 
protein hormone was revealed [4]. In the beginning of the 1980s, the recombinant DNA 
technology became available, and rbST could be produced in E. coli on large-scale [2]. 
In the US, the Food and Drug Administration (FDA) approved the use of rbST for increasing 
milk yield in 1993. In 1994 rbST became available on the US market and within 6 years, 
approximately 40 % of the US dairy farmers had adopted it [5]. Also other countries, such 
as South Africa, Brazil and Korea, approved the use of rbST for increasing milk production 
[6]. However, there are consumers’ concerns about hormone use in food production, 
and therefore, some US retailers and dairies indicated not to use or sell products, which 
contain milk from rbST-treated cows. 
In contrast in the EU, a moratorium was put on rbST use in 1990 to perform further 
research on potential negative effects on human health and animal welfare. Eventually, 
the administration and sales of rbST were banned for animal welfare reasons since January 
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2000 [7, 8]. RbST use has also been forbidden in other countries, such as Australia, New 
Zealand and Canada [9]. Since there is a ban on this veterinary drug, monitoring of its 
possible abuse is required. So far, no method has been implemented EU-wide for rbST 
abuse monitoring. 
2 Endogenous and recombinant bovine somatotropin
2.1 Molecular structure
Bovine ST (bST) is a proteohormone and is produced by the anterior pituitary gland. 
Naturally, bST occurs in four different forms consisting of 190 or 191 amino acids (the 190 
amino acid form lacks the N-terminal phenylalanine) and having either leucine or valine at 
position 126 or 127 respectively [10, 11]. It is a single polypeptide chain that is folded and 
stabilized by two internal disulfide bonds [4] (Figure 1). 
During production of rbST, the N-terminal amino acid alanine is replaced by methionine, 
leading to a 60 Da difference in molecular weight (Figure 1) [12]. Despite the amino 
acid exchange, 99 % of the molecular structures are identical for the endogenous and 
recombinant forms of the hormone. Other forms of rbST having different N-terminal ends 
have been produced and they were shown to be fully bioactive in vivo [13].
2.2 Physiology 
After ST is produced in the anterior pituitary gland, it is released into the blood stream 
under the control of several different hormones, such as growth hormone-releasing 
hormone (GHRH), somatostatin and ghrelin (Figure 2) [14]. In blood, ST binds to binding 
proteins (GHBPs) and is transported to target tissues. In general, ST exerts direct effects 
on target tissues and indirect effects via the mediator insulin-like growth factor-1 (IGF-1) 
[15]. Direct effects of ST are for instance increased protein synthesis in muscle, increased 
lipolysis and the release of IGF-1 from liver tissues. Indirect effects via IGF-1 are for 
instance increased protein synthesis in bone and organs [15, 16]. As illustrated in Figure 
2, also IGF-1 is bound to binding proteins (IGFBPs) in the blood stream, which regulate its 
bioavailability [14].
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Figure 1: Amino acid sequence of endogenous and recombinant bST (reproduced with 
permission according to Le Breton et al. [12]). The endogenous bST carries an alanine at 
the N-terminus whereas the recombinant form of the hormone carries a methionine.
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Figure 2: GH regulatory circuit including feed-back loops (reproduced with permission 
from Holt et al. [14])
Many studies have been performed on the kinetics of bST in circulation. Toutain et al. 
compared plasma bST concentrations after intravenous bolus injection of pituitary bST or 
rbST [17]. They found a slightly shorter half-life time for the tested rbST of 54.8 minutes 
compared to pituitary bST, which showed a half-life time of 61.8 minutes. Le Breton et al. 
studied the kinetics of rbST administrated in a slow-release formula [12, 18]. Maximum 
rbST concentrations were found in serum approximately one day after administration 
and ranged from 9 up to 120 ng mL-1 between individual cows. In all tested animals, the 
concentrations dropped to half of the maximum concentration within 2-3 days after the 
last administration. Moreover, Breton et al. reported that they were able to find rbST 
for 13 days in the cow’s circulation. However, that study was performed with cows who 
received a double rbST injection within , which is not suggested for regular practice.
2.3 RbST administration as a veterinary drug
When rbST is administered to dairy cows, milk yield on average increases by 11.3 % for 
primiparous and 15.6 % for multiparous cows [19]. According to the suggestions by the 
manufacturer, rbST should be injected starting from the ninth or tenth week in lactation 
(57-70 days) when the lactating performance of the cow is at its maximum [20]. If rbST 
administration is repeated every 14 days until the end of lactation, the decrease in milk 
 
Chapter 1
12
yield, which is usually observed in untreated cows, is slowed down (Figure 3). Therewith, 
the milk production of rbST-treated animals is increased over the entire lactation period. 
Increased lactation performance was found to be due to higher milk synthesis rates of 
the mammary gland and increased maintenance of mammary gland cells [2]. Moreover, 
nutrients required for milk synthesis are taken up more efficiently and the blood ﬂow in 
the mammary gland increased after rbST administration [2]. 
Even though rbST increases milk yield in dairy cows, hardly any effect on milk composition 
was observable [19]. In a meta-analysis comparing 18 rbST treatment studies, very little 
increases in milk butter fat were found and a slight increase in protein concentration in 
multiparous cows was described [19]. Dohoo et al. concluded that these small effects had 
no practical consequences for the dairy industry [19].
 
Figure 3: Typical lactation curves for control cows (solid line) and cows administered with 
rbST (dotted line) (obtained from Elanco website [21]).
Administration of rbST does not only increase milk yield but also has general effects on 
the cow’s body and physiology. Similar to the physiologic actions of endogenous bST, 
rbST leads to elevated lipolysis and glycogenolysis to provide the body with energy and 
resources for the increased milk production and protein synthesis [2, 15]. The increased 
energy requirement also leads to an increased feed uptake in dairy cows of approximately 
1.5 kg day-1 [19]. The increases in milk production are, however, not proportional to 
the increased feed intake, which means that rbST also causes an increased production 
efficiency (more kg milk per kg feed intake) [2].
Apart from the effects on milk production, rbST was also shown to have effects on bull 
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calves for beef production. Observed effects were increased protein and decreased fat 
content in muscle tissue and a general growth enhancement [22].
2.4 Controversial debate about rbST use in milk production
Ever since rbST has been placed on the market, there has been a public debate about its 
potential negative effects on human and animal health.  
The concerns relating to human health mainly focus on rbST presence and potentially 
increased IGF-1 levels in milk. The rbST molecule is only 66 % identical with the human 
form of ST and non-primate STs have been shown to be non-active in humans regarding 
growth and anabolic actions [13, 21, 23-25]. However, Froesch et al. found effects of 
rbST on the carbohydrate metabolism in men, indicating a selective effect of the bovine 
hormone [25]. The amount of the administrated rbST was, however, much higher (150 mg 
per day) than what would be expected to be ingested by milk consumption [26]. Note that 
rbST levels in milk are in the ng mL-1 range. Additionally to that, it has been shown that 
rbST levels in milk are decreased by more than 85 % after pasteurisation and is further 
broken down in the human digestion system [27]. Therefore, it is not expected that rbST 
residues in milk exert quantifiable effects on human.  
IGF-1 levels in milk were shown to be significantly increased after rbST administration 
[28] and the molecular structures of bovine and human IGF-1 are identical [29]. Based on 
studies performed on behalf of Elanco and Monsanto (rbST-producing companies), the 
FDA concluded that increased IGF-1 levels found in milk from rbST-treated cows are in the 
range of IGF-1 levels usually found during lactation of untreated cows [24]. A discussion 
paper criticized that this statement might be scientifically correct but misleading, as 
colostrum (milk produced during first days after calving comprising the highest IGF-1 
concentrations during the lactation period [28]) is not used for the dairy market anyway 
[30]. Furthermore, IGF-1 was shown to have oral bioactivity in rats and effects on the 
gastrointestinal tract in piglets and calves [24, 31-33]. However, orally ingested IGF-1 was 
hardly taken up into the blood stream in piglets [34]. Despite these controversial findings, 
the Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF) defined the 
maximum residue limits and acceptable daily intake of rbST as ‘not specified’, which means 
that milk from rbST-treated cows is declared as being safe for human consumption. This 
opinion is shared by more than 50 countries including the EU [21]. 
However, there are many concerns relating to the effects of rbST on animal welfare. Even 
the accompanying package insert of rbST preparations provides information on possible 
side effects for the injected cow. These include reduced pregnancy rates, increased 
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risk of mastitis, injection site reactions, udder oedema and foot and leg disorders [35].
Furthermore, it is indicated that the incidence of antibiotic treatments might be increased 
to treat the mentioned disorders. A meta-analysis performed by Dohoo et al. summarized 
adverse health effects observed after rbST treatment in dairy cattle. They found a 25 % 
increased risk of clinical mastitis and 40 % increased risk of unsuccessful conception.
Additionally to that, rbST-treated cows had a 55 % increased risk of lameness [36]. Also the 
EU published a “Report on Animal Welfare Aspects of the Use of Bovine Somatotrophin”, 
in which similar effects are described [37]. Based on this report, rbST use has been banned 
in the EU because of animal health and welfare reasons [8].
Despite potential adverse health effects for the cows, rbST use is approved in the US and 
other countries. However, consumers were and are concerned about the use of artificial 
hormones in food production. Therefore, US dairy companies and retailers started labelling 
milk that has been produced without the use of rbST [38]. The ‘rbST-free’ labelling relies 
on a form signed by dairy farmers, wherewith they pledge not to use rbST. So far, since the 
approval of rbST in 1994, there is no method to control for correct labelling of milk and 
milk products. 
3 Monitoring of milk quality and safety in the European Union 
and the Netherlands
According to Council Directive 96/23/EC, it is required to monitor unauthorized substances 
in animals used for food production or their products [39] and the technical requirements 
for the analytical methods used are described in Commission Decision 2002/657/EC [40]. 
The control of dairy products in the Netherlands is divided into two parts: the official 
governmental food safety control and the quality control by the producers. 
The EU member states are obliged to perform residue analyses within the framework of 
the national residue control plan and this residue control plan should adequately assure 
food safety [40]. This means that efforts must be made to identify potential food safety 
risks, i.e., the use of banned substances in food producing animals. In the Netherlands, 
this obligation is implemented by using a multi-level surveillance system. First, there 
are general inspections, which usually occur on farms directly. During these inspections, 
packaging or preparations of veterinary drugs might be found, which can indicate a 
violation of food safety regulations. Second, small surveillance programs are run for the 
monitoring of a specific drug residue or contaminant to identify a potential new food 
safety issue. At this stage, up to a few hundred samples are measured preferably using 
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a simple screening method. Results of such surveillance studies are also used to provide 
the European Food Safety Authority (EFSA) with data necessary for risk assessment. 
Member States of the EU have the obligation to assist EFSA with this task [41]. If suspicious 
samples are found during screening, then a confirmatory method is required to detect 
and quantify the residue or contaminant itself. Third, if a new food safety issue has been 
identified, the specific drug residue or contaminant is included in the national residue 
control plan. This national residue control plan is a yearly-defined program based on EU 
legislation, which is performed at official laboratories and the results have to be reported 
to the EU. According to Commission Decision 97/747/EC, the minimum amount of milk 
samples analysed should be 1 per 15,000 tons of the annual milk production, but at 
least 300 samples [42]. Milk is tested for substances that belong to group A6 (certain 
pharmacologically active substances) and several of the B sub-groups (e.g., antibacterials, 
anthelmintics, non-steroidal anti-inﬂammatory drugs and environmental contaminants) 
[39]. In the Netherlands, approximately 1500 samples are analysed annually by the Food 
Authority [43]. Fourth, if non-compliant results occurred during the national residue plan, 
follow-up actions are undertaken at EU level or national level and specific policies might 
be developed to decrease the use of the veterinary drug or to better enforce regulations 
in the future. Furthermore, in case of a food crisis, large-scale testing is performed on all 
relevant matrices at all relevant locations.
Apart from the official food safety control, the Dutch dairy sector developed a 
comprehensive control system for safety and quality control to maintain its strong position 
as a milk-exporting country. This quality assurance system for raw milk comprises controls 
on farm level, on truck level as well as tank level at the dairy plant. These controls mainly 
focus on protein and fat content, somatic cell count, the presence of antibiotics residues 
and microbial ﬂora. They are performed by a private central controlling station [44]. For 
instance, there are 2.3 million quality analyses performed each year in the Netherlands 
already during transport of the milk from the farm to the dairy plant [45]. 
For most of the described food safety analysis levels, screening methods are required, 
which are defined by the Commission Decision 2002/657/EC as “methods that are used 
to detect the presence of a substance or class of substances at the level of interest. 
These methods have the capability for a high sample throughput and are used to sift 
large numbers of samples for potential non-compliant results. They are specifically 
designed to avoid false compliant results.” [40]. After such a screening method has been 
developed, it needs to be validated, which means that it must perform according to 
specific performance criteria. The “Guidelines for the validation of screening methods for 
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residues of veterinary medicines” emphasised the key requirement for screening methods: 
if the analyte in question is present in the sample, the analytical method must identify the 
sample as screen-positive with a false-compliant rate of <5 % [46]. Minimum performance 
criteria for screening methods are in general recovery, specificity (discrimination between 
the analyte and closely related substances) and the above-mentioned false-compliant rate 
below 5 % [40]. 
Note that the validation of the analytical performance of the developed method needs to 
be discriminated from biomarker validation. Biomarker validation assesses the specificity 
of the biomarker for the applied treatment as described in Chapter 2 in this thesis.
4 RbST detection strategies
For detection of rbST abuse, different approaches are possible and have been followed so 
far. Basically, these approaches can be classified in direct and indirect detection methods. 
Direct detection methods detect the presence of the rbST molecule itself and indirect 
detection methods detect the effect of rbST in the cow’s body. 
4.1 Direct detection methods
Direct detection methods can be divided in immunological methods, which employ specific 
antibodies, and mass spectrometric methods for detection of rbST in a sample. In general, 
rbST detection has always been challenging because of the similarities of the endogenous 
form and the recombinant form of the hormone and the expected concentrations in blood 
and milk in the ng mL-1 range [26]. 
4.1.1 Immunological methods
Immunological methods developed for rbST detection in biological samples employed two 
different antibodies specific for rbST [47]. A monoclonal capture antibody and a polyclonal 
detection antibody in a sandwich ELISA format yielded an EC
50
 of approximately 5 ng 
mL-1 and a limit of detection of 0.15 ng mL-1 [48]. Even though strongly increased rbST 
concentrations could be measured after rbST treatment, no discrimination between the 
endogenous and recombinant form of the hormone was possible [48]. Recently, polyclonal 
antibodies have been produced against the two N-terminal amino acids of rbST, which 
showed a higher affinity to rbST compared to the endogenous bST and these might be 
promising in future immunological detection approaches [49].
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4.1.2 Mass spectrometric methods
Because of the differences in the N-terminal end of rbST and the endogenous bST (Figure 
1), rbST can potentially be detected in the cow’s circulation. A method based on LC-MS 
was developed, which allowed the detection and quantification of rbST in serum obtained 
from rbST-treated animals [26, 50]. RbST residues were detectable until 4 or 11 days 
after treatment, depending on the treatment protocol [12, 18]. However, the observed 
concentrations were below the limit of quantification of the developed method already 
three days after treatment. Moreover, for milk, rbST itself could only be detected at 
unrealistic high spiking levels and not in milk samples from rbST-treated animals [51]. 
Therefore, in the future, better extraction procedures and more sensitive confirmatory 
analysis methods shall be developed that enable direct rbST detection in biological 
samples. 
4.2 Indirect detection methods
The principle of indirect detection methods is the analysis of the effect of rbST onto the 
cow’s body; hence, rbST-dependent biomarkers are measured. A biomarker is defined as 
“a factor that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacological responses to a therapeutic 
intervention” [52]. These can include metabolomic biomarkers (e.g., altered blood or 
urine parameters), transcriptomic biomarkers (e.g., changed mRNA levels) and proteomic 
biomarkers (e.g., increased or decreased protein levels). 
The work described in this thesis focusses on the analysis of protein biomarkers of rbST 
treatment, thus up- or down-regulated levels of proteins in easily accessible biological 
matrices, such as blood and milk. A thorough consideration of protein biomarkers in 
sports doping and veterinary control is presented in Chapter 2 of this thesis. Here, 
complementary explanations of the specific protein biomarkers analysed in this thesis 
work are given.
4.2.1 Insulin-like growth factor-1 (IGF-1)
IGF-1, also called somatomedin C, is a 7.6 kDa growth factor with high sequence 
similarities to insulin [53]. It is mainly produced by liver tissues and is involved in the 
growth and function of almost all organs. Its synthesis in liver and release into the blood 
stream are promoted by ST binding to its hepatic receptors (Figure 2). IGF-1 is found in 
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circulation bound to binding proteins, which modulate its actions. After treatment with 
rbST, IGF-1 levels were found to be increased in bovine serum and milk [28, 48]. Since IGF-
1 is bound to binding proteins, it has to be released for quantification of total IGF-1 using 
immunoassays. In this thesis, a specific pretreatment including an acidification step was 
used for IGF-1 release, which has been published previously by our group [54]. 
4.2.2 IGF binding protein 2 (IGFBP2)
IGFBP2 is an approximately 30 kDa protein produced by hepatic tissues and binds IGF 
molecules in circulation in a binary complex [55]. Its affinity to IGF-2 is fourfold higher than 
to IGF-1. IGFBP2 levels are inversely correlated to ST levels [55]; IGF-1, however, increases 
IGFBP2 concentrations. 
4.2.3 Osteocalcin
Osteocalcin, also called bone γ-carboxylglutamic acid-containing protein (BGLAP), is a 
biomarker of bone turnover [56]. This 5.8 kDa protein is produced by mature osteoblasts 
[57], is the most abundant non-collagenous protein in the bone matrix and its levels in 
blood were found to be inﬂuenced by hormone treatment, such as by ST [58, 59]. Thus, 
monitoring osteocalcin levels can give an indication whether rbST was administered.
4.2.4 Anti-rbST antibodies
After administration of rbST to dairy cows, an rbST-specific immunological response has 
been observed by the development of anti-rbST antibodies [60, 61]. These antibodies are 
only present after administration of rbST and are therefore very specific biomarkers for 
rbST use or abuse.
4.2.5 Other possible biomarkers for rbST treatment
As described above, ST has growth-promoting effects on many tissues including bone, 
muscle, soft tissue, and others. Therefore, also growth-related biomarkers from these 
tissues might be indicative for rbST treatment. Potential protein biomarkers shown to be 
ST-responsive in other mammalian species are N-terminal propeptide of procollagen III 
(PIIINP) [59, 62], C-terminal cross-linked telopeptide of collagen I (CTx) [59], acid-labile 
subunit (ALS) [63], myostatin [64], and insulin [65].
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For all biomarkers, it has to be considered that they might be affected by other factors 
than the drug treatment itself and therefore, the candidate biomarkers need to be 
thoroughly validated for their capability to pinpoint drug abuse as discussed in Chapter 2 
of this thesis.
5 Analytical methods applied in this work
To be able to measure several protein biomarkers at the same time in a single sample, 
multiplex immunoassay methods were applied in this thesis. Mainly two different 
approaches were used, the first one is based on microspheres and the second one is based 
on a protein microarray, which both will be explained below.
5.1 Microsphere-based immunoassay methods
Three different microsphere-based immunoassay methods are used for the work in 
this thesis, namely a ﬂow cytometric immunoassay (FCIA), a planar imaging array and a 
cellphone ﬂuorescence immunoassay. For all methods, proteins are covalently immobilized 
on the surface of carboxylated microspheres by using similar chemical protocols. 
Then, similar sandwich or inhibition immunoassays are performed in a microsphere 
suspension. There, a detection antibody is employed that carries a ﬂuorescence label for 
quantification. For the final ﬂuorescence detection, different platforms namely a ﬂow 
cytometer, a planar imaging array platform or a cellphone with a dedicated cellphone 
attachment, are used.
5.1.1 Microsphere coupling
Different microspheres were used for all the microsphere-based methods as outlined in 
Table 1. The colour-encoded microspheres are commercially produced by mixing red and 
infrared dyes in specific ratios, thereby creating more than 50 different microsphere sets 
with distinct colour codes. For the FCIA, four different microsphere sets were employed; 
one for each of the four different protein biomarkers. For the planar imaging array 
platform, only one microsphere set was used. When using paramagnetic microspheres, 
experimental handling is easier, because only a simple magnet is required to sediment 
the microspheres, whereas non-magnetic microspheres need to be centrifuged. Protein 
immobilization was done equally for all, using a two-step carbodiimide reaction employing 
N-hydroxysulfosuccinimide sodium salt (NHS) and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC). In the first step, the carboxylic groups on the 
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microspheres were activated by EDC and NHS and in the second step, an amino group 
of the protein is reacting with the activated carboxylic group and an amide bond is 
created. The detailed experimental protocol can be found in the Materials and Methods 
sections of Chapters 3 - 7. During microsphere coupling, the protein biomarkers IGF-1, 
IGFBP2, osteocalcin or rbST were covalently attached to the surface of a specific set of 
microspheres respectively (left column in Figure 4).
Table 1: Overview of the ﬂow cytometric immunoassay, the planar imaging array and the 
cellphone ﬂuorescence immunoassay employed in this thesis.
Flow cytometer-based 
analysis
Planar imaging array-
based analysis
Cellphone-based 
analysis
Microspheres Non-magnetic, 
carboxylated and 
colour-encoded (Ø 
5.6 μm) 
Paramagnetic, 
carboxylated and 
colour-encoded (Ø 
5.6 μm)
Paramagnetic and 
carboxylated (Ø 
8-10 μm)
Biomarkers 
simultaneously 
detected
4 1 1
Discrimination of 
microspheres
By internal colour code By internal colour code Not demonstrated
Microﬂuidics for 
microsphere separation
Flow channel in ﬂow 
cytometer
Microspheres 
dispersed on a planar 
magnetic surface
Sample sandwiched 
between microscope 
cover slides
Fluorochrome R-Phycoerythrin 
(excitation wavelength: 
532 nm; emission 
detection: 565 – 
585 nm)
R-Phycoerythrin 
(excitation wavelength: 
511 nm; emission 
detected by CCD 
imager)
Quantum Dots 
(excitation wavelength: 
380 nm; emission 
detection: >610 nm)
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Figure 4: Assay formats for all protein biomarker (analyte) detection immunoassays. For 
IGF-1, IGFBP2 and osteocalcin, free analyte in the sample and the immobilized standard 
protein compete for antibody binding (inhibition format). The analyte anti-rbST antibody 
is sandwiched between rbST standard protein on the microsphere surface and the anti-
bovine detection antibody.
5.1.2 Sandwich and inhibition immunoassay formats
Depending on the analysed protein biomarker, sandwich or inhibition immunoassay 
formats were used. Traditionally in the sandwich format, the biomarker is sandwiched 
in between two biomarker-specific antibodies. For the detection of anti-rbST antibodies 
(Figure 4), however, the biomarker anti-rbST antibodies was sandwiched in between rbST 
on the microsphere surface and the labelled goat anti-bovine detection antibody. In this 
case, the ﬂuorescence signal coming from each microsphere is positively correlated with 
the biomarker in the sample (Figure 5A). 
 
Chapter 1
22
Figure 5: Exemplary standard curves for (A) the sandwich immunoassay format and (B) the 
inhibition immunoassay format. 
For all the other biomarkers, IGF-1, IGFBP2, and osteocalcin, the inhibition format was 
chosen. In this format, a standard protein of the biomarker is covalently coupled to the 
microsphere surface (Figure 4). When the biomarker is present in the sample, the free 
biomarker and the biomarker standard on the microsphere surface compete for the 
biomarker-specific antibody used in the immunoassay. Consequently, the ﬂuorescence 
signal coming from each microsphere is negatively correlated with the biomarker 
concentration in the sample (Figure 5B). 
For both immunoassay formats, it is important to account for day-to-day variations, 
which can occur due to temperature shifts or other small interferences. For the sandwich 
immunoassay format, normalization can be done by dividing all obtained sample signals 
by the signal of a control sample or set of control samples, which are measured every 
time. For the inhibition immunoassay, all sample signals can be normalized to the signal 
obtained from the standard curve sample with zero protein concentration. Using this 
normalization strategy, inter-assay variations can be corrected.
5.1.3 Fluorescence detection
As mentioned above, three microsphere-based approaches are used in this thesis. The 
FCIA approach combines the simultaneous detection of four protein biomarkers; the 
planar imaging array and the cellphone microsphere ﬂuorescence immunoassay are used 
to detect the biomarker anti-rbST antibodies (Table 1). In all approaches, it is important 
that the microspheres are separated from each other to enable the analysis of individual 
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microspheres.
For the FCIA, the Luminex technology is used, in which a ﬂow cytometer is required to 
analyse the microspheres. In the ﬂow channel of the ﬂow cytometer, the microspheres 
pass by the lasers individually and are analysed one by one. The ﬂow cytometer has two 
lasers; a red laser for identification of the microsphere colour code (i.e., the assay type) 
and a green laser for quantification of the ﬂuorescence on the microsphere surface (Figure 
6A). In this Luminex approach, R-phycoerythrin (R-PE) is used as a ﬂuorochrome, which is 
excited with a 532 nm laser and its ﬂuorescence emission is detected in the range of 565 – 
585 nm (Figure 7). The light signals are detected by a photo multiplier tube and shown as 
median ﬂuorescence intensities (MFI). 
For the planar imaging array, the MagPix instrument is used, in which the paramagnetic 
microspheres are dispersed on a magnetic planar surface (Figure 6B). The ﬂuorescence in 
the microspheres is excited by a 621 nm LED. A CCD camera images the emission and from 
the image, the microspheres are located and classified by software. A second LED is used 
for exciting the ﬂuorescence label; in this case also R-PE (Figure 7), on the microsphere 
surface at 511 nm. The ﬂuorescence is quantified after imaging with the internal CCD 
camera.
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Figure 6: Detection setups of (A) the ﬂow cytometric immunoassay, (B) the planar imaging 
array and (C) the cellphone ﬂuorescence immunoassay. 
 
General introduction
25
Figure 7: Excitation (dotted line) and emission (solid line) spectra of R-phycoerythrin 
(yellow) and Quantum Dots (orange). Obtained from www.lifetechnologies.com [66] .
In the cellphone ﬂuorescence immunoassay approach, a dedicated cellphone attachment 
is required, which houses light-emitting diodes (LEDs) for excitation of the ﬂuorochrome 
and an optical filter to only allow the ﬂuorescence light to reach the cellphone camera. 
In this approach, Quantum Dots (QD) are used because of their preferable excitation 
and emission characteristics. The emplozed QDs are excited in the UV range of light and 
emit at 625 nm wavelength (Figure 7). Therefore, UV LEDs (380 nm) and a simple 610 nm 
long-pass filter are used to image the ﬂuorescence light coming from the QDs on the 
microspheres (Figure 6C). To ensure that the microspheres are separated from each other, 
the microsphere suspension is sandwiched between two microscope cover slides. In this 
approach, all microspheres have the same colour and therefore, no discrimination based 
on a colour code is possible. That means that only a single biomarker can be analysed 
using the cellphone ﬂuorescence immunoassay format. Multiplexing can be achieved 
in the future by using differently sized microspheres or colour-encoded microspheres. 
For the latter, different LEDs for excitation are required. For each excitation event, a 
separate image needs to be taken and analysed. Therefore, it has to be ensured that 
the microspheres remain at their specific location for microsphere identification and 
ﬂuorescence quantification in a way that the ﬂuorescence results can be assigned to a 
specific microsphere set. 
5.2 Microarray-based immunoassay approach
The second immunoassay approach used in this thesis does not employ microspheres, 
but is based on a protein microarray. In a microarray, each spot is assigned to a specific 
protein to be analysed and because of the known fixed spot locations, multiplexing is 
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straightforward. Another advantage is that on-chip positive and negative controls can be 
incorporated to correct the ﬂuorescence signals for background and day-to-day variations. 
For biomarker detection, proteins are covalently coupled to activated glass slides carrying 
carboxylic groups using the same chemistry as described before (sub-section 5.1.1). In 
this microarray approach, only sandwich immunoassays are performed. The developed 
protein microarray immunoassay is analysed using the same cellphone and cellphone 
attachment, and therefore, the same QDs were used as ﬂuorochrome. Two different rbST-
dependent biomarkers, IGF-1 and anti-rbST antibodies, are simultaneoulsy analysed using 
the microarray platform.
Figure 8: Detection setup of the protein microarray immunoassay approach.
6 Scope and thesis outline
The main purpose of this thesis is the development of protein biomarker-based techniques 
for the detection of rbST administration to dairy cattle. Existing rbST detection methods 
mainly lack sensitivity, reproducibility or selectivity for rbST and are therefore not widely 
applied. Even though rbST use has been banned in the EU since 2000, no method has 
been implemented so far to monitor its abuse in dairy farming. Therefore, this thesis 
focuses on an alternative approach using rbST-dependent protein biomarkers. For this 
end, laboratory-based and on-site testing platforms for serum and milk are developed 
to meet the needs of current testing procedures. In Chapter 2, a thorough review about 
protein biomarker-based methods used for sports doping and in veterinary control is 
given to provide the required background on protein biomarker-based approaches, their 
development and validation criteria. 
The experimental chapters of this thesis are divided in two parts based on the type of 
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sample, which was analysed: the first part focuses on blood biomarker profiling including 
serum and plasma samples and the second part focuses on milk biomarker profiling. 
For the first part of the thesis (blood biomarker profiling), the development of a multiplex 
assay combining the detection of three different rbST-dependent biomarkers is described 
in Chapter 3. The biomarkers analysed were IGF-1, IGFBP2 and anti-rbST antibodies. 
This triplex FCIA was applied to serum samples from an rbST treatment animal study to 
evaluate its capabilities to identify rbST abuse. In order to increase the rbST detection 
capabilities of the existing triplex FCIA, an additional biomarker (osteocalcin) was added 
to the biomarker panel and this resulting fourplex FCIA was applied to serum samples 
from two different rbST treatment animal studies. In Chapter 4, the performance of each 
of the individual biomarkers in the fourplex FCIA is assessed. Then, all possible biomarker 
combinations are evaluated using an advanced statistical model aiming at identifying as 
many as possible rbST-treated cows and discriminating them from the untreated cows. As 
protein biomarkers might be indicative for different treatments, the developed fourplex 
FCIA was also applied for biomarker profiling in plasma samples obtained from steroid-
treated cattle. The resulting treatment-specific biomarker profiles are discussed in Chapter 
5. Since all the methods described in Chapters 3 – 5 require a ﬂow cytometer, these 
methods can only be performed in a laboratory.
For the second part of the thesis, milk samples from rbST-treated and untreated cows 
were used for analysis. Chapter 6 describes the assay development for the detection of 
the biomarker anti-rbST antibodies in raw milk, pasteurized milk and tank milk samples 
using an FCIA approach. This method is also bound to a laboratory, but on-site testing 
platforms are preferable for on-farm analysis. Therefore, the development of a cellphone 
microsphere ﬂuorescence immunoassay for anti-rbST antibodies is described in Chapter 
7. Using this cellphone platform, rbST-treated and untreated cows can be discriminated 
based on their anti-rbST antibody presence in raw milk. All methods described in Chapters 
3 – 7 are based on immunoassays on the surface of microspheres. In Chapter 8, a protein 
microarray approach for multiplex protein biomarker detection is presented, with which 
two different rbST-dependent biomarkers are analysed in milk samples.
The research presented in this thesis is thoroughly discussed in Chapter 9. Thereby, 
specific topics regarding this thesis, general scientific implications of the work performed 
and its societal impact are considered. Moreover, an outlook is given and potential future 
developments are described.
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Abstract
There are several similarities between sports doping and veterinary control. Prohibited 
substances, e.g. anabolic agents and peptide hormones, are similar and analytical methods 
applied are immunoassays and chromatography mass spectrometry in both worlds. In 
recent years, protein biomarker-based detection strategies were successfully developed 
and adopted in sports control. When measuring biomarkers, the window of detection can 
be extended due to a prolonged biological response. Thus, a whole range of substances 
may be tackled in an indirect manner. In view of the similarities in intended biological 
effects, such as increased muscle mass, it is envisaged that biomarker-based detection may 
be adopted in future veterinary control. In this review, protein biomarker-based detection 
strategies are discussed against generic challenges in biomarker discovery and method 
development. The lessons learnt from successfully implemented biomarker strategies into 
doping regulations, advocate adoption in the future veterinary world and revision of the 
current restrictive regulations concerning analytical methods.
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Abbreviations
2D-DIGE two-dimensional differential gel electrophoresis 
2D-GE two-dimensional gel electrophoresis 
ALS acid-labile subunit 
CERA continuous erythropoietin receptor activators 
EASIA enzyme-amplified sensitivity immunoassay 
ELISA enzyme-linked immunosorbent assay 
Epo erythropoietin 
eST equine somatotropin 
FCIA ﬂow cytometric immunoassay 
GC gas chromatography 
GH growth hormone 
GHRH GH releasing hormone 
GHRP GH releasing peptide 
ICMA immunochemiluminescence assay 
ICTP C-terminal telopeptide of type I collagen 
IGF insulin-like growth factor 
IGFBP IGF binding protein 
kDa kilo Dalton 
LC liquid chromatography 
MALDI matrix-assisted laser desorption ionisation 
MS mass spectrometry 
ORF open reading frame 
PCR polymerase chain reaction 
PICP procollagen type I C-terminal propeptide 
PIIINP N-terminal propeptide of procollagen type III 
rbST recombinant bovine somatotropin 
rhGH recombinant human GH 
r-HuEPO recombinant human Epo 
RIA radio immunoassay 
rpST recombinant porcine somatotropin 
SHBG sex hormone-binding globulin 
SPR surface plasmon resonance 
SRM single reaction monitoring 
TOF time-of-ﬂight 
uHPLC ultra-high-performance liquid chromatography 
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VEGF vascular endothelial growth factor 
WADA World Anti-Doping Agency
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1 Introduction
Increasing muscle mass and enhancing performance or productivity are common aims 
of athletes and in food production. It is well known that muscle growth is facilitated by 
the use of certain prohibited substances. Therefore, it is not surprising that during and 
after major sports events, a substantial number of athletes is accused of doping and 
also during routine veterinary controls in food production, the presence of prohibited 
growth promoters is detected. For both, in sports and food production, the use of similar 
substances is banned, such as anabolic agents (e.g., exogenous and endogenous steroid 
hormones and clenbuterol), peptide hormones and growth factors (e.g., growth hormone) 
[1, 2]; hence similar monitoring and detection methods can be used for their detection.
The best proof of drug abuse is obtained if the abused substance itself is found in the 
athlete’s or animal’s body. Numerous methods for their direct detection are available for 
a multitude of different possibly abused substances. These conventional methods are 
mainly based on chromatographic separation, such as gas chromatography (GC) or liquid 
chromatography (LC), followed by mass spectrometric (MS) or tandem mass spectrometric 
(MS/MS) detection of target ions or ion transitions [3, 4]. Also ligand binding assays, such 
as the enzyme-linked immunosorbent assay (ELISA) can be used for their direct detection 
[5]. Furthermore, bioassays detecting compounds with androgenic or anti-androgenic 
activity in urine may be applied [6].
As an alternative to these conventional direct detection methods, indirect analysis 
approaches can be used. One approach is monitoring certain biomarkers in the body, the 
levels of which are specifically increased or decreased after administration of a specific 
active substance. Thus, the biological effects of an illegal substance are measured and 
therewith, an indirect proof of doping can be delivered. Such an approach has several 
advantages over the classical direct detection:
(1) Usually, the biological effect of a substance lasts longer than the presence of   
 the substance itself in body ﬂuids and therewith, the window of detection of   
 doping is expanded.  
(2) It can be expected that different substances for growth promotion exert similar   
 effects onto the body and therefore, biomarker-based detection methods have   
 the potential to detect a whole class of substances, including designer substances  
 with unknown chemical structure and synthetic versions of natural hormones. 
(3) Low-dose mixtures of different banned substances, which might escape from   
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 direct detection of each individual substance used, could be still detected by the  
 combined effect they exert [7].
Biomarkers, which can be used for the described effect monitoring can be either mRNA, 
metabolites or proteins, which can be analysed using transcriptomic, metabolomic and 
proteomic techniques, respectively [7-10]. 
This review, covering the period from 1997 until 2013, focuses on protein and peptide 
biomarkers that have been and can be used for the detection of abused drugs in sports 
and veterinary control. Consequently, only endogenous peptides and proteins are 
considered, the levels of which are specifically changed after drug administration. The 
described biomarker-based approaches are not limited to the detection of substances 
enhancing muscle growth, but also include substances improving performance in athletes 
and milk production in cattle.
In Section 2, the protein biomarker discovery pipeline in sports doping and veterinary 
control is outlined. Some of the protein biomarker-based methods, described in detail 
in Section 3, have already been implemented in routine doping control. In contrast, 
so far, no protein biomarker-based method has been successfully implemented for 
veterinary control, because current regulation has not adopted biomarker-based detection 
approaches yet. Nevertheless, lessons learnt during the biomarker identification process 
for doping control may support and stimulate the development and acceptance of protein 
biomarker-based detection methods in future veterinary control programmes, which is 
discussed in Section 4.
2 Techniques used in the development of protein biomarker-
based methods
2.1 Biomarker-based method development process
For the development of biomarker-based methods in sports doping and veterinary control, 
several phases have to be successfully completed before final implementation of the 
biomarker-based tests is possible (Figure 1).
The first phase in the development of biomarker-based methods is the discovery phase, 
in which candidate biomarkers for substance abuse are identified by either untargeted 
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or targeted proteomic approaches. In general, well-controlled treatment studies are 
performed to obtain samples comprising a limited biological variation. Samples from a 
treated and an untreated group are compared to create candidate biomarker lists. Unlike 
in clinical biomarker studies, where also cell culture and animal models can be used during 
the discovery phase, in doping and veterinary control, bioﬂuids or tissues are analysed, 
which are also the target sample matrix in the final assay. In any case, easily accessible 
samples are chosen for analysis, which are mainly urine and blood samples in sports 
doping control and urine, blood and tissue samples, such as muscle or liver, in veterinary 
control.
Figure 1: Overview of the protein biomarker discovery, verification and validation process 
in sports doping and veterinary control.
After completion of the first phase, a separate qualification phase, as done in clinical 
biomarker studies, is often not necessary in doping and veterinary control. The clinical 
qualification phase is required for two reasons [11]: First, if cell culture or animal model 
samples were used during the discovery phase, the discovered biomarkers have to 
be confirmed in the final sample matrix. Second, an analytical method, which will be 
subsequently used during the following verification phase, is introduced and evaluated. 
In contrast, for doping and veterinary control, the final sample matrix was used already 
during the discovery phase and if necessary, the alternative analytical method is evaluated 
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in combination with the subsequent verification phase.
During the verification phase, targeted proteomic biomarker analysis techniques are used 
to confirm the previous findings and to assess the specificity of the candidate biomarkers. 
From this point, methods are necessary that allow high-throughput measurements of large 
numbers of samples. Using the untargeted biomarker discovery techniques (Section 2.2.1) 
for rapid screening is not feasible, because of their complex and elaborate nature. Targeted 
approaches (Section 2.2.2), however, are easier and faster and are mainly applied during 
biomarker verification, assay optimization and validation phases.
During the assay optimization and validation phases, the targeted biomarker detection 
method is tested on a large set of samples from treated and untreated individuals to 
assess the biological variation of the biomarkers in a reference population, thereby 
including as many as possible confounding factors (Figure 1). In sports doping control, 
this usually includes factors such as gender, age, ethnicity, and effects of sports discipline, 
injury, nutrition and training [12], whereas in veterinary control, these factors would 
include at least age, gender, breed and feeding regime.
Going from one phase to the next, the number of candidate biomarkers decreases, 
whereas the required number of samples increases from a few tens to many thousands to 
reach sufficient statistical evidence for the biomarker [11].
Since the final biomarker-based screening methods often comprise the detection of 
more than one biomarker, suitable statistical methods are necessary to evaluate the 
data obtained. For instance for the detection of growth hormone (GH) abuse in athletes, 
discriminant functions were used to combine the results of two biomarkers and correct 
their levels according to age and gender [12]. A different approach was chosen for 
recombinant bovine somatotropin (rbST) abuse detection in cows where the statistical 
model k-nearest neighbours was used to discriminate between rbST-treated and untreated 
animals [13]. For discrimination of heifers treated with growth-promoting agents and 
untreated heifers, support vector machines were used to combine the results of 20 
measured clinical biomarkers [14].
According to the current 2002/657/EC regulation for veterinary control, an additional 
phase is necessary upon non-compliant screening results [15]: the abused substance itself 
has to be confirmed by chromatographic and mass spectrometric methods, thus currently, 
biomarker-based methods can only be used for the initial screening stage. However, it is 
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envisaged that eventually biomarker-based approaches will be adopted in the veterinary 
field as previously done in sports doping and horse racing regulations.
2.2 Approaches for biomarker method development
2.2.1 Untargeted biomarker discovery methods
For a completely unbiased discovery of proteins as candidate biomarkers, untargeted 
proteomics is the method of choice. The total protein composition in samples from treated 
and untreated individuals is analysed semi-quantitatively and compared to find significant 
differences in concentrations of individual proteins, which then may be considered 
as candidate biomarkers. The unbiased discovery is very meaningful, because also 
unexpected candidate biomarkers can be found. 
The main sample matrix chosen for biomarker studies is blood (Table 1). It should be 
considered that the human plasma proteome covers a wide concentration range from 
almost 200 mg mL-1 down to a few pg mL-1 [16]. To be able to also identify and analyse 
low-abundant proteins, not only highly sensitive methods have to be applied, also good 
depletion strategies for the high-abundant proteins or selective enrichment methods for 
the low-abundant proteins are necessary.
Depleting serum from the most abundant proteins can be done by precipitation, 
ultracentrifugation or commercially available immuno-depletion columns, but it should be 
noted that depletion will also remove other than the abundant proteins non-specifically 
[44, 45]. Selective enrichment protocols, on the other hand, are used to extract a specific 
protein subfraction out of the complex matrix. In that way, glycoproteins can be affinity-
enriched by binding to lectins or low-abundant serum proteins can be enriched by protein 
capture to hexapeptide library columns and therewith, the entire dynamic range of serum 
samples can be greatly reduced [46, 47]. Also here, a certain bias is introduced since only 
a very specific subfraction of the proteome will remain for the following analysis and 
thereby other candidates are possibly excluded at this early step. As a result of depletion 
or enrichment, however, sample complexity is obviously reduced and therewith the 
detection of low-abundant proteins by untargeted techniques becomes possible. 
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2.2.1.1 Two-dimensional fluorescence differential gel electrophoresis
Two-dimensional ﬂuorescence differential gel electrophoresis (2D-DIGE) has been 
frequently applied in biomarker discovery phases for sports doping and veterinary control 
[20, 21, 23, 31, 37]. Here, protein compositions of two samples are relatively compared 
by labelling each sample with a specific ﬂuorescent dye. Before protein separation on a 
2D electrophoresis gel, the dyed samples are mixed. The relative abundance of proteins 
in the samples can be compared by ﬂuorescence gel imaging using light with dye-specific 
excitation wavelengths [45, 48, 49]. For gel-to-gel comparisons, an internal standard, which 
was labelled with an additional ﬂuorescent dye, has to be included. After assessment of 
the significantly different protein spots, the spots are excised, an in-gel protein digestion 
is performed and the proteins are identified using liquid chromatography coupled to 
mass spectrometry (LC-MS). Whereas 2D-DIGE really visualizes differences in composition 
between protein samples, its performance is limited since only three different specific 
dyes are available and consequently, only two samples can be compared on one gel if 
an internal standard is necessary. Furthermore, only after removal of interfering high-
abundant proteins, either by depletion or selective enrichment of the target proteins, 
sufficient sensitivity can be achieved for detection of very low-abundant proteins [45].
2.2.1.2 Quantitative mass spectrometric techniques
Instead of using 2D-DIGE for relative comparison of protein compositions, also quantitative 
MS can be directly applied. Several techniques for absolute and relative protein 
quantification have been described, which can be classified into isotope label-based and 
label-free techniques [50]. Despite the fact that untargeted quantitative MS techniques 
offer a great potential in unbiased identification of protein biomarkers, its application in 
sports doping control is limited to a very few studies [30]. 
2.2.1.3 Antibody microarrays
As an alternative, also affinity-based strategies can be followed. In this field so far, 
untargeted biomarker discovery was not possible due to the limited number of highly 
specific antibodies. The Human Protein Atlas, however, aims at production of recombinant 
proteins deriving from all open reading frames (ORF) of the human genome and the 
production of specific antibodies against all these proteins. So far, more than 10,000 
antibodies have been produced within this project, which makes the production of 
high-density antibody microarrays possible [51, 52]. Because of the high specificity of 
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the immobilized antibodies, only minimal sample pretreatment would be required. Since 
during biomarker discovery only a very limited number of samples is tested, the sample 
throughput of the antibody microarrays is adequate for the purpose. Simplified antibody 
microarrays, comprising a limited number of specific antibodies, or reverse-phase protein 
microarrays can then be used during the verification and validation phases or as a targeted 
biomarker discovery approach (Section 2.2.2.2).
2.2.2 Targeted biomarker methods
As an alternative or complementary approach to untargeted biomarker discovery, a more 
targeted approach can be chosen. This is advantageous if information about the expected 
outcome is already available, for instance from literature search. Moreover, for the 
biomarker verification and validation phases, targeted biomarker detection methods, such 
as affinity-based assay strategies and targeted MS analysis, are highly desired due to their 
high-throughput potential.
2.2.2.1 Biological pathway investigation
For targeted biomarker discovery, the biological pathway of the administered hormone 
is analysed by screening available literature for proteins that are up-regulated or down-
regulated [7]. As an example, if one is interested in protein biomarkers of growth hormone 
(GH) administration, the first choice is to investigate candidate biomarkers, which are 
directly or indirectly regulated by GH. These include mediators of GH action, as well as 
specifically regulated proteins of the target tissues, where the effect takes place (such as 
liver, bone and soft tissue) as well as proteins from the endocrine feedback loops (Figure 
2). Note that the regulation of protein synthesis is tissue-specific and not all candidate 
biomarkers will show altered concentrations in all target tissues. Therefore, care has to be 
taken in the choice of the analysed bioﬂuid or tissue, which should, on one hand, be easily 
accessible for sampling and, on the other hand, show strong biomarker responses after 
treatment. 
The biological pathway investigation has been frequently applied for biomarker searches 
in sports doping, as for instance for GH biomarker discovery [12, 26-29], and in veterinary 
control for somatotropin (ST) biomarker discovery [33-35].
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Table 1: Overview of abused substances, their candidate biomarkers, which were identified 
using a specific detection method, and the reported studies, which were performed to 
validate the candidate biomarkers.
Substance 
class
Abused 
substance
Analysed 
in
Biomarkers Detection 
method
Biological validation Ref.
Steroids Testoste-
rone
Human 
blood
Inhibin B ELISA 15 male body builders, 
whereof 8 used testos-
terone
[17]
Equine 
blood
Clusterin and 
leucine-rich 
α-2-glycopro-
tein
Strong cation 
exchange 
fractionation 
followed by 
LC-MS
Two horses undergoing 
testosterone treatment
Forty untreated reference 
population horses
Two horses for longitudi-
nal biomarker study
[18]
Nortestos-
terone/ 
estradiol 
cocktail
Bovine 
blood
SHBG, IGF-
BP3, PIIINP, 
ir-inhibin, 
myostatin
DHT binding 
assay (SHBG), 
Western Blot 
(IGFBP3) and 
immunoassays 
12 male and 12 female 
calves, whereof 6 each 
untreated controls
[7]
Estradiol Bovine 
blood
IGFBP2 Multiplexed 
FCIA
6 estradiol-treated male 
beef cattle and 6 untrea-
ted controls
[19]
Predniso-
lone
Bovine 
blood
IGF-1 Multiplexed 
FCIA
6 prednisolone-treated 
male beef cattle and 6 
untreated controls
[19]
Dexamet-
hasone
Bovine 
blood
PIIINP, osteo-
calcin, IGF-1, 
IGFBP2
Multiplexed 
FCIA (osteo-
calcin, IGF-1 
and IGFBP2), 
immunoassay 
(PIIINP, osteo-
calcin)
6 dexamethasone-treated 
male beef cattle and 6 
untreated controls (IGF-1, 
IGFBP2, osteocalcin) 
12 male and 12 female 
calves, whereof 6 each 
untreated controls (PI-
IINP, osteocalcin)
[7, 
19]
Boldeno-
ne and 
boldione
Bovine 
blood
Apolipopro-
tein A1
2D-GE and 
MALDI-TOF 
and µLC-ESI-
IT-MS
5 calves sampled before 
and after boldenone/bol-
dione A treatment
[20]
Other 
anabolic 
agents
Clenbu-
terol/ 
dexamet-
hasone/ 
estradiol 
combina-
tion
Bovine 
hepatic 
cytosols, 
microso-
mes
Adenosine 
kinase, reti-
culoalbin
2D-GE follo-
wed by LC-MS
6 GPA combination-trea-
ted calves and 6 untrea-
ted calves
[21]
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Substance 
class
Abused 
substance
Analysed 
in
Biomarkers Detection 
method
Biological validation Ref.
Eryth-
ropoie-
sis-sti-
mulating 
substan-
ces
Recom-
binant 
human 
erythro-
poietin 
(rhEpo)
Human 
blood
Hematocrit, 
serum Epo 
concentrati-
on, soluble 
transferrin 
receptor con-
centration, 
reticulocyte 
hematocrit 
and % 
macrocytes 
Flow cytome-
tric analysis 
(erythrocyte 
and reti-
culocyte 
parameters), 
ELISA (Epo 
and soluble 
transferrin 
receptor)
Epo treatment study 
including 27 healthy 
athletes
[22]
Specific iso-
forms of hap-
toglobin and 
transferrin
2D-GE and 
MALDI–TOF
RhEpo treatment study 
including 8 healthy men
[23]
  Equine 
blood
Hemoglobin 
concentra-
tion
na RhEpo treatment study 
including 8 horses
[24]
Anti-Epo 
antibodies
Protein micro-
array
Rabbit anti-Epo antibo-
dy used as standard for 
proof of principle
[25]
Growth 
hormo-
ne, its 
releasing 
factors 
and in-
sulin-like 
growth 
factor-1
Recom-
binant 
human GH 
(rhGH)
Human 
blood
Different GH 
isoforms
Differential 
immunoassays 
Tested in 155 serum 
samples from endo-
genous GH stimulation or 
exogenous rhGH adminis-
tration
Ring test with 27 blinded 
samples analysed in seve-
ral laboratories
[12, 
26]
IGF-1/PIIINP 
combination
RIAs Several studies with large 
number of treated and 
untreated individuals
Confounding factors, such 
as age, sex, ethnicity, 
injury, sports discipline 
tested
Validation of statistical 
analysis with indepen-
dent data set
[12]
IGF-1/IGFBP2 
ratio and IGF-
BP2/IGFBP3 
ratio
RIAs Tested in 8 healthy men [27]
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Substance 
class
Abused 
substance
Analysed 
in
Biomarkers Detection 
method
Biological validation Ref.
IGF-1/ PI-
IINP/IGFBP3 
combination
Competitive 
ﬂuorescence 
immunoassay 
(IGF-1), RIA 
(PIIINP), ELISA 
(IGFBP3)
Blind placebo-controlled 
study in 15 male athletes
Validation of statistical 
analysis with indepen-
dent data set
[28]
IGF-1/ICTP 
combination
RIAs Tested in 96 male and 
female recreational 
athletes
Co-administration of 
testosterone tested
[29]
Hemoglobin 
α-chain
SELDI-TOF Identified in 120 serum 
samples obtained from 
the GH-2000 study
[30]
Specific 
isoforms of 
α-1 anti-
trypsin and 
transthyretin, 
apolipopro-
tein A-1, 
hemoglobin 
β-chain
2D-GE and 
MALDI-TOF
rhGH and placebo admi-
nistration to eight male 
individuals in a randomi-
zed cross-over study
[31]
IGF-1 and 
leucine-rich 
α-2-glycopro-
tein
uHPLC-MS 22 serum samples from 2 
rhGH treatment studies
[32]
Equine ST 
(eST)
Equine 
blood
IGF-1, IGF-
BP3
RIAs Tested in 4 eST-, 4 bST- 
and 4 pST-treated horses
Confounding factors, such 
as training, age and sex 
on IGF-1 analysed
[33]
  Anti-eST 
antibodies
ELISA and 
SPR-BIA
Biomarker identified in 
two eST-treated horses
[33]
Recom-
binant 
bovine ST 
(rbST)
Bovine 
blood
Anti-rbST 
antibodies/
osteocalcin 
combination
Multiplexed 
FCIA
Tested in 11 treated and 5 
placebo-treated cows
Confounding factor age 
considered by testing 
reference population
[13]
Bovine 
milk
Anti-rbST 
antibodies
FCIA Tested in 11 treated and 5 
placebo-treated cows
[34]
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Substance 
class
Abused 
substance
Analysed 
in
Biomarkers Detection 
method
Biological validation Ref.
Trout 
blood
IGF-1, 
anti-rbST 
antibodies
Immunoassay 
and Western 
Blot
Four studies including 
285 fish in different treat-
ment groups
[35]
CJC-1295 Human 
blood
GH, IGF-1 RIA (IGF-1), 
ICMA (GH)
20 healthy CJC-1295-tre-
ated men
[36]
   Apolipo-
protein A1, 
transthyretin 
isoform, 
β-hemoglo-
bin
2D-GE and 
MALDI–TOF
Biomarker identified in 11 
healthy CJC-1295-treated 
men
[37]
GHRP-2 Human 
blood
GH, IGF-1 
and IGFBP3
Chemilumi-
nescent assay 
(GH), RIA (IGF-
1, IGFBP3)
Identified during a clinical 
study
[38]
IGF-1/
IGFBP3 
cocktail
Human 
blood
IGF-2, IGF-
BP2, ALS
Immunoassays 26 female and 30 male 
recreational athletes tre-
ated with IGF-1/IGFBP3 
combination or placebo
[39]
Metabolic 
modula-
tors
Insulin Human 
blood
Insu-
lin/C-peptide 
ratio
EASIAs Untreated reference po-
pulation study including 
elite and recreational 
athletes and sedentary 
individuals
[40]
  Human 
urine 
Urinary insu-
lin degrada-
tion product 
profiles
Immunoaffini-
ty chromato-
graphy and 
LC-MS
Urine samples from 
healthy and diabetic 
individuals
[41]
Gene 
doping
Myostatin 
inhibitor 
gene 
doping
Human 
blood 
and 
muscle
Follistatin/
myostatin 
propeptide 
ratio
Immuno-PCR 22 healthy male individu-
als of different training 
status
[42]
GH gene 
doping
Salmon 
muscle
Myostatin 
protein levels
Western Blot 8 transgenic salmon and 
8 wildtype salmon
[43]
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Figure 2: GH regulatory circuit including feed-back loops (reproduced with permission 
from Holt et al. [53])
2.2.2.2 Ligand-binding assay techniques
For targeted biomarker discovery studies and for biomarker verification and validation, 
ligand-binding techniques, such as immunoassays, receptor assays, transport protein 
assays and aptamer assays, can be used. Ligand-binding assays have been very frequently 
applied in sports doping and veterinary control (Table 1) [7, 12, 13, 17, 19, 22, 24-29, 33-
36, 38-40], because of their simple operation and great high-throughput characteristics as 
compared to untargeted proteomic approaches. Here, only a protein subset of the entire 
proteome is analysed in samples from treated and untreated individuals. The successful 
development of ligand-binding assay techniques always depends on the availability of 
key bioreagents such as standard proteins and target-specific antibodies, receptors or 
aptamers of good quality. Several different affinity-based assay techniques are available; 
the classical immunoassay setup, employing specific antibodies against the target proteins, 
remains the most commonly used format.
Single-analyte immunoassay formats
Traditionally in diagnostics as well as for targeted biomarker approaches, single-analyte 
assay formats are used for high-throughput testing. These are mainly radioimmunoassays 
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(RIA) and ELISAs, which typically employ two specific antibodies against the target protein 
in a sandwich format. In RIAs, a radiolabelled secondary antibody or standard protein, 
which competes with the target protein for binding, is used for analysis in a gamma 
counter and in ELISA, an enzyme, which is coupled to the secondary antibody, causes 
a colour change of the added substrate, which can be read using a spectrophotometer. 
Both formats are highly sensitive and can also detect low-abundant serum proteins in 
the pg mL-1 range, but the ELISA format is preferably used because it does not employ 
radiolabels. Single-analyte formats are very suitable for the late validation phase, when the 
candidate biomarker list is already reduced to a single or only a few individual biomarkers. 
This format has been extensively applied across many biomarker studies in sports doping 
and veterinary control [7, 12, 17, 22, 26-29, 33, 35, 36, 38-40].
Multiple-analyte immunoassay formats
Multiple-analyte formats offer the possibility for combining the measurement of many 
biomarkers into one assay, which reduces reagent costs and saves sample volume and 
work load [54]. Usually, they employ specific antibodies against the target proteins and 
have a similar assay principle as the single-analyte platforms. Several setups are available 
for the simultaneous detection of several biomarkers in one sample.
For multiplexing, either suspension bead assays, surface-plasmon resonance (SPR)-based 
biosensors or planar antibody microarrays have been developed [54]. Sets of colour-
coded beads can be coupled with specific antibodies and a traditional sandwich ELISA 
can be performed in suspension. Since a specific antibody is coupled to each bead set, 
the number of available bead sets and the cross talk between biointeractions define 
the theoretical limit of how many target proteins can be detected simultaneously. For 
quantification, the secondary antibody is labelled with a ﬂuorescent protein, which 
can be measured in a specific ﬂow cytometer employing two different lasers (ﬂow 
cytometric immunoassay; FCIA). One laser is used to identify the bead set by its colour 
code, thus the target protein identity, and the other laser is used to quantify the amount 
of the ﬂuorescent label, thus the target protein abundance in the sample. The FCIA 
technology has been applied in biomarker-based studies for rbST and steroid hormone 
abuse detection in veterinary control [13, 19, 34]. SPR-based biosensors detect protein 
interactions on the modified surface of a gold-coated glass prism by changes in the angle 
of the reﬂection minimum. Therewith, the amount of target protein binding to the specific 
antibody can be quantified without the use of any label. Since many antibody spots can be 
coupled to a single SPR chip, simultaneous quantification of up to hundreds of proteins is 
possible [55]. SPR-based approaches were used for protein biomarkers of equine ST (eST) 
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[33]. A simplified version of the already described antibody microarray (Section 2.2.1.3), 
only comprising the specific antibodies for the target proteins, can be used as a targeted 
multiplex protein quantification method and has been applied for biomarker analysis after 
erythropoietin (Epo) doping in racing horses [25].
Reverse protein microarrays
For the verification and validation phases, high sample throughput is required to confirm 
that the discovered candidate biomarkers can still discriminate treated from untreated 
individuals in a diverse population. Reverse protein microarrays are designed to measure 
the concentration of one biomarker in hundreds to thousands of samples simultaneously 
[52]. Samples (body ﬂuids or tissue lysates) are printed onto a nitrocellulose membrane-
coated array chip and the target biomarker is quantified by a specific antibody. The 
advantage of this technology is that it only requires a minimal amount of sample and that 
all samples can be tested simultaneously and therewith, technical interassay variability is 
greatly reduced.
2.2.2.3 Targeted mass spectrometric analysis
As an alternative to high throughput ligand binding assays, targeted MS methods can be 
applied in biomarker discovery, verification and validation. Here, stable isotope-labelled 
internal standards for the target protein or peptide are used for protein quantification 
and comparison across many samples [8]. A tandem mass spectrometer operated in the 
selected reaction monitoring (SRM) mode selectively analyses and quantifies preselected 
ion transitions from the target candidate biomarkers [32]. This technique has been often 
applied for biomarker quantification in sports doping and veterinary control [18, 32, 41].
3 Biomarker-based analysis methods for banned substances in 
doping and veterinary control
For increasing muscle mass as well as enhancing performance in sports and productivity 
in food production, similar illegal substances are abused, such as anabolic agents, peptide 
hormones and growth factors. In both fields, protein biomarker-based approaches were 
followed to detect drug abuse and similar biomarkers were found to be indicative for the 
same abused substance (Table 1). As explained in Figure 1, several phases have to be 
completed for development of a biomarker-based method for drug abuse detection in 
sports doping and veterinary control. In all biomarker studies, that are introduced in this 
chapter, candidate biomarkers were successfully discovered, but only a limited number of 
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these studies followed up with the verification, optimization and validation phases. 
3.1 Anabolic agents
Growth-promoting agents, such as anabolic steroids, are banned in competitive sports 
and in food production in several countries. Control authorities often face the problem 
of short detection windows for measuring the abused substance itself. Also mixtures of 
different substances, so called low-dose-cocktails are used, in which the concentrations of 
the single substances are well below the detection limits of direct detection technologies. 
Furthermore, designer drugs, having the same biological effect but different chemical 
structures than the known substances, cannot be detected by targeted analysis methods. 
Therefore also here, biomarker-based detection strategies are of great interest.
3.1.1 Steroids
Steroids, such as sex steroids (estrogens, androgens and gestagens) and 
glucocorticosteroids, have many functions in the body. They are endogenously produced 
from their common precursor cholesterol and regulate, among others, glucose 
homeostasis and are responsible for reproductive function. In the World Anti-Doping 
Agency (WADA) prohibited list, only androgenic steroids are listed as anabolic agents that 
are banned at all times; glucocorticosteroids are prohibited in-competition and estrogenic 
steroids are not mentioned at all [2]. In food production, however, steroid administration is 
prohibited in general [56] and therefore, also estrogenic steroids and glucocorticosteroids 
are discussed here.
3.1.1.1 Androgenic steroids in sports doping
Testosterone is expected to be abused for its anabolic effects on muscle growth and faster 
recovery times after exercise. A pilot study analysed the effects of testosterone treatment 
on several blood biomarkers in weightlifting men. Inhibin B was measured in serum 
by ELISA and it was found to be significantly decreased after testosterone treatment. 
Therefore, it may serve as a candidate biomarker for an indirect testosterone abuse test 
[17]. Currently, testosterone abuse is detected by an altered testosterone/epitestosterone 
ratio in urine, which is determined by GC-MS-based methods. However, indirect 
biomarkers such as inhibin B can also be indicative for unknown designer substances 
having similar biological effects.
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In competing race horses, anabolic steroids are expected to be abused for performance 
enhancement. Two proteins, namely clusterin and leucine-rich α-2-glycoprotein, were 
increased after testosterone treatment and were mentioned as candidate biomarkers for 
testosterone abuse detection in race horses [18].
3.1.1.2 Steroids in veterinary control for food production
Steroids exert anabolic effects on the body and are interesting compounds for increasing 
meat production and quality. Certain steroids also have a water-retaining effect and may 
be abused short before slaughter to increase the carcass weight. Direct detection of the 
abused steroids has limited value if synthetic versions of natural hormones are used 
and therefore, biomarker-based detection strategies offer an advantage over the direct 
detection. Direct and indirect interaction partners of the administered substance, such 
as binding proteins, mediators of the hormone action and markers of target tissues may 
be candidate biomarkers. Several protein biomarkers were identified after treatment 
with dexamethasone or a cocktail of estradiol and nortestosterone, such as sex hormone 
binding globulin (SHBG), insulin-like growth factor binding protein 3 (IGFBP3), N-terminal 
propeptide of procollagen type III (PIIINP), ir-inhibin and myostatin [7, 57]. To measure 
several of these biomarkers at once, a multiplex method based on SPR biosensor 
technology was developed [7]. Furthermore, using a fourplex protein biomarker FCIA, 
originally developed for detection of rbST abuse (Section 3.2.2.4), administration-specific 
biomarker profiles were obtained from cattle treated with estradiol, dexamethasone or 
prednisolone. These profiles were distinguishable from the profiles from rbST-treated 
animals (Table 2) [19]. These findings suggest that it should be possible to detect a full 
range of anabolic substances by using a limited number of protein biomarkers. The effects 
of boldenone and boldione were analysed using 2D gel electrophoresis (2D-GE) and 
matrix-assisted laser desorption ionisation time-of-ﬂight mass spectrometry (MALDI-TOF/
MS) and LC-MS analysis [20]. These steroids increased plasma apolipoprotein A1 (ApoA1) 
levels in veal calves. 
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Table 2: Biomarker profiles after treatment with prednisolone, dexamethasone and 
estradiol in comparison to treatment with rbST. Biomarker responses are indicated as 
being significantly increased (+), decreased (-) or stable (Ø) after treatment (reproduced 
with permission from Ludwig et al. [19]).
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rbST1 + - + +
prednisolone + Ø Ø Ø
dexamethasone + - - Ø
estradiol Ø + - Ø
1 adapted from Ludwig et al. (2012) [13].
So far, no biomarker-based detection methods have been implemented for official control 
of steroids in food-producing animals. However, in the future, biomarker-based methods 
could be used as a fast screening procedure for thousands of samples prior to elaborate 
MS-based blood confirmatory analysis to identify the responsible component for only the 
few suspicious samples.
3.1.2 Other anabolic agents
Clenbuterol is a β-adrenergic agonist and illegally used in food production to obtain leaner 
meat. In sports it appears on the WADA 2014 prohibited list, because it is used by athletes 
to increase aerobic capacities [2]. When calves were treated with a combination of 
different anabolic agents (clenbuterol, estradiol and dexamethasone), the concentrations 
of two proteins, namely adenosine kinase and reticulocalbin, were significantly altered in 
hepatic cytosols and microsomes as shown using 2D-GE and LC-MS/MS [21]. Therefore, 
these proteins could serve as candidate biomarkers for detection of anabolic agent 
abuse including clenbuterol. Future studies should elucidate whether these proteins are 
specific for the administered steroids or clenbuterol and whether the observed changes 
in biomarker levels are also affected in serum, because liver sampling is only possible at 
slaughter and more laborious from a sample preparation point of view. This study design, 
however, shows that even a combination of several different drugs leads to the discovery 
of candidate biomarkers, which confirms the potential of biomarker strategies for the 
detection of cocktails comprising several substances.
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3.2 Peptide hormones, growth factors and related substances 
In the WADA 2014 prohibited list, this class of substances comprises several different 
peptide hormones, growth factors and other substances with similar chemical structure 
or physiological effects [2]. Biomarker-based approaches for the detection of these were 
so far followed for erythropoiesis-stimulating substances and GH, its releasing factors and 
insulin-like growth factor-1 (IGF-1).
3.2.1 Erythropoiesis-stimulating substances in sports doping
Erythropoietin (Epo) is an endogenous glyco-proteohormone, which is produced upon 
low oxygen levels in blood. It regulates and promotes the production of red blood cells in 
the body. Furthermore, it decreases the plasma volume and therewith increases the total 
hemoglobin content and the oxygen carrying capacity of blood [23]. Epo can be produced 
recombinantly and is used for treatment of diseases, such as anaemia. But it is also known 
to be abused by athletes because of its endurance-enhancing effects. There are direct 
methods for recombinant human Epo (r-HuEPO) detection in urine and blood, which are 
used by WADA to test athletes for possible abuse. These methods detect the different 
glycosylation patterns of endogenous and recombinantly produced Epo by isoelectric 
focussing.
Indirect protein biomarker-based methods are used as well, in which different blood 
parameters are analysed. These parameters include hematocrit, reticulocyte hematocrit 
and % macrocytes, which are measured by ﬂow cytometric analysis. Moreover, serum Epo 
concentration and soluble transferrin receptor concentration are analysed using specific 
ELISAs [22]. All the above mentioned biomarkers increase upon Epo administration (Figure 
3). When combining these biomarkers by using mathematical models, a final score is 
obtained which gives information whether recombinant Epo was used. A combination 
of this indirect approach and the direct Epo detection was used at the Sydney Olympic 
Games in 2000 for detection of blood doping. But it was decided that blood sampling 
in-competition is not feasible and nowadays, Epo abuse is detected by the direct urinary 
isoelectric focussing method [22]. Other potential protein biomarkers, such as haptoglobin 
and transferrin isoforms, were identified by using 2D-GE and MALDI-TOF [23]. Using 
biomarker-based detection, also other blood-doping methods, such as blood transfusion, 
administration of continuous erythropoietin receptor activators (CERA), gene doping or 
Epo analogues could be detected [22, 23]. Challenges that remain are the inter-individual 
differences in these blood biomarkers.
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Figure 3: Human blood biomarkers hematocrit (A), reticulocyte hematocrit (B), 
% macrocytes (C), serum Epo (D) and soluble transferrin receptor (E) after 25 days 
recombinant human Epo administration. Mean values and standard error of the mean 
are shown for the different treatment groups: EPO+OR group (r-HuEPO and oral iron 
treatment), EPO+IM (rHuEPO and intramuscular iron treatment) and placebo group 
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(sham r-HuEPO injections, sham iron injections, sham iron tablets). Statistically significant 
differences (p<0.05) are: † = EPO+OR versus placebo group. * = EPO+IM versus placebo 
group. ‡ = EPO+OR versus EPO+IM group (reproduced with permission from Parisotto et al. 
[58]). 
To further increase the value of the indirect biomarker test for Epo detection, the 
biological passport for athletes was introduced recently [59]. By using this passport, an 
athlete’s blood parameters are compared to the own previous parameters and therewith, 
false-positive or false-negative results are avoided.
Also in horse racing, an increase of red blood cell volume and aerobic capacity was 
observed after repeated treatment with recombinant Epo and therefore, the increased 
hemoglobin concentration was identified as a candidate biomarker for Epo administration 
[24]. Furthermore, horses injected with recombinant Epo develop specific antibodies as 
an immunological response. These antibodies were detected using a protein microarray 
approach, where different available recombinant Epo preparations were coupled to a 
microarray surface and the presence of anti-Epo antibodies was detected by ﬂuorescence-
labelled secondary antibodies [25].
Epo is not expected to be abused in food production, because improved aerobic capacity 
does not have a major impact on increased meat production or quality. However, the 
concept of the biological passport and the implemented biomarker-based method for Epo 
abuse detection are great examples for how biomarkers can be used to indirectly pinpoint 
drug abuse.
3.2.2 Growth hormone, its releasing factors and insulin-like growth factor-1
Growth hormone (GH) or somatotropin (ST) is a proteohormone endogenously produced 
by the anterior pituitary gland (Figure 2). Its release from the gland is triggered by 
many factors. There are GH-inducing factors, such as GH releasing hormone (GHRH), GH 
releasing peptides (GHRP) and GH-repressing factors, such as somatostatin and IGF-1 [60]. 
GH has also many different effects on the body, which are exerted either directly onto the 
target tissues or indirectly via IGF-1 release from hepatic tissues. The main effects of GH 
are growth promotion, lipolysis in adipocytes and muscle and bone growth promotion 
[60]. In all the affected tissues, different proteins are either upregulated or downregulated 
and can be considered candidate biomarkers for the detection of exogenous GH 
administration.
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3.2.2.1 Recombinant human growth hormone
Recombinant human growth hormone (rhGH) is abused by athletes, because of its 
anabolic and lipolytic actions on the body. The direct detection of rhGH abuse is 
very difficult, because of several reasons: First, both, the pituitary-derived and the 
recombinantly produced forms have identical molecular structures. Second, endogenous 
GH has a pulsatile release pattern and the hormone has a short half-life in circulation, 
leading to large concentration ﬂuctuations in blood. To overcome these difficulties, 
biomarker-based detection methods were considered and two complementary approaches 
have been followed: the ‘isoform’ approach and the ‘biomarker’ method.
The ‘isoform’ approach
In a normal situation, the pituitary produces mainly two isoforms of GH: 70 % of which 
are the 22 kDa GH form, 5-10 % are the 20 kDa GH form and the remaining forms are 
oligomers, modified forms or fragments [12]. If rhGH, which consists only of the 22 kDa 
form, is injected, first, the total amount of the 22 kDa GH form in circulation increases 
and second, the endogenous GH production is inhibited by negative feedback loops and 
therewith, the total amount of the other isoforms decreases. The different GH isoforms 
are measured by using two immunoassays with different specific monoclonal antibodies. 
In the ‘pituitary’ assay, a variety of pituitary-derived GH forms are detected, whereas in 
the ‘recombinant’ assay, preferably the 22 kDa GH form is measured [61]. From the results 
of these two immunoassays, a 22 kDa/non-22 kDa ratio is calculated, which increases 
upon rhGH administration [53]. Thus, with this test, it can be detected whether rhGH was 
injected. This method has, however, a rather limited detection window of less than 48 
hours and if hGH extracted from pituitaries of corpses or growth hormone releasing agents 
are used, the ratio will not be affected and the test fails to detect the abuse [12].
The differential isoform test has been first implemented for sports doping control at the 
Athens Olympic Games in 2004. WADA considers a sample an adverse analytical finding as 
soon as the pituitary/recombinant isoform ratio exceeds a certain gender-specific decision 
limit [61]. By doing so, eight adverse analytical findings were reported for hGH in 2012 
[62].
The ‘biomarker’ approach
As described in Section 3.2.2, GH exerts effects on many different target tissues and 
there it causes the up- or downregulation of specific proteins. The proteins with altered 
concentrations serve as candidate biomarkers for the detection of rhGH abuse. The study 
Chapter 2
58
group GH-2000 identified two significant GH-dependent protein biomarkers out of a 
variety of possible candidates [12]. These were IGF-1 and PIIINP, which are both measured 
in serum by immunoassays. IGF-1, which is a member of the GH/IGF-axis was measured 
after acid/ethanol extraction using a RIA and PIIINP, a marker of soft tissue turnover, 
was measured using a two-stage sandwich RIA [63]. For validation, reference values for 
these biomarkers were obtained from a multitude of elite athletes and the results were 
used to correct for age and gender by using discriminant functions [12]. In a follow-up, 
the GH-2004 study group found out that neither ethnicity nor injury changed the overall 
outcome of the test. Furthermore, the inﬂuence of sports discipline, co-administration 
of testosterone or acute exercise were analysed and none of them inﬂuenced the 
performance of the test negatively. Other groups also identified candidate biomarkers of 
GH abuse detection [27-32], which are summarized in Table 1. Although a high number 
of candidate biomarkers has been identified, these candidates still need to undergo a 
similar validation procedure as done by the GH-2000 and GH-2004 teams including a 
large set of reference samples and covering all possible confounding factors, such as 
age, sex, effects of exercise, nutrition and injury. Despite the thorough validation of the 
biomarker approach for human GH detection using the IGF-1 and PIIINP biomarkers, the 
test has not been implemented yet for official anti-doping testing. WADA states that prior 
to implementation, it has to be proven that the test can withstand scientific and legal 
challenge [64].
3.2.2.2 Equine somatotropin
Somatotropin administration also plays a role in equine sports, where it is abused for 
performance enhancement. Equine ST (eST) has effects on many target tissues and 
regulates and modulates different protein concentrations. Thus, changed concentrations of 
these target proteins are indicative for eST abuse and these candidate biomarkers can be 
used for abuse detection. Proteomic investigations revealed increased IGF-1 and IGFBP3 
biomarker levels after eST administration and also the effects of confounding factors 
such as age, sex and training are well established [33]. Furthermore, specific antibodies 
produced by the horse against the injected eST were analysed by ELISA and by a SPR-based 
biosensor [33]. 
Whereas RIA quantifications of IGF-1 and IGFBP3 levels are already implemented in 
routine horse racing doping control, it was suggested that anti-eST antibodies could serve 
as an additional biomarker when there is still doubt after IGF-1 and IGFBP3 analysis [33]. 
Anti-eST antibodies are a very selective biomarker for eST abuse, because they are not 
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present in circulation if no hormone was injected, whereas IGF-1 and IGFBP3 are always 
present at a certain endogenous level. Therefore, anti-eST antibodies show good potential 
for improving the sensitivity and specificity of the currently used method.
3.2.2.3 Recombinant porcine somatotropin
In growing pigs, recombinant porcine somatotropin (rpST) can be used for increasing 
muscle growth and to improve meat quality [65]. Several biomarkers of rpST 
administration are known [65, 66], but no analytical method has been developed to 
monitor biomarkers for rpST abuse detection.
3.2.2.4 Recombinant bovine somatotropin
In dairy cows, the administration of rbST increases milk production, but its use is banned 
in the EU [67]. Note that the topic of rbST abuse detection in cattle is indeed ongoing 
and remains urgent: recently, a network of illegal rbST distribution was uncovered [68]. 
Similar to the biomarker-based hGH abuse detection, also markers of the GH/IGF-axis 
and markers of bone and soft tissue turnover are affected by rbST administration (Figure 
2) and can therefore be used for rbST abuse detection. Furthermore, cows injected with 
rbST show an immunological response and form specific antibodies against the hormone. 
A fourplex candidate biomarker panel, consisting of IGF-1, IGFBP2, osteocalcin and anti-
rbST antibodies, was tested on rbST-treated and untreated dairy cows [13]. To be able to 
measure all four candidate biomarkers simultaneously in one serum sample, a multiplex 
FCIA (Section 2.2.2.2) was developed. The candidate biomarkers were measured in serum 
samples from two independent rbST treatment studies. Figure 4 shows the differences in 
the biomarker profiles of rbST-treated and placebo-treated cows. Based on these data, a 
thorough biomarker assessment was done and it turned out, that a combination of only 
two biomarkers, namely osteocalcin and the anti-rbST antibodies is sufficient for detecting 
more than 95 % of the rbST-treated cows truly positive directly after the second rbST 
injection until the end of their treatment period and even thereafter [13]. 
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Figure 4: Biomarker profiles of rbST-treated (left; 1) and untreated (right; 2) dairy cows. 
Biomarkers shown are concentrations of IGF-1 (A), B/B0 levels of IGFBP2 (B), B/Bd levels 
of antibodies against rbST (C) and concentrations of osteocalcin (D). The rbST treatment 
schedules are indicated by two black horizontal bars and decision limit per biomarker by 
the grey horizontal line (reproduced with permission from Ludwig et al. [13]).
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The same anti-rbST antibodies are found in raw milk from rbST-treated cows and the 
response was detectable for at least two weeks after the last treatment with rbST [34]. 
Also when analysing tank milk samples from rbST-treated cows, more than 95 % of 
the samples were detected as being positive for rbST-treatment. The biomarker-based 
screening for detection of rbST abuse in dairy cattle performs according to EU legislation 
[15]. But note that current EU legislation also requires a subsequent confirmatory method 
to identify the abused substance itself after a sample is found suspect in a screening 
procedure. Since rbST differs in one N-terminal amino acid from the endogenous bST, 
it can theoretically be detected as an exogenous compound in the cow’s circulation. 
A confirmatory method based on LC-MS was developed which allowed the detection 
and quantification of rbST in serum obtained from animals treated with rbST [69, 70]. 
Residues of rbST remained detectable until 4 or 11 days after treatment, depending on 
the treatment protocol [71, 72]. The concentrations, however, were below the limit of 
quantification already three days after treatment. Furthermore, for milk, rbST itself could 
only be detected at unrealistic spiking levels [73]. Thus, there is an urgent need for better 
extraction procedures and more sensitive confirmatory analysis methods for detection of 
rbST in serum and in milk.
3.2.2.5 Somatotropins in fish production
In fish production, rainbow trout and tilapia are potentially injected with ST to increase 
body weight and length. Because rbST and rpST are easily available and also show 
growth effects in fish, rbST and rpST are the main forms used as growth enhancers. As 
a physiological response to exogenous rbST hormone treatment, fish show increased 
serum IGF-1 levels as well as a specific immunological response [35, 74]. Interestingly, 
the negative feedback loop of decreased endogenous somatotropin, as observed in 
mammalians, was not affected by rbST treatment in trout and tilapia. In trout, IGF-1 levels 
were determined by RIA and specific endogenous trout anti-rbST antibodies were found 
by Western Blot analysis [35]. In tilapia, anti-rbST antibodies were detected by ELISA [74]. 
The observed altered protein levels as the physiological response upon rbST treatment 
are candidate biomarkers for the indirect proof of the hormone use. So far, no biomarker-
based method for detection of rbST use in fish production was developed and validated. 
Aquaculture control is frequently based on feed and water analysis and does not yet 
include systematic control for somatotropin.
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3.2.2.6 Growth hormone releasing hormone
As shown in Figure 2, growth hormone releasing hormone (GHRH) and its analogues 
elevate growth hormone production and release from the pituitary gland by binding to 
the GHRH receptor. GHRH has a very short half-life of only approximately 7 minutes in 
circulation. One of its synthetic analogues CJC-1295, however, shows an increased half-life 
of up to 8 days and is therefore expected to be abused for performance enhancement [75]. 
As GH levels in circulation are increased after administration of GHRH or its analogues, GH-
dependent biomarkers are also expected to be changed. Therefore, research for biomarker 
discovery focussed on similar biomarkers as for growth hormone abuse itself. Ionescu et 
al. used an immunochemiluminescence assay (ICMA) for GH measurements and a RIA 
for IGF-1 detection. They found increased basal serum GH levels and IGF-1 levels after 
administration of CJC-1295 in healthy men [36]. Sackmann-Sala et al. analysed the same 
samples using 2D-GE and MALDI-TOF and identified several significantly altered proteins, 
such as an ApoA1 isoform, a transthyretin isoform and β-hemoglobin, which were already 
identified as biomarkers for hGH abuse (Section 3.2.2.1) [37]. Moreover, ApoA1 was also 
affected by steroid treatment in veal calves (Section 3.1.1.2), indicating that it is involved 
in a general anabolic mechanism and is therefore a potential protein biomarker [20]. 
Before these identified candidate biomarkers can be implemented for detection of GHRH 
or GHRH analogue detection, they need to be validated on a large reference population 
including as much as possible confounding factors.
3.2.2.7 Ghrelin and growth hormone releasing peptides
Ghrelin and its exogenous mimetics are growth hormone releasing peptides (GHRP) and 
stimulate GH release via the growth hormone secretagogues receptor 1a [38]. Since 
GH concentrations in blood are elevated after ghrelin or GHRP administration, similar 
biomarkers as for GH detection are expected to be affected. Okano et al. tested whether 
the isoform ratio of GH is affected by GHRP-2 treatment as well (Section 3.2.2.1). But this 
approach was not successful to detect GHRP-2 abuse [76], because endogenous growth 
hormone release from the pituitary is stimulated and therefore, no change in the isoform 
pattern was observed. Clinical studies, on the other hand, analysed several candidate 
biomarkers and indeed showed increased levels of GH by chemiluminescence assay, IGF-1 
and IGFBP3 by RIA after treatment with ghrelin or GHRP-2 [38]. In addition to that, a useful 
next step to detect ghrelin or GHRP abuse, is to also include PIIINP measurements, which 
proved to be a good biomarker for GH abuse in the biomarker approach (Section 3.2.2.1).
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3.2.2.8 IGF-1
Since IGF-1 mainly mediates the indirect anabolic actions of GH (Figure 2), it is expected 
to be abused in sports. It is believed that the same biomarkers, which are indicative for 
GH abuse detection, would be indicative for IGF-1 misuse. Therefore, the GH-2000 and 
GH-2004 teams investigated markers of the GH/IGF-axis and markers of bone and collagen 
turnover after administration of a cocktail of recombinant human IGF-1 and recombinant 
human IGFBP3 to healthy volunteers [39]. They found that some protein biomarkers of 
the GH/IGF-axis, such as IGF-2, IGFBP-2 and acid-labile subunit (ALS), are affected by 
IGF-1/IGFBP3 treatment, whereas the markers of bone and collagen turnover remained 
unaffected [39]. Future studies should elucidate if a combination of the investigated 
biomarkers can be a reliable indicator for IGF-1 abuse.
3.3 Metabolic modulators
One of the metabolic modulators mentioned in the WADA 2014 prohibited list is insulin 
[2]. It is released if blood glucose levels rise and facilitates the transport of glucose and 
amino acids into cells and increases protein synthesis, thereby enhances muscle growth. 
Besides its anabolic actions, insulin inhibits catabolic pathways and therewith prevents 
protein breakdown. Its use is banned in sports because of its physiological anabolic 
effects and the impact on a prolonged endurance and accelerated recovery. During insulin 
production, mature insulin and C-peptide, a fragment of proinsulin, are released in an 
equimolar ratio and an altered ratio is expected to be indicative for exogenous insulin. 
Abellan et al. investigated the feasibility of using the ratio of insulin to C-peptide in serum 
[40]. Specific enzyme-amplified sensitivity immunoassays (EASIA) for insulin and C-peptide 
were used and it was found that serum baseline levels of insulin and C-peptide differ in 
between recreational athletes and elite athletes and are also depending on the athlete’s 
discipline. Furthermore, the levels differed according to training season, age, gender 
and body mass index of the athlete. The same variations were found when insulin and 
C-peptide concentrations were analysed in urine [77]. It was concluded that extensive 
future research is needed for considering all possible inﬂuencing factors on insulin and 
C-peptide levels.
Another approach is the detection and quantification of three urinary degradation 
products of insulin by immunoaffinity chromatography and LC-MS [41]. These insulin 
fragments were found to be differently abundant in urine depending on whether insulin 
was endogenously produced or injected. No conclusions were drawn whether these 
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altered insulin fragment profiles can serve as candidate biomarkers for insulin abuse 
detection in athletes. Further studies should elucidate whether different insulin fragment 
profiles are indeed present when comparing healthy untreated individuals and healthy 
insulin-treated individuals thereby excluding the effect of the disease diabetes.
Insulin administration to food-producing animals also increases muscle growth and this 
effect can be further enhanced by co-administration of dexamethasone [49]. Therefore, 
it is expected that insulin is illegally administered to food producing animals. To date, no 
biomarker studies were done for insulin abuse detection. Considering similar mammalian 
physiology, similar biomarkers as in human insulin biomarker studies are expected to be 
indicative for insulin abuse in food production.
3.4 Gene doping
In sports as well as in food production, the use of gene doping is expected to increase 
in the future. Gene doping is the abuse of gene therapy, in which viral vectors carrying 
genes encoding certain proteins are introduced into cells of the athlete or food-producing 
animal [42]. These cells start to produce the encoded proteins and since the protein 
production uses the endogenous cell machinery, most likely, the produced proteins are 
indistinguishable from their endogenous forms. Candidate proteins for gene doping are 
mainly those abused for promoting endurance, such as Epo and vascular endothelial 
growth factor (VEGF) or for increasing muscle mass, such as myostatin inhibitors, 
insulin, GH and IGF-1 [7, 42, 78]. IGF-1 gene transfer was successfully performed in vivo 
to muscle of mice and rat and, additional to increased muscle mass and performance 
enhancement, a local increase in IGF-1 concentration was observed; but no increase of 
IGF-1 concentration was measured in circulation [79]. This situation is cumbersome for 
detection of IGF-1 gene doping, since muscle biopsies would be necessary, which is not 
acceptable for sports doping controls. Myostatin is a protein that inhibits muscle growth. 
If the biological activity of myostatin or its endogenous production is reduced or inhibited, 
biomarkers of the whole myostatin regulation pathway, such as follistatin and myostatin 
propeptide, are affected as well. The levels of these two proteins were analysed using 
immuno-PCR and the ratio of both proteins was shown to be affected in individuals with 
increased muscle mass [42]. Thus, this biomarker strategy is a possible detection method 
for myostatin inhibitor gene doping.
In food production, transgenic approaches are already used to increase growth rates 
in marine animals, such as carp, catfish, salmon and tilapia. When transgenic salmon 
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overexpressing GH was compared to wildtype salmon, altered myostatin levels were 
found in different fish muscle tissues [43]. Moreover, all protein biomarkers related to GH 
administration are expected to be affected as well by the increased circulating GH levels 
in fish. Therefore, protein biomarkers are a valuable tool to monitor whether genetic 
approaches were used to increase muscle growth and productivity.
4 Discussion & Outlook
Biomarker discovery, verification, assay optimization and biomarker validation are the 
phases that have to be followed for the development of a biomarker-based method 
for detection of drug abuse (Section 2.1 and Figure 1). A large range of different illegal 
substances is used in sports and food production for increasing muscle mass and 
enhancing performance or productivity. As outlined in Section 3, similar substances are 
abused in both fields to achieve these common aims and therefore, the same biomarker-
based detection methods may be employed (Section 2.2).
Two main approaches are followed during biomarker discovery: targeted methods, mainly 
applying affinity-based techniques such as immunoassays and untargeted methods, 
applying 2D gel electrophoresis methods combined with MS analysis or LC-MS. Both 
targeted and untargeted methods, successfully discovered candidate biomarkers for 
several different drug treatments in sports doping and veterinary control (Table 1). 
When looking more closely into the data and the expected ranges of specific protein 
concentrations in serum, targeted methods were much more sensitive compared to 
untargeted methods (Figure 5). So far, untargeted methods mainly discovered high-
abundant proteins as candidate biomarkers in the concentration range of around 
20 µg mL-1 up to 100 mg mL-1. Targeted biomarker discovery methods, however, detected 
proteins down to the concentration of around 10 pg mL-1. That means that targeted 
approaches can be a factor of 2x106 more sensitive compared to untargeted methods. 
Though both, targeted and untargeted approaches, are highly specific, MS techniques 
are severely hindered by high concentrations of non-specific proteins. Good depletion 
strategies, however, may allow the detection of low-abundant candidate biomarkers in 
serum. LC-MS-based techniques used in targeted analysis are highly sensitive methods and 
offer great potential for detection of several candidate biomarkers [18].
Certain candidate biomarkers were identified in blood for more than one specific drug 
treatment, such as IGF-1, leucine-rich α-2-glycoprotein or PIIINP, meaning that they are 
indicative for several different groups of abused substances. It was shown that biomarkers 
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used to identify rbST treatment in dairy cattle were also affected by different steroid 
treatments in beef cattle and all different treatments induced a treatment-specific 
biomarker profile [19]. This finding allowed the preliminary conclusion that a certain 
biomarker profile can indicate the group to which the abused drug belongs, which clearly 
highlights the importance of biomarker-based detection strategies.
 
Figure 5: Normal human serum protein concentration ranges of discovered candidate 
protein biomarkers of different drug treatments, analysed with targeted approaches (for 
instance immunoassays) and untargeted approaches (MS-based methods) [80-86].
Even though many candidate biomarkers for several different illegal drug treatments 
were discovered, methods for only a very limited number have been implemented so far. 
In 2000, the indirect approach based on five blood parameters for the detection of Epo 
abuse was applied during the Sydney Olympic Games, but thereafter it was decided that 
only urine sampling is feasible during competition [22]. The blood parameters are still 
monitored, but mainly out of competition. Longitudinal biomarker results of each tested 
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athlete are collected in the blood parameter module of the athlete`s biological passport 
[59]. Using the passport, the blood parameters of one athlete are compared to his or her 
own previous values and therewith, inter-individual variation does not play a role in the 
evaluation of the results anymore. Furthermore, the out-of-competition testing is likely 
to detect more doping attempts, since especially the substances targeting enhanced 
aerobic capacity and faster recovery are mainly used during training. There are also other 
upcoming modules going to be implemented in the athlete´s biological passport, namely 
the steroid and endocrine modules [59]. Since the 2004 Athens Olympic Games, the 
differential immunoassays for determination of the hGH isoform ratio are used and already 
several athletes were charged based on the results of this method [62]. During the 2012 
Olympic Games in London, the biomarker-based approach for rhGH abuse detection was 
applied for the first time during a competition.
Several lessons can be learnt from the successful path of biomarker discovery until full 
method implementation in sports doping control: 
(1) Extensive prior knowledge is available from literature on the physiological effects  
 of certain drugs including hormones, growth factors and others. From this, a lot of  
 information can be retrieved on candidate biomarkers for drug abuse. By doing   
 so, elaborate untargeted approaches can be avoided and the time invested in   
 thorough literature studies for targeted biomarker discovery will pay off. 
(2) A final method format should be chosen, which is widely accepted and applied in  
 testing laboratories. If specific and expensive equipment and additional training  
 are required to perform the final biomarker-based method, the acceptance   
 chances will be very low. 
(3) The availability of bioreagents, such as standard proteins and high-quality   
 antibodies is a key issue for the development of reliable and robust high-  
 throughput biomarker methods. The long-term availability has to be ensured   
 to continuously perform the same high-standard methods for biomarker-based   
 drug abuse testing. 
(4) There is an essential need for properly planned comprehensive validation studies  
 to assess the specificity of the discovered biomarkers (Figure 1). Consider at an   
 early stage what types of samples are needed to perform biomarker validation   
 and include all conceivable confounding factors (age, gender, ethnicity, etc.). From  
 this follows the required number of samples, which can easily comprise many   
 thousands. Therefore, it is advised to establish international collaborations with  
 partners, who can contribute by either providing a fraction of the total  samples  
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 and/or performing a part of the validation experiments.  
(5) Inter-individual variations observed in the analysed biomarkers seem to be a   
 challenge for method implementation. Therefore, either biomarkers should be   
 chosen that are not inﬂuenced by other factors than the drug treatment itself or  
 biomarker panels including several different biomarkers should be analysed,   
 which have to show a specific biomarker profile after drug treatment. The   
 problems arising from inter-individual biomarker differences are avoided,   
 when individual biological passports are used. The same strategy is possible for   
 monitoring longitudinal biomarker profiles of racing horses. In veterinary   
 control, however, the introduction of an animal’s biological passport is not   
 feasible, because of the large number of food-producing animals and the random  
 sampling in monitoring programs. On the other hand, note that animal herds for  
 food production are much more homogenous than individual athletes and   
 therefore, inter-individual differences are expected to play a less important role. 
(6) During the entire process from biomarker discovery up to biomarker validation,  
 it should be aimed for a close collaboration with control authorities who will   
 decide about the final implementation of the biomarker-based method in the   
 regulations. Therewith, it can be ensured that the biomarker-based method fulfils  
 the requirements established in the field. Moreover, foreseen limitations, such as  
 an inappropriate regulatory background, can be communicated and necessary   
 changes can be discussed at an early stage of the developmental phase.
In contrast to successful implementation of several biomarker-based strategies in doping 
control, none of the biomarker-based approaches for detecting drug abuse in food-
producing animals has been implemented so far in routine veterinary control. There are 
various reasons for this situation. To be implemented in official veterinary control, an 
analytical method has to be validated. Until now, no validation approach for performance 
criteria of a biomarker-based method has been proposed. However, with the upcoming 
more risk-based veterinary control programmes, in which the proactive search for yet 
unknown residues is an important part, it is expected that the interest in biomarker-based 
screening will increase. Eventually, this will result in adjusted validation requirements 
specific for biomarker-based screening. Note that, in non-statutory surveillance 
programmes in several EU member states, methods for detecting endogenous antibodies 
produced upon ST treatment in cattle and horses are already being used [7]. Another 
important point for implementation in veterinary control is that so far, a subsequent 
confirmatory analysis for unequivocal identification of the substance of abuse itself or its 
metabolite is required. Likely, a biomarker-based method can still detect drug abuse while 
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the drug levels in the animals body fall below the limit of detection of the instrument used 
for subsequent confirmatory analysis. To solve that issue, there are at least two different 
approaches: on the one hand, additional efforts can be put on confirmatory methods to 
be used in combination with biomarker-based screening methods. Improved sensitivity, 
mass accuracy and mass resolution will be important issues. It is to be expected that 
future generations of MS equipment will be able to provide that level of performance. 
On the other hand, the successful implementation in sports doping control can be taken 
as a guideline to also implement biomarker-based techniques for veterinary control into 
the EU regulations, which are under revision anyway. In doping control, it was shown that 
when efforts for method validation are extended in a way that the majority of confounding 
factors is assessed, then a confirmatory analysis for the abused substance itself is not 
necessary anymore. Therefore, it can be expected that if biomarker-based detection 
methods are comprehensively validated, confirmatory methods may become less crucial in 
future veterinary control.
As seen in the cases of the biomarker approach for hGH abuse detection or the biomarker-
based Epo test, a single biomarker is not sufficient to pinpoint drug abuse, because it is 
also inﬂuenced by confounding factors, such as age, gender and nutrition. To circumvent 
this problem, multiple protein biomarkers are combined in a biomarker panel and then, a 
specifically altered biomarker profile indicates the drug abuse. For future developments, 
it is also possible to combine different types of biomarkers into one panel. A lot of work 
has been done for detection of drug abuse applying metabolomic and transcriptomic 
methodologies [8-10]. Therefore, additional biomarkers do not necessarily have to be 
proteins; they can also be mRNA or metabolites, which are significantly altered after drug 
treatment. Taking together protein (proteomic), mRNA (transcriptomic) and metabolic 
biomarker profiles can further strengthen the analytical power and increase the sensitivity 
for finding more samples from illegally treated athletes or animals.
In summary, a lot of effort has been made to discover candidate biomarkers for many 
different illegal drug treatments in sports doping and veterinary control. Biomarker-
based technologies have several advantages when direct detection methods reach their 
limitations. Nevertheless, proper validation of the candidate biomarker is very complex 
and method development for ultimate implementation requires the availability of high 
quality standards and bioreagents. For the detection of GH and Epo abuse, biomarker 
methods have been successfully implemented in sports control. Even though biomarker-
based detection is accepted in sports doping control as sufficient proof of drug abuse, in 
veterinary control, so far, the unequivocal identification of the abused substance itself 
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is still required. Lessons learnt from the successful path of biomarker discovery until 
full method implementation in sports doping control will facilitate the acceptance of 
biomarker-based detection strategies in veterinary control of food-producing animals in 
the future.
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Abstract
Recombinant bovine somatotropin (rbST) is licensed for enhancing milk production in 
dairy cows in some countries, for instance the United States, but banned in Europe. Serum 
biomarker profiling can be an adequate approach to discriminate between treated and 
untreated groups. In this study a multiplex screening tool on a small set of biomarkers 
for pinpointing recombinant bovine somatotropin (rbST) (ab)use was developed and 
evaluated: insulin-like growth factor 1 (IGF-1), IGF binding protein 2 (IGFBP2) and rbST-
induced antibodies were selected as rbST-dependent markers and combined in one parallel 
assay format. For this, the colour-encoded microspheres were used in a suspension array, 
with a dedicated ﬂow cytometer. Serum samples obtained from an animal experiment 
with rbST-treated and untreated dairy cows were measured with the developed triplex 
immunoassay and biomarker responses on rbST treatment were evaluated. This resulted 
in characteristic treatment-dependent responses for all three individual biomarkers. 
Combining these results with the statistical prediction model k-nearest neighbours (kNN), 
resulted in good discrimination of treated and untreated animals: an overall sensitivity 
(true-positive rate) of 89.1 % and an overall specificity (true-negative rate) of 97.7 % was 
reached. Therefore, this is the first multiplex method which can be applied with high 
confidence for screening of unknown herds of cattle pinpointing at rbST (ab)use.
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1 Introduction
Recombinant bovine somatotropin (rbST) can be used to enhance growth and lactating 
performance in cattle. Within the EU, rbST is banned since 2000 [1], therefore, routine 
screening methods are urgently needed. A liquid chromatography-mass spectrometry (LC/
MS) method for direct rbST detection in blood samples was developed [2], however it 
showed a small detection window, due to the short half-life of rbST in blood [3]. Moreover, 
the similarity with the endogenous hormone (bST, also called growth hormone), the low 
concentrations of bST and rbST in serum, and strong ﬂuctuations of bST hamper the direct 
detection. Therefore, detection of rbST-dependent biomarkers having a longer half-life 
offers a promising alternative, as already reported for steroid abuse and in sports doping 
[4-8]. As rbST strongly inﬂuences the growth hormone/insulin like growth factor I (GH/
IGF-I) axis, the following biomarkers are considered as indicative for administration of 
rbST: insulin-like growth factor-1 (IGF-1) and its binding proteins IGFBP2 and 3, rbST-
induced antibodies, and several markers of bone and collagen turnover [9-12]. So far, 
immunoassays detecting single rbST-related biomarkers were developed on different 
platforms like radio immuno assays (RIA) [9, 13, 14], enzyme-linked immunosorbent assays 
(ELISA) [15-19], Western Blot techniques (WB) [20, 21] and ﬂow cytometric immunoassays 
(FCIA) [22-24]. Looking at single biomarkers, by using the above mentioned techniques, 
an indication of potential rbST abuse might be obtained. However, a much more powerful 
screening tool can be designed by combining multiple biomarkers into a multiplex assay 
format. The advantage of biomarker screening in serum of dairy cows using ﬂow cytometry 
in comparison to surface plasmon resonance (SPR)-based techniques was demonstrated 
recently [22]. Using colour-encoded microspheres in a suspension array format, in theory 
100 different analytes can be detected simultaneously with high throughput in minimal 
sample volume. In this study, we evaluated the suitability of this technique for multiplex 
detection of rbST-related biomarkers: IGF-1, its binding protein IGFBP2 and rbST-induced 
antibodies. This set was selected from literature as it includes two biomarkers with a quick 
response upon rbST treatment (IGF-I and IGFBP2) and one with a long half-life (rbST-
induced antibodies), i.e., together offering the possibility of a prolonged detection window. 
The development of a biomarker-based method for rbST (ab)use required the analysis of a 
large population of untreated cow samples to determine endogenous background levels, 
and the biological variation of each biomarker. Decision limits were then established. Next, 
the applicability of the developed triplex assay was demonstrated with serum samples 
from rbST-treated and untreated cows. Using the statistical prediction tool k-nearest 
neighbours (kNN), the origin of serum samples, treated or untreated, was predicted based 
on single biomarker analysis and combined biomarker analysis. Finally, both biomarker 
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analysis approaches were compared on their capabilities for pinpointing rbST (ab)use in 
dairy cattle.
2 Experimental
2.1 Materials and instruments
Posilac® 500 mg single-dose syringes and syringes with only the slow-release formula 
were purchased from Monsanto company (St. Louis, MO). Hydrochloric acid, potassium 
phosphate, sodium azide, sodium chloride, sodium hydroxide, sodium phosphate, Tween 
20 and the ultrasonic cleaner were purchased from VWR International (Amsterdam, 
The Netherlands) and glycine was from Duchefa (Haarlem, The Netherlands). 
N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) was supplied by Fluka (Steinheim, 
Switzerland) and sodium dodecyl sulfate (SDS) by Serva (Heidelberg, Germany). 
Bovine serum albumin (BSA), insulin-like growth factor-I (IGF-I; human recombinant), 
2-(N-morpholino)ethanesulfonic acid (MES hydrate) and N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (EDC) were purchased from Sigma-Aldrich Chemie 
(Zwijndrecht, The Netherlands). Monsanto rbST standard was obtained from the 
National Hormone & Peptide Program (NHPP) of Dr. Parlow (Torrance, CA). Insulin-like 
growth factor binding protein-2 (IGFBP-2; bovine recombinant) was purchased from 
IBT (Reutlingen, Germany). Mouse anti-IGF-1 was supplied by Spring Bioscience (clone 
SPM406, Fremont, CA) and the rabbit anti-IGFBP-2 was from USBiological (Swampscott, 
MA). R-Phycoerythrin (PE)-labelled goat anti-bovine immunoglobulins (GAB-PE) were from 
Santa Cruz Biotechnology (Santa Cruz, CA) and R-Phycoerythrin (PE)-labelled goat anti-
mouse immunoglobulins (GAM-PE) and goat anti-rabbit immunoglobulins (GAR-PE) were 
purchased by Prozyme (San Leandro, CA). MultiScreen HTS filter plates were purchased 
from Millipore (Amsterdam, The Netherlands). Protein Lobind Tubes (1.5 mL) and a 
table centrifuge model 5810R were supplied by Eppendorf (Hamburg, Germany). The 
Luminex 100 IS 2.2 system consisting of a Luminex 100 analyser and a Luminex XY Platform 
programmed to analyse a 96-well plate, was purchased from Applied Cytometry Systems 
(ACS, Dinnington, Sheffield, South Yorkshire, UK). SeroMAP microspheres (sets 025, 050 
and 078) and sheath ﬂuid were purchased from Luminex (Austin, TX). The Snijder test 
tube rotator was purchased from Omnilabo International (Breda, The Netherlands). The 
microtiter vari-shaker was purchased from Dynatech (Guernsey, UK).
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2.2 Sample materials
Eight 5 year old Holstein dairy cows were divided into two groups. After two weeks 
adaptation, treatment consisted of subcutaneous injections of 500 mg rbST in a slow-
release formula for the first group (a-d, referred to as rbST-treated) and the slow-release 
formula only for the second group (e-h, referred to as untreated). The cows were injected 
with a two week interval four times and subsequently twice with a one week interval. 
During the two week adaptation period, blood samples were collected weekly. During 
the treatment period blood samples were collected a day before, a day after and a week 
after injection and after the last injection, blood samples were collected weekly for four 
more weeks. Unfortunately, one untreated cow (denoted e) died in the beginning of the 
animal experiment, due to swollen hocks, which led to general inﬂammation and sepsis. 
Therefore, in this experiment results could be obtained for 4 treated and 3 untreated 
cows. The experimental procedure was authorized by the ethical committee of the Faculty 
of Veterinary Medicine, Ghent University.
In addition, blood samples were taken from 20 healthy, lactating cows varying in the age of 
two to five years, in different stages of their lactating cycle, to reﬂect a normal population 
of untreated dairy cows. Based on the origin of these cows the assumption of being 
untreated with rbST was justified. 
After blood collection, all blood samples were placed at room temperature for 4 h to 
coagulate. Then, samples were centrifuged for 10 min at 3000 g, and serum samples were 
collected and stored at -80 °C until further use. 
2.3 Pretreatment of serum samples
For the generic ﬂow cytometric immunoassay (FCIA) sample preparation procedure [22, 
24], serum samples were pretreated by adding 25 µL glycine solution (27.5 mM glycine 
pH 0.5 (pH adjusted by addition of HCl)) to 25 µL of serum sample or standard solution 
in a polypropylene tube under constant vortexing. Samples were then incubated at room 
temperature for 60 min. After incubation, 50 µL glycine-SDS solution (400 mM Glycine, 
0.3 % m/v SDS, pH 10 (pH adjusted by addition of NaOH)) was added under constant 
vortexing. Samples were further diluted with 0.1 % BSA in PBST to a final dilution of 
80-times. No further preparation was needed prior to the FCIA.
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2.4 Microsphere preparation for the ﬂow cytometric immunoassay (FCIA)
IGF-1, rbST standard and IGFBP2 were coupled to seroMAP microsphere sets 025, 050 and 
078, respectively, according to Bremer et al. [22]. Brieﬂy, for each microsphere set 2.5 x 106 
microspheres were coupled with a two-step carbodiimide reaction using 500 μL of a 
100 µg mL-1 protein solution in MES buffer for IGF-1 and rbST, and 500 μL of a 10 µg mL-1 
protein solution in MES buffer for IGFBP2. After coupling, the microspheres were stored in 
blocking buffer (PBS, 0.1 % BSA, 0.02 % Tween 20 and 0.05 % NaN3) at 2-8 °C in the dark 
until use. Under these storing conditions, microspheres were stable for more than one 
year. 
2.5 FCIA procedure 
Standards and sera were pretreated as described (paragraph 2.3). One hundred μL of 
the pretreated and diluted serum samples or standard solutions were added to a filter 
bottom microtiter plate. Hereafter, 10 µL antibody mixture, containing 1500 times diluted 
anti-IGF-1 and 25000 times diluted anti-IGFBP2 antibody was added and incubated for 15 
min on a microtiter plate shaker. Then, microspheres (10 µL diluted suspension containing 
about 1250 microspheres per microsphere set) were added to each well and incubated 
for 1 hour on a microtiter plate shaker. After incubation, the plate was centrifuged (1 min 
at 130 g) and the microspheres were washed with 200 µL PBST. After washing, 125 µL PE-
labelled antibody mixture containing 625 times diluted GAM-PE, 1000 times diluted GAR-
PE and 1000 times diluted GAB-PE, was added and incubated for 30 min on a microtiter 
plate shaker. After this incubation step, the plate was centrifuged and 125 µL of PBST was 
added per well. Then, the microspheres were detected, according to bead assay type and 
PE-label in the ﬂow cytometer (1 µL s-1 was measured until 100 events per microsphere set 
were reached with a maximum of 50 μL well-1). 
2.6 In-house validation study of the developed FCIA
As an in-house validation study, the intra- and inter-assay precision of the individual 
biomarkers in the triplex FCIA were assessed. The intra-assay variation was calculated 
by averaging the percentaged standard deviation of each sample obtained by mean 
ﬂuorescence intensity (MFI) signals of a 10-times repeated triplex FCIA on 8 serum 
samples obtained from 7 cows. The inter-assay variation was calculated by averaging the 
percentaged standard deviation of each sample obtained by duplicate measurements of 
the same 8 sera at 9 different days, using B/B0 results for the IGF-1 and IGFBP2 assay and 
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normalized values as described in the next paragraph for rbST-induced antibodies.
2.7 Signal normalization for rbST-induced antibodies
Due to the lack of standard for rbST-induced antibodies, the daily variations in assay 
performance and technical performance of the Luminex 100 IS 2.2 system, a normalization 
step to enable in between days comparison of signals from rbST-induced antibodies is 
needed. As the 8 sera used for the in-house validation study were measured in every 
experiment, MFI signals of these 8 sera were used for normalization: responses of the 8 
sera were averaged and responses of the measured samples were divided by that average. 
2.8 Assessment of decision limits
To be able to discriminate between treated and untreated dairy cows, a decision limit is 
needed for each biomarker. For assessing the decision limits with most accuracy, sera from 
27 untreated dairy cows (20 untreated cows and 7 from the animal experiment during 
their adaption period) were measured with the triplex assay. For IGF-1 concentrations 
were used for the calculations, for IGFBP2, B/B0 values were used due to the absence 
of a pure standard for obtaining a calibration curve, and for rbST-induced antibodies, 
median ﬂuorescence intensities (MFI) were used. Concentrations, B/B0 values and MFIs 
were averaged and the standard deviation determined respectively. Decision limits with 
95 % confidence were calculated. Theoretically, IGF-1 concentrations increase due to rbST 
treatment [10, 12, 25], therefore, 2-times standard deviation were added to the average 
IGF-1 concentration. IGFBP2 concentrations theoretically decrease due to rbST treatment 
[12], which results in less inhibition of maximum MFI signals (B0) and consequently in 
higher B/B0 values. Therefore, 2-times standard deviation was added to the average B/B0 
value. RbST-induced antibodies could be formed due to rbST treatment [23, 24], therefore 
2-times standard deviation were added to the average MFI signal. 
2.9 Statistics
To assess the suitability of the combination of the three analysed biomarkers is already 
capable to predict rbST abuse, a k-nearest neighbours prediction model in the R 
environment [26] was used. B/B0 values for IGF-1 and IGFBP2 as well as MFI signals for 
rbST-induced antibodies for every sample from the animal experiment were included in 
the data analysis. First of all, the whole data set was divided into a training and test set 
by using a stratified repeated random sub-sampling approach, which means that 70 % of 
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the rbST-treated and 70 % of the untreated samples were chosen for the training set and 
the remaining 30 % of both groups for the test set. Subsequently, B/B0 values and MFI 
signals of the training set were auto-scaled and a kNN model was built using the training 
dataset. The optimal number of k (1 ≤ k ≤ 10) was chosen based on the bootstrapping 
approach leaving out 10 % of the training data (randomly with replacement), which was 
repeated 10-times [27] and the resulting model was tested by predicting the remaining 
auto-scaled test set data. Correctly and falsely predicted results were evaluated carefully. 
To obtain an average performance of the kNN model, this procedure was repeated 10000 
times; each time different randomly chosen training and test sets were applied and an 
overall sensitivity (true-positive rate), specificity (true-negative rate) and misclassification 
rate could be calculated for every sample, for every time point and for the whole animal 
experiment.
3 Results and discussion
3.1 Development of the triplex FCIA
For the development of the triplex screening assay, three single immunoassays were 
combined, the previously developed IGF-1 assay [22], the assay for rbST-induced 
antibodies [24] and a newly developed IGFBP-2 assay. Despite the fact that IGF-1 and 
IGFBP2 are indirect competitive assays and the assay for rbST-induced antibodies is 
an indirect assay, one single straight forward approach in terms of pretreatment and 
incubation times was feasible. Therefore, the colour-encoded microspheres, primary 
antibodies and secondary antibodies from the individual assays were simply mixed (Figure 
1). This approach, however, led to an increase in MFI signal of approximately 150 % for 
serum samples measured in the multiplex IGF-1 and IGFBP2 assays, compared to the 
same samples analysed in singleplex format, while no increased signal was observed 
for the standard solution (B0). This phenomenon might be caused by serum antibodies 
that directly bind to the microspheres unspecifically [28], whereas the standard solution 
only consisted of a 80 mg mL-1 BSA in PBS. No inﬂuence of multiplexing was found on the 
detection of rbST-induced antibodies. To further investigate the source of the increased 
signal, the inﬂuence of the individual primary antibodies and the individual secondary 
antibodies in combination with or without primary antibodies on all three microsphere 
sets, were tested. This pointed to unspecific binding of PE-conjugated secondary 
antibodies to all three microsphere sets, in particular GAR-PE and GAB-PE, as the cause 
of the increased MFI signals. Therefore, to decrease this background, the PE-coupled 
secondary antibodies were diluted more until MFI signals were just above 1000 MFI for the 
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blank standard. Thus, the main modification of the triplex conditions versus the singleplex 
assays were secondary antibody dilutions for GAM-PE, GAR-PE and GAB-PE of 625, 1000 
and 1000 times, respectively, instead of the former 625, 375 and 100 times dilutions. By 
doing so, the increase in MFI signals upon multiplexing became less than 2 %.
Figure 1: Triplex assay format, the indirect format for IGF-1 and IGFBP2 and direct format 
for antibodies formed against rbST, all combined within one well. 
3.2 In-house validation study of the developed triplex FCIA
For all three assays, high repeatability in both intra-assay and inter-assay variation was 
assessed. Average coefficients of variation of 5.4 %, 5.4 % and 6.5 % in intra-assay- and 
5.3 %, 4.3 % and 7.5 % in inter-assay variation for the detection of IGF-1, IGFBP2 and 
rbST-induced antibodies respectively were found. This is in very good agreement with the 
formerly found variations in the IGF-1 singleplex assay.[22]. 
3.3 Triplex FCIA applicability to real samples
As the ultimate goal is to detect rbST abuse with a biomarker-based method, the 
applicability of the triplex FCIA was tested.
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3.3.1 Establishment of decision limits
For determination of IGF-1 concentrations, a calibration curve was recorded and used to 
calculate IGF-1 concentrations in sera of the 27 untreated cows (data not shown). Average 
IGF-1 concentrations of 94 ± 21 ng mL-1 were found, resulting in an IGF-1 decision limit 
of 136 ng mL-1. As no recombinant IGFBP2 suitable for obtaining a good calibration curve 
was available, decision limit was determined on MFI signals normalized on the maximum 
MFI signal (B0). For IGFBP2, this resulted in a B/B0 of 0.43 ± 0.04 resulting in an IGFBP2 
decision limit of 0.51. For the decision limit of rbST-induced antibodies, an average MFI 
signal of 193 ± 37 was found resulting in a decision limit of 266 MFI. 
For evaluating the applicability of the assays, sera of the animal experiment (4 rbST-treated 
and 3 untreated dairy cows) were analysed and results were compared to the decision 
limits as shown in Figure 2. As expected, for IGF-1 and IGFBP2, a rapid upcoming and 
decaying response, and for rbST-induced antibodies a response with a long half-life were 
observed. All three biomarkers showed specific characteristics in their response upon rbST 
treatment, together offering a wide detection window with great potential.
3.3.2 Biomarker IGF-1
Following rbST treatment, IGF-1 concentrations were elevated in all four treated cows 
(Figure 2A). This elevation was, however, only for a short period of time in all treated 
animals. Serum samples taken on the first day after the first treatment already showed an 
increase in IGF-1 concentration with the highest IGF-1 concentrations seen in sera taken 
one week after treatment. Then, concentrations declined towards the initial concentration 
as it can be seen in sera taken two weeks after treatment. In human serum this increase 
was also observed, however, only for two days after GH treatment [29], whereas similar 
responses were determined in lactating cows before [30]. Although the increase in IGF-1 
concentration is clearly seen in all 4 cows (a-d) after the last rbST treatment, only a part 
of the serum samples tested showed IGF-1 concentrations beyond the decision limit. 
Therefore, 37 % of the serum samples were determined as true-positive and subsequently 
63 % were classified as false-negatives (Table 1A). The untreated cows, as expected, 
showed no increase in IGF-1 concentration, leading to a true negative rate of 100 %.
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Table 1A: Classification of serum samples from the animal experiment based on the single 
biomarker results in the triplex FCIA assay. Table 1B: Average classification based on the 
single biomarker results.
A. B.
 Untreated rbST-treated Average prediction
Biomarker True-
negative (%)
False-
positive (%)
True-
positive (%)
False-
negative (%)
Classified 
correct (%)
Classified 
incorrect 
(%)
IGF-1 100 0 37 63 64 36
IGFBP2 90 10 31 69 56 44
α-bST 86 14 80 20 83 17
3.3.3 Biomarker IGFBP2
The rbST treatment was also reﬂected by the results from the IGFBP2 assay. As 
described in literature, IGFBP2 concentrations decreased due to rbST treatment [9, 31]. 
Consequently, maximum MFI signals (B0) were inhibited less in sera of rbST-treated 
animals than in sera of the untreated animals yielding in general an increased B/B0 
response due to the decreased IGFBP2 levels. The first and most pronounced IGFBP2 
response upon treatment was found one week after the rbST treatment (Figure 2B); 
i.e., later in time than for IGF-1. Two weeks after treatment IGFBP2 signals were back to 
original signals. In literature, only responses to daily rbST injections were studied, resulting 
in a return to concentrations within 4 days after rbST treatment cessation [9]. In this study 
however, responses to the slow-release rbST formula were studied. The IGFBP2 assay 
showed responses upon rbST treatment in three out of the four rbST-treated cows (a, 
c and d), but only a part of the serum samples taken from treated animals showed a B/
B0 higher than the decision limit. Therefore, 31 % of the serum samples were classified 
true-positive, whereas subsequently 69 % were tested as false-negative. The sera from 
untreated animals f and h, were all true negative; only some serum samples of the 
untreated animal g showed less inhibition, yielding a total of 90 % true-negative samples 
and 10 % false-positives (Table 1A). 
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Figure 2: Effect of rbST treatment on serum biomarker levels of dairy cows in time. 
Time points of treatment (rbST-formula or matrix-formula) are marked by arrows. IGF-
1 concentrations (A), IGFBP2 B/B0 values (B) and normalized signals of rbST-induced 
antibodies (C) are shown for rbST-treated animals a (open diamond), b (open square), 
c (open circle) and d (open triangle), and untreated animals f (closed square), g (closed 
triangle) and h (closed circle).
3.3.4 Biomarker rbST-induced antibodies
Two weeks after the first rbST treatment, an increase in antibodies specific for rbST was 
clearly seen (Figure 2C). This increase in rbST-induced antibodies was stable for a longer 
period of time, i.e., no MFI signal decline to start values in between rbST injections was 
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seen. Even four weeks after the last rbST treatment, MFI signals for rbST-treated animals 
a, c and d were still beyond the decision limit, the maximum time point being investigated. 
This resulted in a true-positive rate of 80 % and subsequently in a 20 % false-negative rate. 
These results are in agreement with literature [17, 32] where 70-80 % of rbST-treated cows 
responded with antibody production. The untreated cows, f and h were tested negative 
and only for cow g some serum samples were found just above decision limit. This resulted 
in a true-negative rate of 86 % and a false-positive rate of 14 % (Table 1A). 
3.3.5 Average classification of serum samples from (un)treated cows based on 
single and multiple biomarkers
Summarizing, for IGF-1, IGFBP2 and rbST-induced antibodies respectively, on average 
64 %, 56 % and 83 % of the tested samples were classified correctly (Table 1B). According 
to Commission Decision 2002/657/EC a 95 % true-positive rate is needed for screening 
assays. None of the single biomarkers on its own can pinpoint rbST abuse with that 
confidence. Combining results of the three biomarker assays, however, could increase the 
confidence rate for pinpointing rbST abuse. A statistical prediction model, the k-nearest 
neighbours (kNN) algorithm, was used to discriminate between rbST-treated and untreated 
animals. After building kNN models on all triplex serum sample data, an overall sensitivity 
(true-positive rate) of 89.1 % and specificity (true-negative rate) of 97.7 % were obtained 
(Table 1C). 
Table 1C. Classification of serum samples based on all three biomarker results following 
kNN statistics.
C.
kNN statistic prediction
Classified correct 
(%)
Classified 
incorrect (%)
Untreated 97.7 2.3
rbST-treated 89.1 10.9
Most of the false-negative results (10.9 %) occurred two weeks after the beginning of 
the rbST treatment and three and four weeks after termination of the treatment. False-
negative results at the beginning of the treatment period could be accounted to IGF-1 
and IGFBP2 levels, which declined rapidly after injection, and the antibody titres, which 
did not increase that much after the first rbST treatment. After multiple treatments, as to 
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be expected in practice, the false-negative rate became lower. Three to four weeks after 
termination of the rbST treatment, the prediction power of the model diminished for the 
same reasons (Figure 3). Overall a correct prediction of 93.6 % was observed. Further 
improvements of this biomarker triplex screening method can be achieved by simply 
adding additional biomarkers.
Figure 3: Prediction of correct and incorrect classification, using kNN modelling. Results of 
all serum samples taken in the animal experiment were categorized by sampling day and 
used for building the model and predict classification. Time points of treatment (rbST-
formula or matrix-formula) are marked by arrows.
4 Conclusion
A unique multiple biomarker FCIA assay has been developed to pinpoint rbST (ab)use in 
serum samples of dairy cows. Individual immunoassays could be combined into a robust 
triplex format with only minor modifications. Thus, a reproducible and sensitive platform 
was obtained. The developed triplex FCIA enables pinpointing rbST abuse by combining 
results of three biomarkers, IGF-1, IGFBP2 and rbST-induced antibodies. IGF-1 and IGFBP2 
biomarkers responded rapidly after the first rbST injection, while responses for rbST-
induced antibodies were characterized by a long half-life. For that reason, the combination 
of these three biomarkers resulted in a very long detection window. The individual 
biomarkers yielded on average correct classification of 64 % for IGF-1, 56 % for IGFBP2 
and 83 % for rbST-induced antibodies in serum samples. A kNN prediction model build on 
the combined triplex data, enabled even a 93.6 % correct prediction rate. Therefore, this 
triplex FCIA provides a detailed biomarker profile in serum, ultimately pinpointing rbST 
abuse in cattle with the highest possible confidence. 
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Abstract
Biomarker profiling, as a rapid screening approach for detection of hormone abuse, 
requires well selected candidate biomarkers and a thorough in vivo biomarker evaluation 
as previously done for detection of growth hormone doping in athletes. The bovine 
equivalent of growth hormone, called recombinant bovine somatotropin (rbST) is  
(il)legally administered to enhance milk production in dairy cows. In this study, first a 
generic sample pretreatment and 4-plex ﬂow cytometric immunoassay (FCIA) were 
developed for simultaneous measurement of four candidate biomarkers selected from 
literature: insulin-like growth factor 1 (IGF-1), its binding protein 2 (IGFBP2), osteocalcin 
and endogenously produced antibodies against rbST. Next, bovine serum samples 
from two extensive controlled rbST animal treatment studies were used for in vivo 
validation and biomarker evaluation. Finally, advanced statistic tools were tested for the 
assessment of biomarker combination quality aiming at to correctly identify rbST-treated 
animals. The statistical prediction tool k-nearest neighbours using a combination of the 
biomarkers osteocalcin and endogenously produced antibodies against rbST proved 
to be very reliable and correctly predicted 95 % of the treated samples starting from 
the second rbST injection until the end of the treatment period and even thereafter. 
With the same biomarker combination, only 12 % of untreated animals appeared false-
positive. This reliability meets the requirements of Commission Decision 2002/657/EC 
for screening methods in veterinary control. From the results of this multidisciplinary 
study, it is concluded that the osteocalcin – anti-rbST-antibodies combination represent 
fit-for-purpose biomarkers for screening of rbST abuse in dairy cattle and can be reliably 
measured in both, the developed 4-plex FCIA as well as in a cost-effective 2-plex 
microsphere-based binding assay. This screening method can be incorporated in routine 
veterinary monitoring programmes: in the European Union for detection of rbST abuse and 
in the control of rbST-free dairy farms in the United States of America and other countries.
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Introduction
Many different techniques are available for detection of hormone abuse in sports doping 
and veterinary control, which all have to fulfil the requirements to be reliable, comparably 
fast and affordable. Biomarker profiling was suggested as a rapid screening approach for 
detection of doping practices because of its many advantages over the direct detection of 
the particular abused substances [1]. Biomarker profiles are indicative for more than one 
administered agent as they reﬂect the physiological effect, hence, the abuse of unknown 
compounds can also be detected [1, 2]. Furthermore, in many cases, the analysis of 
biomarker profiles enables the detection of abused substances for a longer time period, 
because the biological effect lasts longer than the abused substance itself can be detected 
in the body [3, 4]. A lot of work was focused on the identification of indicative biomarkers 
and the development of assays for detection of those [2, 5-10]. But the suitability and 
discriminative power of each biomarker has to be evaluated in controlled studies where a 
treated group is compared with an untreated one [11-13].
Extensive studies were done for the biomarker-based detection of recombinant 
somatotropin (ST; or growth hormone, GH) in sports doping, where ST is abused by 
athletes for their performance enhancement [14-18]. A similar screening approach can 
be chosen for the detection of recombinant bovine ST (rbST) abuse in dairy cattle, where 
the hormone is administered for enhanced milk production [19, 20]. The administration 
to dairy cattle is approved by the U.S. Food and Drug Administration in the United States 
of America and allowed in several other countries [21]. But treating cows with rbST is 
forbidden in the European Union since 1999 because of animal health and welfare reasons 
[22]. By European regulation, screening and confirmatory methods should be available 
for the detection of (ab)used veterinary drugs, with for screening, a maximum false-
compliant rate of 5 % (β error) [23]. In contrast to the well-established human biomarker-
based screening approach, the issue of rbST-dependent biomarker detection is still in its 
infancy: actually, routine veterinary control for rbST abuse has not been implemented 
at all, despite the EU ban. So far developed methods which detect rbST directly, such 
as immunoassays or mass spectrometry-based methods, suffer from the short half-life 
of rbST. Although biweekly injections containing slow-release formulations are used to 
prolong the presence of rbST in the cows’ body, the protein levels in treated animals 
cannot be distinguished from the background level throughout the whole two-week inter-
injection period and large inter-individual differences in blood rbST levels were reported 
[19, 20, 24-27]. Furthermore, rbST immunoassays were not capable to distinguish the 
almost identical recombinant and endogenous forms of bST [19, 20, 24, 25] and mass 
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spectrometry-based methods on the other hand required very tedious sample preparation 
procedures [26, 27]. For screening of rbST in cattle, a few biomarker-based methods were 
developed, but focused on a single candidate biomarker only [4, 9, 28-30]. In a recent 
study, three candidate biomarkers were combined in one screening tool, but the <5 % 
false-compliant rate target could not be achieved [31]. Nevertheless, biomarker-based 
screening for rbST can be considered a very promising start for detecting rbST abuse in 
dairy cows.
Biomarkers indicative for ST abuse are described in detail in literature and several of them 
are listed and referenced in Table 1. From these, we selected four different candidate 
biomarkers. These included two biomarkers of the IGF-1 axis, which respond quickly 
upon rbST treatment, namely insulin-like growth factor-1 (IGF-1) and IGF binding protein 
2 (IGFBP2). The other two biomarkers were expected to show a delayed but long-lasting 
response; these are osteocalcin (marker of bone turnover) and antibodies which are 
endogenously produced against rbST (anti-rbST-antibodies).
Table 1: Candidate biomarkers for ST abuse and their expected response upon ST 
treatment in human and cows.
Biomarker response to ST described for reference
Acid labile subunit (ALS) increase human [45]
Anti-rbST-antibodies increase bovine [30, 31, 33, 34]
Apolipoprotein A-1 (APOA1) decrease human [8]
C-terminal cross-linked 
telopeptide of collagen I (ICTP) increase human [13, 45, 46]
C-terminal propeptide of 
procollagen I (PICP) increase human [13]
Hemoglobin α-chain (HbA1) increase human [6]
IGF binding protein 2 (IGFBP2) decrease bovine [31, 47]
IGF binding protein 3 (IGFBP3) increase human [45]
Insulin-like growth factor (IGF-1) increase human [45, 46]
Inter-alpha-trypsin inhibitor heavy 
chain H4 (ITIH4) decrease human [8]
Leucine-rich α-2-glycoprotein 
(LRG) increase human [9]
N-terminal propeptide of 
procollagen I (PINP) increase human [12, 45]
N-terminal propeptide of 
procollagen III (PIIINP) increase human [12, 13, 45, 46]
Osteocalcin increase human [12, 13]
Transthyretin (TTR) increase human [8]
α-1 antitrypsin (AAT) increase human [8]
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To be able to screen for these four candidate biomarkers in serum, we developed a 4-plex 
ﬂow cytometric immunoassay (FCIA) enabling parallel biomarker analysis in a single 
sample. For IGF-1, IGFBP2 and osteocalcin, a competitive inhibition assay format was 
chosen, where the respective candidate biomarker is covalently coupled to one set of 
colour-encoded microspheres. The different microsphere sets can be discriminated by 
a red laser (Figure 1). Biomarker-specific and generic ﬂuorescent secondary antibodies 
are used for quantification with a green laser. Due to the inhibition format, high sample 
biomarker concentrations yield low ﬂuorescence signals and vice versa. For the anti-
rbST-antibodies, a direct assay format with an rbST-coupled colour-encoded microsphere 
set was used, where the anti-rbST-antibodies bind and can be detected by ﬂuorescently 
labelled anti-bovine detection antibodies. Here, a high biomarker level leads to a high 
ﬂuorescence signal.
With this 4-plex FCIA, biomarker profiles were measured in serum samples. Based on 
the biomarker profiles of 67 untreated animals from different origins, we assessed the 
inter-individual and physiological variability of these biomarkers within dairy cattle and 
determined decision limits, beyond which a sample could be classified rbST-treated. 
Then, we used a large set of serum samples obtained from two independent controlled 
rbST animal treatment studies to evaluate the discriminative power of each candidate 
biomarker and of all combinations of biomarkers for distinguishing rbST-treated from 
untreated cows. Following thorough statistical evaluations, the value of individual and 
multiple biomarkers was assessed for the prediction of rbST abuse in dairy cows.  
The overall aim of the study was the development and validation of a chemical analytical 
method for rbST-dependent biomarker detection according to European legislation 
for screening methods [23] and a data analysis approach for identifying biomarker 
combinations, which can reliably predict rbST abuse. This aim was reached with the help 
of a statistical prediction model based on the biomarker combination endogenously 
produced antibodies against rbST and osteocalcin.
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Figure 1: Work ﬂow for serum preparation, generic serum pretreatment and 4-plex FCIA 
for serum candidate biomarkers. A detailed description can be found in supplementary 
information. Abbreviations: h – hour, IGF-1 – insulin-like growth factor 1, IGFBP2 – IGF 
binding protein 2, GS I – glycine solution I, GS II glycine solution II, min – minutes, PBST – 
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phosphate-buffered saline with 0.05 % (v/v) Tween-20, PBSTB – 0.1 % (m/v) BSA in PBST, 
PE – phycoerythrin ﬂuorescent label, rbST – recombinant bovine somatotropin, RT – room 
temperature, sec - seconds; Symbols:  incubation time;  vortex;  centrifugation; ↔ 
orbital shaking; o o o free IGF-1, mouse anti-IGF-1 antibody, IGF-1-coupled microsphere;
ooo free IGFBP2, rabbit anti-IGFBP2 antibody, IGFBP2-coupled microsphere; ooo  
osteocalcin, mouse anti-osteocalcin antibody, osteocalcin-coupled microsphere; oo  
bovine anti-rbST-antibodies, rbST-coupled microsphere; Y PE-labelled goat anti-mouse 
antibody;
Y
PE-labelled goat anti-rabbit antibody; PE-labelled goat anti-bovine 
antibody.
2 Results and discussion
For the prediction of rbST abuse in dairy cows, we selected candidate biomarkers based 
on information found in literature (see Table 1). These were markers of the IGF-axis (such 
as IGF-1 and IGFBP2) and bone markers (such as osteocalcin), known to be inﬂuenced by 
somatotropin and previously examined by the GH-2000 group for detecting somatotropin 
abuse in athletes [13, 32]. Furthermore, the immune response of cows treated with 
rbST was examined thoroughly and we used the presence of the specific endogenous 
antibodies against rbST as a biomarker for its abuse [4, 30, 33, 34]. Although PIIINP, a 
marker of collagen turnover, is known to show potential in human and bovine hormone 
abuse detection [10, 18], it has not been included into our biomarker panel yet because of 
the lack of a suitable commercially available standard protein and antibody.
2.1 Development of a 4-plex ﬂow cytometric immunoassay
For the simultaneous detection of these four candidate biomarkers, we developed a 
generic sample pretreatment and 4-plex ﬂow cytometric immunoassay (FCIA). To this end, 
our previously reported 3-plex assay [31] was extended with the biomarker osteocalcin. 
Adding osteocalcin to the existing triplex FCIA did not result in major interferences of any 
of the assay components of the four combined biomarker assays (data not shown). IGF-1 
and osteocalcin concentrations of tested serum samples were calculated based on the 
obtained standard curves in serum-matched buffer (Supplementary Figure 1). The 4-plex 
FCIA is capable of determining IGF-1 and osteocalcin concentrations in the relevant range 
in serum, namely 64 – 400 ng mL-1 for IGF-1 and 32 – 320 ng mL-1 for osteocalcin (note that 
serum samples were diluted 80-times prior to analysis, thus the standard curves cover 
protein concentrations of 0.8 – 5 ng mL-1 for IGF-1 and 0.4 – 4 ng mL-1 for osteocalcin). For 
IGFBP2, the standard protein could not completely inhibit the B0 signal, therefore, we 
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decided to work with normalized responses (B/B0) for the data analysis. For the induced 
anti-rbST-antibodies, we worked with the responses normalized to a single standard serum 
(B/Bd).
The generic sample pretreatment was necessary for releasing IGF-1 from its binding 
protein-complex and preventing nonspecific binding in the detection of anti-rbST-
antibodies. The rather harsh pretreatment protocol did not affect the detection quality of 
osteocalcin, thus it could be adopted for the combined 4-plex FCIA. Note that, adding IGF-2 
in excess, as done in commercially available human IGF-1 immunoassays, did not improve 
the normalized standard curves, nor the detection of biomarker level differences in 
between treated and untreated animals. The developed assay showed high reproducibility 
for all measured candidate biomarkers (Table 2) and a comparable sensitivity to previous 
single biomarker methods [35, 36]. However, the newly developed 4-plex FCIA has several 
advantages, such as the simultaneous measurement of all four markers in one sample 
from one well of a microtiter plate, which saves sample material, work load and time. 
Additionally, only one washing step was required compared to an average of six washing 
steps in a conventional enzyme-linked immunosorbent assay, making the 4-plex FCIA much 
faster and easy-to-use. The whole assay procedure, starting from a serum sample until 
the results from the ﬂow cytometer for all four candidate biomarkers, takes 3.5 hours for 
a whole 96 well microtiter plate. This demonstrates that the 4-plex FCIA is a rapid and 
promising screening tool for the detection of the four candidate biomarkers in serum.
2.2 Single candidate biomarker profiles of untreated and of rbST-treated 
cows
After successful development of the 4-plex ﬂow cytometric immunoassay, decision limits 
for each single candidate biomarker were calculated by analysis of sera from 67 untreated 
dairy cows (see paragraph 3.9.1). Compared to the number of tested athletes in human 
studies, the number of tested control animals may seem to be rather low, but the variation 
within the dairy population is expected to be much lower, because of several reasons: 
First, only female cows have to be taken into account. Second, milking only occurs after 
first calving (usually at 20-24 months of age), thus after puberty, in which levels of IGF-1, 
IGFBP2 and osteocalcin are mainly changed due to growth and are more stable thereafter 
[37-39]. Third, since in this region of Europe mainly Frisian Holstein cows are used for 
milk production, we focussed on this particular race for the development of the test. And 
fourth, we do not need to consider sick animals, since their milk will not be allowed for 
consumption due to the presence of veterinary drug residues and therefore treatment 
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with rbST is useless for sick dairy cows. Thus, the overall relative variation expected in 
dairy cows is anyway much lower than in athletes, where gender, different ethnicities, the 
effect of sports discipline, injury and all age groups need to be considered. 
Table 2: 4-plex FCIA assay performance characteristics for the single candidate biomarkers. 
IC 
50
 relates to 80-times diluted samples.
Candidate biomarker
Performance 
characteristics
IGF-1 IGFBP2 Anti-rbST 
antibodies
Osteocalcin 
IC
50
 [ng mL-1] 1.5 9.5 - 1.1
Precision and 
Ruggedness: 
Interassay 
variation [%]
Intraassay 
variation [%]
 
 
15.7
 
6.4
 
 
7.9
 
5.7
 
 
22.3
 
9.4
 
 
17.1
 
9.5
Decision limit 216 ng mL-1 0.52 B/B0 1.62 B/Bd 160 ng mL-1
Stability The 4plex FCIA can be performed stably over several months by different staff.
Specificity No unwanted interaction in between the assays (analytes and antibodies) 
observed.
Decision limits were 216 ng mL-1 for IGF-1, 0.52 B/B0 for IGFBP2, 1.62 B/Bd for anti-rbST-
antibodies and 160 ng mL-1 for osteocalcin and are shown as green horizontal lines in 
Figure 2. Results of samples exceeding this limit were considered positive.
Then, biomarker profiles of the dairy cows from both animal studies were measured 
(Figure 2). Results of the cows from animal study I are shown in dotted lines whereas the 
results of animal study II are shown in solid lines. Note that the animals from animal study 
I received two additional weekly rbST injections after the biweekly treatment period (the 
treatment schedules of both animal studies are indicated by the black horizontal bars 
above the graphs).
IGF-1 levels were found to be elevated directly after rbST treatment (Figure 2 A.1) and 
returned back to baseline before the next treatment. This short response time was 
observed before in human studies, where IGF-1 concentrations were back to baseline 
one week after termination of somatotropin treatment [32]. Nevertheless, in athletes, 
IGF-1 stayed elevated throughout the treatment period. This difference in IGF-1 response 
to somatotropin treatment could be due to the fact, that athletes were injected daily 
and, although a slow-release formulation was used in the here presented study, the 
biweekly treatment schedule does not reﬂect the same situation of permanently present 
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somatotropin in circulation. IGF-1 levels of untreated animals (Figure 2 A.2) remained 
below the decision limit. The found IGF-1 concentrations are consistent with previously 
reported serum IGF-1 concentrations in dairy cows [31, 40].
IGFBP2 levels (Figure 2B) are expected to decrease upon rbST treatment [32, 41]. The 
IGFBP2 assay is of an inhibition format, thus B/B0 levels are inversely correlated with the 
concentration. Hence, higher B/B0 levels are expected after rbST treatment. For some of 
the rbST-treated cows, a slight increase in B/B0 levels can be observed after treatment 
(Figure 2 B.1) with a decrease to baseline before the next treatment. But this pattern is not 
as pronounced as for IGF-1. Furthermore, only occasionally a value exceeded the decision 
limit. Only the results of one cow were clearly above the decision limit, but these values 
were observed already during the adaptation period. In humans and despite large inter-
individual differences, mean IGFBP2 levels responded quite well upon ST treatment, but 
the athletes were treated daily on three subsequent days [32]. B/B0 levels of untreated 
animals (Figure 2 B.2) remained below the decision limit at almost all times.
For the antibodies, endogenously produced by the cow as an immunological response 
upon rbST treatment [30], a delayed increase in signal was observed (Figure 2 C.1). Most 
of the cows developed antibodies approximately 2 weeks after the first rbST injection 
and a maximum in response could be seen around the third injection (four weeks after 
start of rbST treatment). Thereafter, the responses declined slowly. Zwickl et al. reported 
an increase of antibody formation within the first three months of rbST treatment and a 
decline thereafter, but the amount of rbST administered in their study was much higher 
than recommended by the manufacturer and applied here [34]. For the untreated cows in 
our studies (Figure 2 C.2), only one result was found to be above the decision limit.
For osteocalcin, a slow increase in concentration was observed after rbST treatment 
(Figure 2 D.1) compared to the untreated cows where the concentrations remained below 
the decision limit at almost all times. A similar effect on osteocalcin levels was observed 
in the human GH-2000 study [13]. Osteocalcin concentrations in our studies increased 
consistently in the 8 week treatment period, no gradual decline was observed as for the 
anti-rbST-antibodies. A slow osteocalcin decrease was noticed after rbST withdrawal but 
values remained above the decision limit for some of the cows until the end of the animal 
study.
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Figure 2: Biomarker profiles of rbST-treated (left) and untreated (right) dairy cows. Profiles 
from animal study I (dotted lines) and animal study II (solid lines) are shown. Sera from 
adaption period (3 sera from every cow), treatment period (13 sera per cow from animal 
study I and 9 sera per cow from animal study II) and withdrawal period (5 sera per cow 
from animal study I and 6 sera per cow from animal study II) were measured in duplicate. 
Biomarkers shown are concentrations of IGF-1 (A), B/B0 levels of IGFBP2 (B), B/Bd levels 
of antibodies against rbST (C) and concentrations of osteocalcin (D). The rbST treatment 
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schedules for both animal studies are indicated by two black horizontal bars and decision 
limit per biomarker by the grey horizontal line. Note that cows from animal study II 
received two additional rbST injections after the biweekly treatment period.
For all of the candidate biomarkers large inter-individual physiological differences in 
biomarker levels were apparent as for example seen in the adaptation period of the 
treated animals. IGF-1, IGFBP2 and osteocalcin levels differed quite a lot between 
individual animals. Biomarker levels are known to be inﬂuenced by many factors such as 
age and state of lactation. Nevertheless, the expected variation is much smaller than in 
athletes tested for ST abuse as already discussed above. Note that we accounted for the 
variation in our untreated reference population used to assess the decision limits. Also 
the response upon rbST treatment differed in every individual cow. Some cows showed a 
big increase in IGF-1 levels short after injection while others did not show any response 
above decision limit (non-responders). Also for osteocalcin, some cows hardly showed any 
response after treatment.
The predictive power of each candidate biomarker was assessed by calculating true-
positive rates for all samples from rbST-treated cows in their treatment and withdrawal 
period (Figure 3). False-positive rates were calculated from untreated cows during the 
whole animal experiment (adaptation period samples from all cows and all the samples 
from untreated cows). High true-positive rates were reached by IGF-1 already at the 
beginning of the treatment period. Similar response patterns were observed for both 
studies. Only the double injections in study I led to a changed IGF-1 pattern. Also for the 
anti-rbST-antibodies, high true-positive rates of 75 % were seen after the second rbST 
injection. But the response was study-dependent: while the animals from study I (equal 
age of 5 years) were found positive after the second injection until the end of the study 
period, a gradual decrease of the number of positively found animals was observed in 
study II (age ranged from 2 to 8 years). This could be due to the different ages of the 
animals in study II. We saw that the antibody response tended to be higher in the older 
animals. Younger animals also showed antibody response, which declined more quickly 
than for the older animals. For osteocalcin, as already seen in Figure 2 D.1, some of the 
rbST-treated cows did not show osteocalcin concentrations beyond the decision limit in 
both studies. The increase of true-positive found samples at the end of the treatment 
period in study I was due to the double rbST injections. As already expected from the 
biomarker profiles (Figure 2 B.1), IGFBP2 did not show high true-positive rates, i.e., none 
of the animals from study I and only some animals in study II were found above the 
decision limit. For all of the candidate biomarkers, false-positive rates were quite low, 
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indicating a high specificity of all of the biomarkers towards rbST treatment. Nevertheless, 
none of the candidate biomarkers reached the targeted 95 % true-prediction (<5 % 
false-compliant) rate at any time point required for a screening method according to 
Commission Decision 2002/657/EC [23].
 
Figure 3: Predictive power of each single candidate biomarker for indicating rbST abuse. 
True-positive rates were calculated for all samples from rbST-treated cows in their 
treatment and withdrawal periods of study I and II. False-positive rates were calculated for 
all samples from untreated cows from the two animal studies (adaptation period samples 
from all cows and all the samples from untreated cows). Samples were considered positive 
if their biomarker value exceeded the respective decision limit. The treatment schedules 
of the two controlled animal studies are indicated by black horizontal bars on top of the 
graph. The targeted 95 % true-positive (<5 % false-compliant) rate according to 2002/657/
EC is indicated by the dotted horizontal line.
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2.3 Additive biomarker analysis
Since no single candidate biomarker was capable of predicting 95 % of the rbST-treated 
samples correctly, we tested different possibilities of combining biomarker results for 
improvement of the predictive power of our 4-plex FCIA. One approach to do this is the 
additive biomarker analysis. In Table 3, the number of candidate biomarkers responding 
above decision limit per cow and per time point within the animal studies is shown. As 
already described in paragraph 2.2, there were big inter-individual differences: some cows 
responded in many markers, others only in one or two for some time points. There were 
also two extreme cases: one cow responded in all four tested markers above decision limit 
at one time point and another rbST-treated cow did not show any response above decision 
limit at any day. On the other hand, there were untreated cows, which showed positive 
responses in one of the candidate biomarkers. Figure 4 shows the true-positive rate 
obtained for the rbST-treated cows of both animal studies considering a sample positive, 
when at least one biomarker reacted above the respective decision limit. 
Table 3: Number of biomarkers reacting above the respective decision limit per cow (in 
animal studies I and II) and day of the controlled animal studies. Each row represents one 
individual cow. Vertical dotted lines indicate the treatment time points in both animal 
studies.
 days 1 8 15 16 22 29 30 36 43 44 50 57 58 64 65 71 72 78 85 92 99
0 0 0 0 0 1 1 1 1 1 1 1 1 1 2 2 2 2 2 1 1
0 0 0 1 1 0 0 2 0 0 2 1 2 2 2 2 2 2 2 1 0
0 0 1 2 2 1 3 3 2 2 2 2 3 3 3 3 3 3 2 2 2
0 0 0 0 0 1 1 1 1 1 1 1 2 1 2 1 1 1 1 1 1
0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0
             
 0 0 0 1 1 1 2 1 2 1 1 1 2  1  0 0 0  
1 1 2 2 2 2 1 2 3 3 3 3 2 2 3 1 1 1  
0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1  
0 0 0 1 1 0 1 1 0 0 1 0 0 1 0 0 1 0  
1 1 1 2 2 2 3 4 2 2 3 1 2 3 1 1 1 1  
1 1 1 1 2 2 2 3 2 2 3 2 2 3 2 2 1 1  
 0 0 0 0 0 0 0 0 0 0 0 0 0  0  0 0 0  
0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0  
0 0 0 0 0 0 0 0 0 0 0 0 0 0  0  0 0 0  
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Figure 4: Predictive power (shown as true-positive and false-positive rates) of the additive 
biomarker analysis. True-positive rates were calculated for all samples from rbST-treated 
cows in their treatment and withdrawal periods of study I and II. False-positive rates were 
calculated for all samples from untreated cows from the two animal studies (adaptation 
period samples from all cows and all the samples from untreated cows). Samples were 
considered positive if one of the candidate biomarkers exceeded its respective decision 
limit. The treatment schedules of the two animal studies are indicated by black horizontal 
bars on top of the graph. The targeted 95 % true-positive (<5 % false-compliant) rate 
according to 2002/657/EC is indicated by the dotted horizontal line.
Although the true-positive rate obtained with the additive biomarker analysis was much 
higher than for the single candidate biomarkers, the 95 % true-positive rate required for 
a screening method was only reached at some time points in study I within the biweekly 
treatment period. After the double rbST injection in study I, all of the cows were found 
positive, but this treatment frequency will not be found in real practice. Furthermore, 
also with the additive biomarker analysis, quite some false-positive results were obtained 
throughout the whole study.
2.4 Statistical multiple biomarker analysis
Since the single biomarker analysis and additive biomarker analysis, which were both 
based on decision limits, did not deliver satisfying results for predicting rbST abuse, a 
different biomarker-combining approach was chosen for analysis of the data. K-nearest 
neighbours (kNN), a statistical prediction tool, was used to build a model from one 
group of data (Group A: all animals of animal study II and untreated animals from animal 
study I) and predict the results of Group B (rbST-treated cows of animal study I and 67 
independent untreated cows) on basis of the built model. Eleven different models (one 
for every possible combination of two to four biomarkers) were evaluated to find the 
optimal biomarker combination for rbST abuse prediction. True-positive rates of Group B 
data were calculated for every biomarker combination over the time of the whole animal 
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study and are shown in Figure 5 (Supplementary Table 1 shows corresponding data). Six of 
the eleven different models yielded true-positive rates above the 95 % true-positive rate 
required for a screening method at several time points. For the biomarker combinations 
IGF-1 - IGFBP2 - anti-rbST-antibodies (IBA) and IGFBP2 - anti-rbST-antibodies - osteocalcin 
(BAO), only one time point within the biweekly treatment period was above 95 %. Note 
that in total, samples from eleven time points were obtained and analysed during the 
biweekly treatment period of animal study I. For the biomarker combinations IBAO and 
IA, four and six time points within the biweekly treatment period were above the 95 % 
target respectively. Seven time points above the 95 % target within the biweekly treatment 
period were reached by the prediction models based on the biomarker combinations IAO 
and AO. For the three best performing models (IA, AO and IAO), true-positive rates above 
95 % (<5 % false-compliant) were reached following the second rbST injection. For IA, a 
true-prediction rate of almost 60 % was observed already one week after the first rbST 
injection, whereas AO only showed 30 %, which is in accordance with expectations since 
IGF-1 is a quick responding biomarker and osteocalcin has a delayed response time. Since 
all of the rbST-treated cows were detected by the three best performing models (IA, AO, 
IAO) at the end of the biweekly treatment period, no further increased prediction rate was 
observed due to the subsequent two weekly injections. After withdrawal of rbST, the true-
positive rate of the models based on IA, AO and IAO remained above 95 % for two more 
weeks and then declined to 70 % four weeks after withdrawal. 
Since we used all of the untreated animals of both animal studies for model building, false-
positive rates for the eleven different models were calculated based on the results of the 
67 independent untreated cows (Supplementary Table 2). For the three best-performing 
prediction models IA, AO and IAO, false-positive rates ranged from 10.6 % to 14.7 %, which 
was quite acceptable, since samples screened positive must be analysed by a subsequent 
confirmatory analysis method according to Commission Decision 2002/657/EC anyway 
[23]. The confirmation method is based on the detection of an N-terminal peptide of 
somatotropin, which has a different terminal amino acid in the recombinant form of the 
hormone [26].
We concluded from the results of the here presented studies that the AO biomarker 
combination is the preferred model for predicting rbST abuse. It yielded seven out of 
eleven time points above the 95 % target and if two biomarkers are equally well-suited for 
prediction as three biomarkers, the more simple version is favoured.
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Figure 5: True-positive rates following statistical multiple biomarker analysis. True-positive 
rates, obtained with the prediction models based on the eleven different biomarker 
combinations, were calculated for rbST-treated cows from animal study I in their treatment 
and withdrawal period. The treatment schedules of animal study I is indicated by black 
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horizontal bars on top of the graphs. The targeted 95 % true-positive rate according to 
2002/657/EC is indicated by the dotted horizontal lines.
The results obtained proof that the developed 4-plex FCIA reduced to an AO biomarker 
combination 2-plex FCIA, applied to an in vivo evaluation and combined with a thorough 
statistical multiple biomarker analysis can detect more than 95 % of the rbST-treated 
cows truly positive directly after the second rbST injection until the end of their treatment 
period and even thereafter. This meets the requirements of Commission Decision 
2002/657/EC for a screening assay for the detection of banned veterinary drugs such as 
rbST [23].
When comparing with previously reported results of a 3-plex FCIA combining IGF-1, 
IGFBP2 and anti-rbST-antibodies [31], the models presented here seemingly perform 
somewhat less, especially at the beginning of the rbST treatment but the new models are 
much more realistic: Note that here, two completely independent groups were used for 
model building (Group A) and prediction (Group B), whereas in the 3-plex experiments 
[31], sample data used for prediction were from the same cows as the data on which the 
model was built, leading to an overestimation of true-positive results in that work.
2.5 Discussion
For the first time, to the best of our knowledge, a 4-plex biomarker assay development 
and data evaluation model is presented for the detection of rbST abuse, which fulfils 
the requirements of Commission Decision 2002/657/EC for screening assays [23]. 
Furthermore, the extensive in vivo validation with two independent rbST animal treatment 
studies followed by statistical analysis revealed that a combination of just two candidate 
biomarkers is actually adequate for detection of rbST treatment. Therefore, even a 2-plex 
version (namely the combination of anti-rbST-antibodies and osteocalcin) of our assay 
would already be fit-for-purpose based on the data presented here. 
Nevertheless some issues should be considered. First of all, for obvious ethical and cost 
reasons, the rbST treatment period was limited to 8 weeks in our animal studies, so we do 
not know yet how the prediction models would perform for long-term treated animals. 
As can be seen in Figure 2 C.1, the antibody biomarker response declined somewhat in 
course of the treatment period and we do not know whether this would inﬂuence the 
prediction quality in a prolonged treatment. Second, in the presented animal studies, 
cows were treated with rbST for the first time in their lives and there are no data about 
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biomarker levels during a second treatment period after calving. According to the 
manufacturers’ treatment schedule, dairy cows are treated starting from 9 weeks after 
calving until the end of the lactation (typically a biweekly treatment) and the following 
year again. Eppard et al. and Zwickl et al. reported that repeated treatment periods did 
not cause an immunological memory effect with enhanced antibody production in the 
second treatment period [33, 34]. For both situations, long-term treatment and repeated 
treatment, the IA, AO and IAO biomarker combinations should be tested and possibly 
the inclusion of other biomarkers could be considered. Since blood sampling in routine 
veterinary monitoring programmes might not be justified in some countries, we suggest 
a tiered approach according to Commission Decision 2002/657/EC. This would consist of 
three steps: First, a fast screening for anti-rbST-antibodies in tank milk using our previously 
described milk FCIA [29]. Second, in case of suspicious findings, a more detailed individual 
bovine serum biomarker profiling using the IA, AO or IAO FCIA presented here will provide 
additional evidence, since they are based on more biomarkers and data for individual 
cows. Note, that in practice, a whole stable and not an individual cow is treated with rbST, 
thus increasing the chance of detecting rbST use. And third, for final confirmation of rbST 
itself in serum samples of suspect individual cows, a highly sensitive mass spectrometric 
confirmatory method, which fulfils the 2002/657/EC confirmatory method requirements, 
is to be used [26].
2.6 Conclusion
In this study a multidisciplinary approach was used for the development of an in vivo 
validated screening assay for rbST abuse in dairy cows. Four candidate biomarkers for rbST 
abuse were assessed using a newly developed 4-plex ﬂow cytometric immunoassay, in vivo 
validation studies and advanced statistics. Biomarkers indicative for rbST administration 
were evaluated based on two extensive animal studies with rbST-treated and untreated 
animals and an additional untreated reference population. Different data evaluation 
approaches were tested. The prediction tool kNN using a biomarker combination 
endogenously produced antibodies against rbST and osteocalcin proved to be very 
reliable and correctly predicted 95 % of the treated samples starting from the second rbST 
injection until the end of the treatment period and even thereafter. This reduced 2-plex 
FCIA method (consisting of biomarkers anti-rbST antibodies and osteocalcin) combined 
with the statistical analysis approach was shown to be a fast, reliable and cost-effective 
approach to screen for rbST abuse in dairy cattle. These methods and models can be 
included in routine veterinary control programmes in the European Union for detection of 
rbST abuse and also in the control of rbST-free dairy farms in the United States of America 
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and other countries.
3 Materials and methods
3.1 Ethics statement
Permission for animal study I (EC2007/71) was obtained from the Ethical Commission of 
the Faculty of Veterinary Medicine of Ghent University (Belgium) on basis of the Dutch law 
on animal studies (Wet op de Dierproeven). For animal study II, permission (EC2010-21) 
was obtained from the Ethical Commission of the Animal Science Group of Wageningen 
University and Research Centre in Lelystad (The Netherlands).
3.2 Chemicals and instruments
Ultrasonic bath, monosodium phosphate monohydrate (NaH2PO4 x H2O), potassium 
dihydrogen phosphate (KH2PO4), sodium chloride (NaCl), sodium azide (NaN3) and 
Tween 20 were obtained from VWR International (Amsterdam, The Netherlands). 
Microcentrifuge Model 16K was purchased from Bio-Rad (Veenendaal, The Netherlands). 
Protein LoBind Tubes, Safe Lock Tubes (amber) and Centrifuge 5810R were obtained from 
Eppendorf (Hamburg, Germany). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
2-(N-morpholino)ethanesulfonic acid (MES) hydrate, ovalbumin and bovine serum albumin 
(BSA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). MultiScreen HTS filter 
plates were purchased from Millipore (Billerica, MA, USA). Purified bovine osteocalcin and 
mouse anti-bovine osteocalcin antibodies were obtained from Haematologic Technologies, 
Inc. (Essex Junction, VT, USA). Insulin-like growth factor-I (IGF-I; human recombinant) 
was purchased from Fitzgerald Industries International (North Acton, MA, USA). Insulin-
like growth factor binding protein-2 (IGFBP-2; bovine recombinant, receptor grade) was 
purchased from IBT (Reutlingen, Germany). Mouse anti-IGF-1 was supplied by LifeSpan 
BioSciences, Inc. (clone SPM406, Seattle, WA, USA) and the rabbit anti-IGFBP-2 was from 
United States Biological (Swampscott, MA, USA). Monsanto rbST standard was obtained 
from the National Hormone & Peptide Program (NHPP) of Dr Parlow (Torrance, CA, USA). 
R-Phycoerythrin (PE)-labelled goat anti-bovine immunoglobulins (GAB-PE) were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and R-Phycoerythrin (PE)-labelled goat 
anti-mouse immunoglobulins (GAM-PE) and goat anti-rabbit immunoglobulins (GAR-
PE) were purchased at Prozyme (San Leandro, CA, USA). Donor adult bovine serum was 
from HyClone (South Logan, UT, USA). Sodium hydroxide (NaOH), disodium hydrogen 
phosphate dihydrate (Na2HPO4 x 2 H2O) and hydrochloric acid (HCl) were purchased from 
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Merck (Darmstadt, Germany). SeroMAP microspheres (microsphere sets 025, 050, 078 
and 084) and sheath ﬂuid were obtained from Luminex (Austin, TX, USA). The Luminex 
100 IS 2.2 system consisting of a Luminex 100 analyser and a Luminex XY Platform was 
purchased from Applied Cytometry Systems (ACS, Dinnington, Sheffield, South Yorkshire, 
UK). Snijder Test tube rotator was from Omnilabo International (Breda, The Netherlands). 
10 mL polypropylene tubes were obtained from Greiner Bio-One (Alphen aan de Rijn, 
The Netherlands). Glycine was purchased from Duchefa (Haarlem, The Netherlands) and 
sulfo-N-Hydroxysuccinimide (Sulfo-NHS) from Fluka (Buchs, Switzerland). Sodium dodecyl 
sulphate (SDS) was obtained from Serva (Heidelberg, Germany). The microtiter vari-shaker 
was purchased from Dynatech (Guernsey, UK). Posilac® (rbST) 500 mg single dose syringes 
and syringes with only the slow release formula were obtained from Monsanto Company 
(St. Louis, MO, USA) for animal study I and from Elanco Animal Health (Greenfield, IN, USA) 
for animal study II.
3.3 Buffers and solutions
Buffers and solutions were prepared as follows: phosphate-buffered saline (PBS; 154 mM 
NaCl, 5.39 mM Na2HPO4, 1.29 mM KH2PO4, pH 7.4), PBST (PBS, 0.05 % v/v Tween 20), 
PBSTB (0.1 % w/v BSA in PBST), glycine solution I (GS I; 27.5 mM glycine, pH 0.5 adjusted 
with HCl), glycine solution II (GS II; 400 mM glycine, 0.3 % w/v SDS, pH 10 adjusted 
with NaOH), MES buffer (50 mM, pH 5), blocking buffer (PBS, 0.1 % w/v BSA, 0.02 % v/v 
Tween 20, 0.05 % w/v NaN3).
3.4 Sample materials
Samples from different sources were used for analysis. Serum samples from two 
independent controlled animal treatment studies were used. In animal study I, eight 
Holstein cows were selected. These cows were all about 5 years old, divided in two 
groups of 4 animals each and treated with 500 mg rbST in slow-release formula or slow-
release formula only. After a two-week adaptation period, they received every second 
week an injection, in total 4-times in accordance with the suggested treatment schedule 
by the manufacturer (http://www.fda.gov/downloads/AnimalVeterinary/Products/
ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm050022.pdf; accessed 2012 
Apr 4). Since we did not know for sure whether we would see any response, the cows 
were thereafter treated two times more but with a weekly interval, followed by a final 
4-week withdrawal period. In animal study II, 10 Holstein dairy cows were divided in 
two groups. In contrast to animal study I, these cows were of different age (2-8 years). 
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After a 2-week adaptation period, 8 cows were treated every second week with 500 mg 
rbST in a slow-release formula during 8 weeks and 2 control cows were treated with the 
slow-release formula only. The biweekly treatment period according to manufacturers’ 
guidelines was directly followed by a 4-week withdrawal period. In both studies, blood 
sampling was scheduled similarly: During the two week adaptation period blood samples 
were collected weekly; during the treatment period blood samples were collected a day 
before, a day after and a week after injection and during withdrawal, blood samples were 
collected weekly for four more weeks, which yielded 21 serum samples per cow in animal 
study I and 18 serum samples per cow in animal study II. The treatment schedule and 
blood sampling time points are shown in Supplementary Figure 2. Unfortunately, one 
untreated cow died in the beginning of animal study I because of swollen hocks, which 
led to general inﬂammation and sepsis. Therefore in study I, results could be obtained for 
4 rbST-treated and 3 untreated cows. Furthermore, one cow from animal study II fell sick 
(hock joint inﬂammation, lung infection and sepsis) in course of the experiment and its 
biomarker level results were excluded from statistical analysis. For investigation of natural 
physiological variations in biomarker levels, sera from 67 healthy, lactating cows varying 
in the age of two to eleven years, from two different locations, in different stages of their 
lactating cycle were analysed, to reﬂect a normal population of untreated dairy cows. 
Based on the origin of these animals the assumption of being untreated with rbST was 
justified. 
3.5 Standard preparation
Protein standards of IGF-1, IGFBP2 and osteocalcin, prepared in serum-matched buffer (80 
mg mL-1 BSA in PBS), were used for standard curves ranging from 0.08 to 20 ng mL-1 for 
IGF-1 and osteocalcin and from 0.2 to 50 ng mL-1 for IGFBP2. Also blank standard samples 
(80 mg mL-1 BSA in PBS without any IGF-1, IGFBP2 and osteocalcin) were measured. Note 
that no standards are commercially available for anti-rbST-antibodies.
3.6 Sample pretreatment
A generic sample pretreatment procedure which was crucial for removing nonspecific 
interferences and making the candidate biomarkers accessible for detection was described 
previously [4, 28, 29], is depicted in Figure 1 and described in-depth in the supplementary 
information.
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3.7 Microsphere preparation
Covalent coupling of 100 µg mL-1 Monsanto rbST standard, 100 µg mL-1 IGF-1 and 
10 µg mL-1 IGFBP2 to seroMAP microspheres (sets 050, 025, 078 respectively) was 
described before [4, 28, 29]. Coupling 75 µg mL-1 osteocalcin to microspheres (set 084) was 
done following the same procedure.
3.8 Four-plex ﬂow cytometric immunoassay procedure
The assay procedure for detection of three biomarkers was described before [31] and is 
similar for four biomarkers in the present study and summarized in Figure 1. The samples 
were analysed in duplicate in the ﬂow cytometer at 1 µL s-1 until 50 microspheres per set 
were counted, up to a maximum of 50 µL per sample. A typical analysis of a full 96 well 
microtiter plate takes 3.5 hours starting from raw serum until the results are obtained.
3.9 Data analysis
Raw median ﬂuorescence intensities (MFIs) were measured by the ﬂow cytometer for 
every single candidate biomarker. Every sample was measured in duplicate and MFIs were 
averaged before further analysis. For IGF-1, IGFBP2 and osteocalcin, B/B0 values were 
calculated per sample by dividing the measured MFI by the MFI of a blank biomarker-free 
standard. Then, concentrations were recalculated from standard curves (non-linear four-
parameter curve fit) using GraphPad Prism program (GraphPad Software Inc., San Diego, 
USA) for IGF-1 and osteocalcin. For IGFBP2, no complete inhibition could be obtained 
with the available standard protein, therefore, no actual concentrations were determined 
and B/B0 values were simply used. For anti-rbST-antibodies, which are endogenously 
produced by the cow in response to rbST treatment, no standard was available. To be able 
to normalize, measured sample MFIs were divided by the MFI of one serum sample, which 
was measured every time (B/Bd). This serum was donor adult bovine serum which was a 
mixture of sera from many cows from one herd. Since this is produced in large amounts, it 
can be used for a long time with constant quality. 
To assess the 4-plex FCIA quality and compare it to other methods, assay performance 
characteristics were calculated, such as IC
50
, interassay and intraassay variation. For IGF-
1, IGFBP2 and osteocalcin, IC
50
 was read from standard curves at 50 % inhibition of the 
signal of the blank. For all candidate biomarkers, interassay variation was determined by 
measuring 8 different serum samples on 8 days. Mean of results (concentrations for IGF-1 
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and osteocalcin, B/B0 for IGFBP2 and B/Bd for anti-rbST-antibodies), standard deviation 
and percentaged standard deviation (% CV) were calculated for every serum. The average 
of the 8 percentaged standard deviations was the interassay deviation. Intraassay variation 
was calculated the same way from 8 repetitions of 8 sera within one microtiter plate.
3.9.1 Single biomarker analysis approach
Using a single biomarker for prediction of unknown samples as rbST-treated or untreated, 
the calculation of decision limits for each biomarker was necessary. These were based on 
the results obtained from a population of 67 untreated dairy cows being diverse in age, 
in lactation stage and in origin. For every biomarker, results were averaged and two-
times the standard deviation was added to obtain the decision limit. Samples found to 
show concentrations (for IGF-1 and osteocalcin), B/B0 (for IGFBP2) or B/Bd (for anti-rbST 
antibodies) beyond the respective calculated decision limit, were considered as rbST-
treated (positive). True-positive and false-positive rates could be calculated for every single 
biomarker from the results of the controlled animal studies.
3.9.2 Additive biomarker analysis
After evaluating biomarker profiles and true-positive rates based on single biomarkers, an 
additive biomarker approach was tested. Here, a sample was considered as rbST-treated 
when at least one of the candidate biomarkers reacted above decision limit and also here, 
true-positive and false-positive rates were calculated.
3.9.3 Multiple biomarker statistical approach
After evaluating single candidate biomarkers and testing the additive biomarker approach, 
we assessed how well a statistical combination of two to four markers was capable to 
predict rbST abuse. Therefore, a k-nearest neighbours prediction model (kNN) in the R 
environment [42] and functions available in R package e1071 [43] were used to evaluate 
all eleven theoretical combinations of two to four biomarkers. As in the single biomarker 
approach, recalculated concentrations for IGF-1 and osteocalcin and B/B0 signals for 
IGFBP2 as well as B/Bd signals for rbST-induced antibodies for every sample from the 
animal studies were included in the data analysis. For obvious ethical reasons, we had 
only a limited number of rbST-treated animals available. Therefore, all serum sample time 
points per cow (21 time points in the trial period of 14 weeks for animal study I and 18 
time points in the trial period of 13 weeks for animal study II) were used for data analysis, 
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despite the fact that these are not completely independent. However, only data from 
independent cows were used for model building and sample prediction. 
First, the whole data set was divided into two groups: Group A data were used to build 
the time-point-independent prediction model. Therefore and to use sufficient sample 
numbers for the model building, this group contained all data from animal study II (diverse 
population with biweekly treatment only). Furthermore, since two control animals were 
not enough to represent untreated cows, Group A also contained the data from the 
untreated animals of animal study I. In total, 98 samples from treated and 119 samples 
from untreated cows were used for model building. Group B data were used for prediction 
based on the Group A model. Group B contained the data from the rbST-treated cows 
of animal study I (uniform in age with biweekly treatment and two additional weekly 
injections) and the 67 untreated cows. Note that these are sample data independent 
from Group A data. For model building of the Group A data, a training and test set were 
chosen by using a stratified repeated random sub-sampling approach, which means that 
70 % of the rbST-treated and 70 % of the untreated samples were selected for the training 
set and the remaining 30 % of both groups for the test set for internal validation, which is 
necessary to build a strong model. Subsequently, concentrations, B/B0 and B/Bd values of 
the training set were auto-scaled and a kNN model was built on the training set data. The 
optimal number of k (1 ≤ k ≤ 10) was chosen based on the bootstrapping approach [44] 
leaving out 10 % of the training data (randomly with replacement), which was repeated 
10-times. The resulting model was validated with the test set data and thereafter used for 
predicting Group B data. To obtain an average performance of the model, this procedure 
was run 10,000 times; every time different randomly chosen training and test sets of 
Group A data were applied. Correctly and falsely predicted results were evaluated for 
Group B and a true-positive rate and false-positive rate could be calculated for every Group 
B sample.
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Supplementary information
Serum preparation
After blood collection, blood samples were kept at room temperature for 4 h to coagulate. 
After coagulation, samples were centrifuged for 10 min at 3,000 g, and sera were 
collected. Serum samples were stored at -80 °C.
Generic serum pretreatment
For the generic serum pretreatment procedure 25 µl glycine solution I (27.5 mM glycine 
pH 0.5) were added to 25 µl serum or standard sample in a polypropylene tube under 
constant vortexing. After 60 minutes incubation at room temperature, 50 µl glycine 
solution II (400 mM Glycine, 0.3 % m/v SDS, pH 10) were added under constant vortexing 
and samples were further diluted by addition of 1.9 mL 0.1 % BSA in PBST (in total 
80-times diluted).
Four-plex ﬂow cytometric immunoassay procedure
For the 4-plex FCIA procedure, 10 µl primary antibody mixture (1:625 mouse anti-IGF-1, 
1:25,000 rabbit anti-IGFBP2, 1:100,000 mouse anti-osteocalcin) were added to 100 µl 
pretreated and diluted sample in a filter bottom microtiter plate and incubated at 4 °C 
under orbital shaking for 15 minutes. Thereafter, 10 µl microsphere mixture suspension 
(containing approximately 1250 microspheres per microsphere set) were added to each 
well and incubated at 4 °C for one hour under orbital shaking. After centrifugation at 130 g 
for one minute, everything not bound to the microspheres was removed from the well. For 
washing, 200 µl PBST were added and the filter bottom microtiter plate was centrifuged 
again at 130 g for one minute. Then, 125 µl PE-antibody mixture (1:625 goat anti-mouse 
PE, 1:1,000 goat-anti rabbit PE, 1:1,000 goat anti-bovine PE) were added to each well and 
the plate was incubated for 30 minutes at 4 °C under orbital shaking. Then, the plate was 
centrifuged at 130 g for one minute and 125 µl PBST were added. Thereafter, the plate was 
put into the LX-100 ﬂow cytometer for measurement. Microspheres from every sample 
were analysed in a ﬂow of 1 µl s-1 until 50 microspheres per set were counted up to a 
maximum of 50 µL per sample. Each microsphere set was identified by its unique colour 
by a red laser and the ﬂuorescence intensity of the PE attached to each microsphere was 
measured by a green laser. Median ﬂuorescence intensities were obtained from every 
analysed sample. 
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Supplementary Table 1: True-positive rates of the statistical multiple biomarker analysis. 
True-positive rates, obtained with the prediction models based on the eleven different 
biomarker combinations, were calculated for rbST-treated cows from animal study I in 
their treatment (day 16 – 71) and withdrawal period (day 72 -99).
biomarker 
combination
IBAO IBO IBA IAO BAO IB IA IO BA BO AO
days true-positive rate [%]
1 0 0 0 0 0 0 0 0 0 0 0
8 0 0 0 0 0 0 0 0 0 0 0
15 0 0 0 0 0 0 0 0 0 0 0
16 25.0 26.4 25.0 25.8 25.1 32.2 27.7 50.2 25.0 1.0 25.0
22 25.1 25.4 25.9 40.6 6.5 35.6 61.4 65.8 18.6 6.3 28.9
29 74.5 0.0 75.3 99.7 73.8 0.0 99.1 32.6 90.4 0.3 99.8
30 75.1 18.3 75.9 99.7 75.0 22.9 100.0 52.5 93.5 25.4 99.8
36 81.2 47.6 83.2 99.9 75.3 52.7 100.0 54.7 75.0 44.9 94.3
43 75.0 0.4 75.0 83.5 75.0 0.5 93.5 53.3 75.3 3.0 99.6
44 75.0 24.0 75.0 75.0 75.0 8.9 77.7 44.4 75.0 37.0 75.0
50 100.0 59.2 78.0 100.0 86.0 32.0 100.0 52.8 75.2 56.8 100.0
57 98.1 25.1 74.6 99.9 94.4 0.1 89.4 61.6 74.7 25.7 100.0
58 99.9 38.7 98.4 100.0 97.8 51.9 100.0 61.5 75.0 46.0 100.0
64 100.0 60.3 83.0 100.0 87.8 51.7 99.9 52.0 75.0 78.6 100.0
65 100.0 86.1 99.3 100.0 86.9 89.2 100.0 84.2 75.0 76.4 99.6
71 100.0 59.2 100.0 100.0 94.6 60.6 100.0 56.2 74.7 59.4 100.0
72 100.0 56.9 100.0 100.0 92.5 63.9 99.1 65.0 75.0 58.0 100.0
78 99.9 57.5 100.0 100.0 98.1 50.4 100.0 75.7 75.0 45.2 100.0
85 99.6 69.0 100.0 100.0 99.5 59.4 100.0 62.8 75.5 54.7 100.0
92 72.6 37.5 73.2 82.0 71.7 4.0 74.8 53.6 74.1 36.2 85.8
99 57.8 0.1 67.3 74.0 60.3 1.5 71.8 22.3 73.2 0.3 74.8
Supplementary Table 2: False-positive rates of the statistical multiple biomarker analysis. 
Results were calculated for 67 independent untreated cows predicted with the eleven 
different biomarker combination models.
biomarker 
combination
IBAO IBO IBA IAO BAO IB IA IO BA BO AO
false-positive rate [%]
67 untreated 
cows
5.5 9.7 6.6 10.6 8.8 25 14.7 24.6 13.4 11.7 11.8
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Supplementary Figure 1: Standard curves of the three rbST-dependent biomarkers IGF-
1, IGFBP2 and osteocalcin. Each data point is the mean of 8 separate measurements in 
a serum-matched buffer (80 mg mL-1 BSA in PBS solution). All curves relate to 80-times 
diluted sera.
 
 
Supplementary Figure 2: Treatment schedule and sampling time points for animal studies I 
and II. Arrows indicate the treatment of the cows with rbST in slow-release formula or the 
slow-release formula only; bold vertical lines indicate blood sampling time points.
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Abstract
Targeted protein biomarker profiling is suggested as a fast screening approach for 
detection of illegal hormone treatment in meat production. The advantage of using 
biomarkers is that they mark the biological response, thus are responsive to a panel 
of substances with similar effects. In a preliminary feasibility study, a 4-plex protein 
biomarker ﬂow cytometric immunoassay (FCIA) previously developed for the detection 
of recombinant bovine somatotropin (rbST) was applied to bovines treated with steroids, 
such as estradiol, dexamethasone and prednisolone. Each treatment resulted in a specific 
plasma biomarker profile for insulin-like growth factor-1 (IGF-1), IGF binding protein 
2, osteocalcin and anti-rbST-antibodies, which could be distinguished from the profile 
of untreated animals. Summarizing, the 4-plex biomarker FCIA is, apart from rbST, also 
capable of detecting treatment with other growth-promoting agents and therefore clearly 
shows the potential of biomarker profiling as a screening method in veterinary control. 
It is proposed to perform additional validation studies covering high numbers of treated 
and untreated animals in order to support inclusion or adaptation of protein biomarker 
approaches in future monitoring regulations.
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1 Introduction
Protein biomarker profiling has been suggested as a fast screening approach for detection 
of illegal treatment practices in human sports doping [1], and in veterinary control [2-6] 
for detection of banned growth-promoting agents (Directives 2008/97/EC, 96/22/EC and 
96/23/EC [7-9]). Using protein biomarkers has several advantages: First, they are indicative 
for any substance having the relevant effect and can therefore give a comprehensive first 
screening result whether any growth-promoting agent was used. Even the use of designer 
substances of unknown chemical structure could be detected. Second, biomarker profiles 
remain changed for a longer period of time than the abused substance can be detected 
in circulation [10, 11]. And third, the use of fast screening methods prior to an extensive 
instrumental confirmatory method is beneficial because of its time saving as it already 
pinpoints suspicious samples and omits compliant samples from the subsequent analysis.
Nevertheless, up till now, protein biomarker analysis tools were specifically developed 
for only a specific treatment setting [12]. In this study, we investigated if a previously 
developed 4-plex biomarker ﬂow cytometric immunoassay (FCIA) for the detection of the 
protein hormone recombinant bovine somatotropin (rbST) abuse [4] can also be used 
to detect treatments with steroid hormones such as estradiol (E2), dexamethasone and 
prednisolone. In contrast to rbST, steroids are not species-specific and also exert hormonal 
effects in humans if residues are consumed. This highlights the importance of a fast 
screening method for steroid abuse detection in meat production to maintain the highest 
possible food safety for the customer.
The biomarker panel of the 4-plex FCIA consisted of insulin-like growth factor 1 (IGF-1), 
IGF binding protein 2 (IGFBP2), osteocalcin and antibodies produced by cows upon rbST 
treatment (anti-rbST-antibodies). This biomarker panel was specifically developed for the 
detection of rbST abuse in dairy cattle and biomarkers were chosen based on information 
from literature stating specific changes in biomarker concentrations after somatotropin 
treatment [13-19]. Nevertheless, three out of these four biomarkers, namely IGF-1, 
IGFBP2 and osteocalcin, are also known to be inﬂuenced by steroid hormone treatments 
such as glucocorticoids and sex steroids [2, 20-27]. IGF-1 and IGFBP2 are members of the 
somatotropin/IGF-axis, which is usually involved in growth-related mechanisms and is 
thereby affected by growth-inducing or -repressing substances, such as growth-promoting 
steroids [2, 20, 22, 23, 25, 26]. One possible target of somatotropin, IGF-1 and steroid 
hormone action is bone, which reacts with an increase or decrease in bone turnover. 
Osteocalcin is a marker of bone turnover and therewith, osteocalcin concentrations 
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respond upon administration of bone turnover altering drugs [21, 24, 27]. Therefore, 
the selected biomarkers might also be inﬂuenced not only by rbST but also by other 
growth promoting steroids. To proof this, in the here presented study, plasma samples 
from an animal study with sex steroid (estradiol) and glucocorticoid (prednisolone and 
dexamethasone) treatments were analysed using the previously developed 4-plex FCIA. 
The obtained biomarker profiles of the treated groups were compared with the ones from 
a control group. Based on the results, the potential of targeted protein biomarker profiling 
is discussed.
2 Materials and methods
2.1 Chemicals
17-β-estradiol-3-benzoate was obtained from Intervet (Boxmeer, The Netherlands) and 
dexamethasone-21-sodium phosphate from Fort Dodge Animal Health (Bologna, Italy). 
Prednisolone was from Novosterol (CEVA VETEM SpA, Agrate Brianza, Italy) and the rbST 
standard from the National Hormone & Peptide Program of Dr Parlow (Torrance, CA, 
USA). IGF-1 standard was purchased from Fitzgerald Industries International (North Acton, 
MA, USA) and IGFBP2 standard from IBT (Reutlingen, Germany). Osteocalcin standard 
and mouse anti-osteocalcin antibody were from Haematologic Technologies, Inc. (Essex 
Junction, VT, USA) and seroMAP microspheres (sets 050, 025, 078 and 084) from Luminex 
(Austin, TX, USA). Bovine serum albumin (BSA) and 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) were bought from Sigma-Aldrich (St. Louis, MO, USA) and sulfo-
N-Hydroxysuccinimide (S-NHS) from Fluka (Buchs, Switzerland). Glycine was from 
Duchefa (Haarlem, The Netherlands) and the polypropylene tubes from Greiner Bio-
One (Alphen aan de Rijn, The Netherlands). Sodium dodecyl sulfate (SDS) was obtained 
from Serva (Heidelberg, Germany) and Tween 20 from VWR International (Amsterdam, 
The Netherlands). Mouse anti-IGF-1 antibody was bought from LifeSpan BioSciences, 
Inc. (Seattle, WA, USA), rabbit anti-IGFBP2 antibodies from United States Biological 
(Swampscott, MA, USA) and the filter bottom microtiter plates from Millipore (Billerica, 
MA, USA). Goat anti-mouse R-phycoerythrin (PE) antibody and goat-anti rabbit PE antibody 
were obtained from Prozyme (San Leandro, CA, USA) and goat anti-bovine PE antibody 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The LX-100 ﬂow cytometer was from 
Applied Cytometry Systems (Dinnington, Sheffield, South Yorkshire, UK) and the software 
Prism 5 from GraphPad Software, Inc. (San Diego, CA, USA).
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2.2 Animals and treatment
Since in the here presented study only the feasibility of the chosen biomarkers was tested, 
Directive 2010/63/EU [28] describing the 3-R-principle in animal testing was considered 
and no new animal experiment was performed. Instead of that, only a limited number of 
samples, which originated from a previous study conducted at Università di Torino, was 
available and used to test the developed method. To assess levels of the four biomarkers 
after treatment of estradiol (E2), dexamethasone and prednisolone, plasma samples 
from an animal study were used. Twenty-four male Charolais bovines (17-22 months) 
were randomly divided in four groups and received the following treatments: six animals 
in group E2 received 0.01 mg (kg bodyweight)
-1 per week 17-β-estradiol-3-benzoate by 
intramuscular injection for 6 weeks. All six animals in group DEX were treated with 0.7 mg 
day-1 dexamethasone-21-sodium phosphate per os for 40 days and all six animals in group 
PRED received 15 mg day-1 prednisolone per os for 30 days. The control group consisted 
of 6 untreated animals. These steroid treatments were chosen because they are expected 
to be illegally used in meat production as growth-promoting agents [29] and dosages and 
administration routes were determined based on literature [30, 31]. Blood samples were 
taken throughout the treatment study; sampling occurred through the external jugular 
vein with evacuated EDTA tubes to prepare plasma samples by centrifugation at 2000 g for 
20 minutes and samples were stored at -80 °C until further use. Plasma samples taken at 
days 25 (during the treatment) and 43 (after the last treatment) were chosen for analysis. 
Samples from day 43 reﬂect the situation of when the animals arrive at the slaughterhouse 
including a delay after the last treatment (3 days for the E2- and dexamethasone-treated 
and 6 days for the prednisolone-treated group). The treatment and sampling schedule is 
depicted in Figure S1 in the supporting information. The animal studies were authorized by 
the Italian Ministry of Health and the Bioethics Committee of the University of Turin.
2.3 Sample pre-treatment, microsphere preparation and assay procedure
For microsphere preparation, 100 µg mL-1 rbST standard, 100 µg mL-1 IGF-1, 10 µg mL-1 
IGFBP2 and 75 µg mL-1 osteocalcin were covalently coupled to colour-encoded seroMAP 
microspheres (sets 050, 025, 078 and 084 respectively) by using the sulfo-NHS-EDC 
coupling chemistry as it was described before [4, 11, 32, 33]. Standard curves were 
prepared with IGF-1, IGFBP2 and osteocalcin standard proteins in plasma-matched buffer 
[80 mg mL-1 BSA in phosphate-buffered saline (PBS)]. Obviously no standard curves can 
be produced for the biomarker anti-rbST-antibodies. For the generic plasma pretreatment 
procedure, 25 µl glycine solution I (27.5 mM glycine, pH 0.5) were mixed with 25 µl plasma 
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or standard sample in a polypropylene tube under constant vortexing. After 60 minutes 
incubation at room temperature, 50 µl glycine solution II (400 mM Glycine, 0.3 % m/v 
SDS, pH 10) were added and samples were further diluted by addition of 1.9 mL 0.1 % BSA 
in PBST (0.05 % v/v Tween 20 in PBS), which led to an overall dilution of the plasma by 
80-times. Detection assays for IGF-1, IGFBP2 and osteocalcin are of competitive format, 
where free protein in the blood sample inhibits binding of the primary detection IgG to the 
respective protein-coupled microsphere. The assay for detection of anti-rbST-antibodies 
is a direct assay, where the antibodies originating from the blood sample, directly bind to 
rbST-coupled microspheres. The 4-plex FCIA procedure was described previously [4] and 
the assay principle is depicted in Figure S2 in the supporting information. Brieﬂy, 10 µl 
primary detection immunoglobulin G (IgG) mixture (1:625 mouse anti-IGF-1, 1:25,000 
rabbit anti-IGFBP2, 1:100,000 mouse anti-osteocalcin) were added to 100 µl pretreated 
and diluted sample in a filter bottom microtiter plate and incubated at 4 °C under orbital 
shaking for 15 minutes. Thereafter, 10 µl microsphere mixture suspension (containing 
approximately 1250 microspheres per microsphere set) were added to each well and 
incubated at 4 °C for one hour under orbital shaking. Microspheres were washed once 
with PBST, then 125 µl PE-IgG mixture (1:625 goat anti-mouse PE, 1:1,000 goat-anti rabbit 
PE and 1:1,000 goat anti-bovine PE) were added to each well, and finally the plate was 
incubated for 30 minutes at 4 °C under orbital shaking. Then, the plate was centrifuged 
at 130 g for one minute and 125 µl PBST were added. Thereafter, the plate was put into 
the LX-100 ﬂow cytometer for measurement. Microspheres from every sample were 
analysed in a ﬂow of 1 µl s-1 until 50 microspheres per set were counted up to a maximum 
of 50 µL per sample. Each microsphere set (= each biomarker assay) was identified by its 
unique colour by a red laser and the ﬂuorescence intensity of the reporter PE attached to 
each microsphere was quantified by a green laser. Median ﬂuorescence intensities (MFI) 
were obtained from every analysed sample and biomarker concentrations of IGF-1 and 
osteocalcin were calculated based on standard curves obtained by using the software 
Prism 5. For IGFBP2, B/B0 values were used, because the slope of the standard curve was 
too ﬂat to work with calculated concentrations. When using a standard curve with a ﬂat 
slope for calculating concentrations, large concentration differences will be obtained even 
though only a small difference in signal was measured. For anti-rbST-antibodies, raw MFI 
signals were used. The average biomarker levels of the six cows in each group are plotted 
in Figure 2 and standard deviations are shown as error bars. Biomarker levels of the 
different treatment groups were compared to their respective time-matched control group 
by using the unpaired, two-tailed Student’s t-test.
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3 Results and discussion
Monitoring biomarker profiles as an indication of possible hormone abuse becomes 
more and more prevalent in sports doping and veterinary control. Since biomarkers 
reﬂect a biological effect and this effect might also be achieved by other hormonal 
substances, several treatments can be indirectly detected by altered biomarker profiles. 
A 4-plex protein biomarker FCIA was previously developed to detect rbST abuse in dairy 
cattle based on an altered biomarker profile. Biomarkers analysed were IGF-1, IGFBP2, 
osteocalcin and anti-rbST-antibodies endogenously produced by the cow as a response 
upon rbST treatment. The tested biomarkers were shown to be all responsive to rbST 
in a previous study: IGF-1 and osteocalcin concentrations were increased, IGFBP2 levels 
were decreased and anti-rbST antibodies were induced by rbST treatment in dairy cattle 
[4]. In this work, the 4-plex protein biomarker FCIA was used to test whether beef cattle 
also shows a change in biomarker levels after steroid treatment. Steroids used were a sex 
steroid (estradiol, E2) and glucocorticoids (prednisolone or dexamethasone), which are 
occasionally used in veterinary practice to illegally improve meat production and quality. 
Plasma biomarker concentrations for IGF-1 and osteocalcin were calculated based on 
standard curves prepared in plasma-matched buffer (Figure 1). IGFBP2 was analysed 
using B/B0 values as already described earlier [4]. For the biomarker anti-rbST-antibodies, 
no standard curve could be obtained, therefore, the presence of these antibodies was 
expressed as raw median ﬂuorescence intensity (MFI) signals.
Two different time points in all four treatment groups were analysed. One time point on 
day 25 was in the middle of the treatment period and reﬂects on-farm testing, whereas 
the other one on day 43, which was a few days after discontinuation of the treatments 
(see Figure S1 in the supporting information), reﬂects when the animals arrive at the 
slaughterhouse.
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Figure 1: Standard calibration curves for the immunoassays for measuring insulin-like 
growth factor 1 (IGF-1), IGF binding protein 2 (IGFBP2) and osteocalcin in a competitive 
format. Standard curves were obtained in plasma-matched buffer.
Compared to the untreated control group, the three different steroidal treatments had 
specific effects on the biomarker levels. IGF-1 concentrations were significantly elevated 
after dexamethasone (+30 % IGF-1 on day 25 and +11 % IGF-1 on day 43) and prednisolone 
(+16 % IGF-1 on day 43) treatment, whereas no significant effect was observed for E2 
treatment (Figure 2.A). The effects of glucocorticoids on IGF-1 levels in different life stages 
were studied before. Acute glucocorticoid treatment of newborn animals resulted in a 
stimulation of the somatotropic axis and increased IGF-1 levels [25, 34]. In early life stages, 
glucocorticoid administration had an inhibiting effect on plasma IGF-1 concentrations [20, 
22]. Nevertheless, glucocorticoid treatment of adults resulted in increased IGF-1 levels 
again [23, 26], which is also supported by the results of our study, where 17-22 month 
old cattle were treated. As already described by Hammon et al., IGF-1 response upon 
glucocorticoid treatment depends on age, dose and duration of the treatment [22]. 
Furthermore in untreated cattle, there is a variability in IGF-1 background levels depending 
on age and sex of the animal [35]. This variability is, however, not a problem as age and 
sex of a tested animal are known to the veterinary inspection services. Therefore, it can 
be easily accounted for these ﬂuctuations following full validation covering different age 
groups.
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Figure 2: IGF-1 concentration (A), IGFBP2 B/B0 values (B), osteocalcin concentrations (C) 
and ﬂuorescence signals of anti-rbST-antibody detection (D) obtained from the 4-plex 
protein biomarker FCIA after treatment with estradiol (E2), dexamethasone (DEX) or 
prednisolone (PRED). Each bar represents the average of 6 cows in one treatment group 
at one time point; error bars indicate standard deviations. Significance levels were: * for 
P≤0.05, ** for P≤0.01 and *** for P≤0.001 and were obtained by comparing a treated 
group at one time point to its time point-matched control group using the two-tailed 
Student’s t-test.
For IGFBP2, B/B0 values were used. Since the IGFBP2 assay is of an inhibition format, 
increased B/B0 values represent decreased plasma IGFBP2 concentrations and vice versa. 
Note that B/B0 values are shown in Figure 2.B. Dexamethasone showed a significant 
IGFBP2-B/B0-increasing effect (+11 % IGFBP2 B/B0 on day 25 and +21 % IGFBP2 B/B0 on 
day 43), thus a plasma IGFBP2 concentration decreased by dexamethasone treatment 
(Figure 2.B). The studies showing an IGF-1 increasing effect also reported an IGFBP2 
decreasing effect due to glucocorticoid treatment [23, 25, 26]. As an exception, Bertozzi 
et al. who reported decreased IGF-1 levels after glucocorticoid treatment, did not see any 
effect on IGFBP2 concentrations [20]. In rbST treatment studies, an IGFBP2-decreasing 
effect was observed together with an IGF-1 level increase as well [13, 36], which might 
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indicate a contrary regulation of these proteins, thus explaining the observed IGFBP2 
decrease after dexamethasone treatment in our study. Here, E2 decreased IGFBP2-B/B0 
values (-12 % IGFBP2 B/B0 on day 25), thus increased plasma IGFBP2 concentrations. In 
contrast to that, IGFBP2 concentrations were not affected by administration of a cocktail of 
estradiol and nortestosterone in veal calves [2]. Nevertheless, in rat hippocampus cells [37] 
as well as in bovine granulosa cells [38] it was shown, that estrogen treatment induced the 
gene expression of IGFBP2. Furthermore, serum IGFBP2 concentrations were increased 
in barrows treated with estradiol [39], which is supported by the findings of our study. 
Also for IGFBP2, background levels in untreated cattle depend on sex and age and can be 
accounted for since these parameters will be known in monitoring practice [40].
Both, E2 (-32 % osteocalcin on day 43) and dexamethasone (-41 % osteocalcin on day 25 
and -49 % osteocalcin on day 43), decreased osteocalcin levels (Figure 2.C). Known effects 
of glucocorticoids are their growth retarding actions on bone. Thus, decreased osteocalcin 
concentrations were seen before [2] and it was described that glucocorticoids repress the 
osteocalcin promoter [24]. It is known that estrogens as well as androgens induce bone 
formation and repress bone resorption [27]. Nevertheless, previous studies described 
that they did not see any effect in osteocalcin levels of calves throughout a 28-day sex 
steroid treatment period with combined treatment of estrogens and androgens [2]. Since 
osteocalcin is released into circulation during bone formation [41] and bone resorption 
[42], it is a matter of the ratio of bone formation and resorption before and after estrogen 
treatment, whether increased or decreased levels are observed. Furthermore, osteocalcin 
turnover is also inﬂuenced by the somatotropin/IGF system in an endocrine and paracrine 
manner [21], which might explain the decreased osteocalcin concentrations observed in 
our study. As well as for IGF-1 and IGFBP2, background osteocalcin levels in untreated 
cattle are age-dependent and it can be accounted for this since these parameters will be 
known to the veterinary inspection services [43].
As expected, none of the steroid treatments affected the endogenous antibody response 
of antibodies directed against rbST (Figure 2.D), which are produced by the animal 
after treatment with this protein hormone. Thus, this is a biomarker, which selectively 
discriminates the rbST treatment from steroidal treatment practices in cattle.
The biomarker profile results of every type of steroid treatment are summarized in Table 
1 and are also compared to the biomarker profile of rbST treatment obtained from a 
previous study [4]. 
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Table 1: Treatment-specific biomarker profiles consisting of significantly increased (+), 
decreased (-) or stable (Ø) biomarker levels after treatment.
 biomarkers
treatments
IG
F-
1
IG
FB
P2
os
te
oc
al
ci
n
an
ti
-r
bS
T 
an
ti
bo
di
es
rbST1 + - + +
prednisolone + Ø Ø Ø
dexamethasone + - - Ø
estradiol Ø + - Ø
1 adapted from Ludwig et al. (2012).
In general, some of the changes in biomarker concentrations are rather low, but it always 
depends on the biological variation in the control group whether an increase of less 
than 20 % will be detectable or not. If the biological variation in the control group is very 
low, the less than 20 % change might be sufficient for discrimination. Furthermore, it is 
not likely that only one biomarker will be indicative for drug abuse. Therefore, always a 
biomarker profile will be used to identify drug abuse. Combining biomarkers into a profile 
will be mainly done using statistical models, such as discriminant functions as previously 
shown for detection of human growth hormone doping in athletes [44], support vector 
machines as done for the detection of growth-promoting hormones in cattle [45] or the 
statistical model k-nearest neighbours as previously described for rbST detection in dairy 
cows [4]. If several biomarkers are combined into a statistical model, even a slight change 
in one biomarker might contribute significantly to the decision making that a sample is 
considered as being positive for drug abuse.
Obviously, biomarkers of growth-promoting drugs are growth-related and therefore 
also affected by other factors such as growth in early life stages. Therefore, before 
implementation of the demonstrated method, the measurement of samples from an 
extensive control population reﬂecting all age groups would be necessary. Then, for the 
ultimate method, age correction of the measured biomarker levels would be necessary 
to determine whether the animals were treated or not. One possibility to do this is to 
compare the results of an individual animal to the biomarker profile of its respective age-
matched control group. In this case, each age group would have a specific age-dependent 
threshold level for each biomarker. Another approach would be to establish discriminant 
functions, in which all relevant biomarker levels and the age of the animal are included 
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as factors for the calculation of a final test score. If the score then exceeds a set limit, the 
sample is considered positive. This approach was already followed for the detection of GH 
abuse in athletes [44].
As can be seen in Table 1, each treatment inﬂuenced the biomarkers in a unique pattern, 
which potentially allows the reverse conclusion that a certain biomarker profile is 
indicative for a specific treatment. Thus, when an unknown sample is analysed by using 
the 4-plex biomarker FCIA, not only the suspicion that an animal was treated would 
become clear, but also the possible abused class of substances might be indicated, which 
is crucial information for the subsequent instrumental confirmatory analysis according to 
Commission Decision 2002/657/EC [46].
To adapt this 4-plex biomarker FCIA for steroidal compounds in routine veterinary control, 
a thorough validation needs to be done, as demonstrated for the detection of rbST [4]. 
First, a large untreated bovine population, representing all age groups, must be analysed 
to get a more detailed impression of the range of naturally occurring biomarker levels. 
Then, a comparison of animal treatment study results with control results would allow the 
calculation of true-positive and true-negative rates thereby considering different steroidal 
treatment regimes. Furthermore, time course studies need to be done to evaluate 
whether changes in biomarker levels remain stable after prolonged treatment or whether 
they decline after a certain period of time in treatment. In Figure 2.A, IGF-1 levels are 
still increased on day 43 after dexamethasone treatment, but they are less pronounced 
as on day 25. We can only speculate whether this is an effect of a prolonged treatment 
or whether the observed decrease in concentration versus day 25 is due to that the 
treatment was discontinued three days before sampling. Furthermore, results have to be 
evaluated based on the animal’s sex and age. If the selected candidate biomarkers would 
not be sufficient yet for pinpointing the abuse of a certain substance according to EU 
guidelines (Commission Decision 2002/657/EC [46]), then more biomarkers can be simply 
added to the developed multiplex screening protocol. The addition of other biomarkers 
might also increase the potential of the method to detect a treatment with a cocktail 
of steroids. Additional biomarker candidates for detection of anabolic hormone abuse, 
such as Ir-inhibin or sex hormone binding globulin (SHBG) [2], were suggested already by 
Mooney et al. and Pinel et al. [47, 48].
Summarizing, the feasibility of a 4-plex biomarker FCIA, initially developed for rbST abuse 
detection, was preliminary demonstrated for detecting treatment with other growth-
promoting agents and therefore clearly highlights the potential of biomarker profiling as 
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future screening methods in veterinary control.
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IGFBP2   IGF binding protein 2 
IgG   immunoglobulin G 
MFI   median ﬂuorescence intensity 
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PBST   0.05 % (v/v)Tween 20 in PBS 
rbST   recombinant bovine somatotropin 
SDS   sodium dodecyl sulfate 
sulfo-NHS  sulfo-N-Hydroxysuccinimide 
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Supporting information
 
Figure S1: Treatment and sampling schedule for the different treatment groups. Bright grey 
areas indicate the treatment periods. Dark grey areas indicate the sampling time points.
Figure S2: Assay principle of the microsphere-based 4-plex FCIA measuring biomarker 
concentrations in a plasma sample on basis of a competitive immunoassay for detection of 
insulin-like growth factor 1 (IGF-1), IGF binding protein 2 (IGFBP2) and osteocalcin and on 
basis of a direct immunoassay for anti-rbST-antibodies. Microspheres were identified with 
a red laser and the reporter label was quantified with a green laser in a ﬂow cytometer.
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Table S1: P-values of the unpaired, two-tailed Student’s t-test corresponding to the results 
shown in Figure 2 in the manuscript. The treated group at one time point was compared to 
its time point-matched control group. 
 IGF-1 IGFBP2 osteocalcin anti-rbST 
antibodies
day 25 43 25 43 25 43 25 43
E2 .8964 .1348 .0356 .3468 .8833 .0211 .1741 .0932
dexamethasone .0123 .0324 .0484 .0016 .0109 .0002 .9688 .5733
prednisolone .1598 .0151 .919 .1615 .4553 .2307 .6423 .4313
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Abstract
Recombinant bovine somatotropin (rbST) can be used to enhance milk production in dairy 
cattle. This is permitted in several countries but unauthorized in the European Union. 
Antibodies, which are produced endogenously in response to rbST administration, can 
be detected as a biomarker for indicating rbST (ab)use. For the first time, a fast and easy 
to perform screening assay for anti-rbST antibodies has been developed and applied to 
raw milk samples. This ﬂow cytometric immunoassay (FCIA) is capable of discriminating 
between milk from rbST-treated animals and untreated animals. In accordance with 
literature, 67 % of the rbST-treated animals responded positively with antibody 
production, whereas 94 % of the untreated animals did not. The analysis of simulated 
tank milk samples showed more than 95 % of the milk mixtures as truly positive for rbST 
treatment, indicating that the 33 % physiologically non-responding cows will not be a 
problem when pooled tank milk samples are considered. FCIA biomarker responses in raw 
milk were specific for rbST and also obtained in pasteurized milk of rbST-treated animals. 
Using milk as a sample matrix for detection has the advantages of non-invasive sampling, 
and for tank milk analysis at the farm only one milk sample is needed to screen the whole 
farm for rbST (ab)use.
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1 Introduction
Increasing milk production by administration of recombinant bovine somatotropin (rbST) 
to dairy cows [1] is permitted in several countries, such as the United States, but banned 
in the European Union [2]. Its use, however, cannot be excluded and therefore, a detection 
method for rbST abuse is necessary. A liquid chromatography-mass spectrometry (LC/MS) 
method for direct detection of rbST in blood and spiked milk samples [3, 4] was developed, 
which has the disadvantages of being time-consuming and of having a rather short 
detection window, because of the short half-life of bST in blood circulation [1]. In contrast, 
the detection of rbST-dependent biomarkers by fast and easy-to-perform immunoassays, 
has the advantage of a longer detection window. Several biomarkers are considered to be 
indicative for rbST treatment, such as markers of the insulin-like growth factor axis, bone 
and collagen turnover markers and specific antibodies produced against rbST [5, 6]. Since 
one marker might not be enough to pinpoint rbST abuse, a combination of several markers 
in one screening tool is considered as well, as already reported for steroid abuse and 
also in human sports doping analysis [7, 8]. An enzyme-linked immunosorbent assay for 
the detection of serum antibodies against rbST has been described recently, but showed 
one out of nine cows reacting false-positively [9]. An optimized sample pretreatment for 
avoiding false-positive results and a ﬂow cytometric immunoassay (FCIA) for detection 
of anti-rbST antibodies in serum were developed in our group [10]. However, sampling 
blood from cows is not justified for routine monitoring in veterinary control, because of 
its invasive nature. Raw milk, on the other hand, can be used for analysis as well. In this 
work, we adapted the serum method for milk and present for the first time a rapid FCIA-
based screening method for the detection of endogenously produced anti-rbST antibodies 
in milk. Its applicability is demonstrated in milk of rbST-treated and untreated animals. 
Moreover, it is shown that tank milk analysis can pinpoint to treated groups since the 
physiological non-responders’ milk will be diluted with the majority of anti-rbST antibody 
producers’ milk and the pooled milk thus obtained will still test positive.
2 Experimental
2.1 Materials and equipment
Monsanto rbST standard was obtained from the National Hormone & Peptide Program 
of Dr Parlow (Torrance, CA, USA). Posilac® 500 mg single-dose syringes and syringes with 
only the slow-release formula were purchased from Monsanto company (St Louis, MO, 
USA). Hydrochloric acid, potassium phosphate, sodium azide, sodium chloride, sodium 
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hydroxide, sodium phosphate, Tween 20 and the ultrasonic cleaner were purchased 
from VWR International (Amsterdam, The Netherlands) and glycine was from Duchefa 
(Haarlem, The Netherlands). N-hydroxysulfosuccinimide sodium salt was supplied by 
Fluka (Steinheim, Switzerland) and sodium dodecyl sulfate (SDS) by Serva (Heidelberg, 
Germany). Bovine serum albumin (BSA), 2-(N-morpholino)ethanesulfonic acid (MES 
hydrate) and N-(3-dimethylaminopropyl)- N’-ethylcarbodiimide hydrochloride were 
purchased from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). R-Phycoerythrin 
(PE)-labeled goat anti-bovine immunoglobulins were from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Multi-Screen HTS filter plates were purchased from Millipore (Amsterdam, 
The Netherlands). Protein Lobind Tubes and a table centrifuge model 5810R were supplied 
by Eppendorf (Hamburg, Germany). The Luminex FM-3D ﬂow cytometer, seroMAP 
microspheres (set 050) and sheath ﬂuid were purchased from Luminex (Austin, TX, USA). 
The Snijder test tube rotator was purchased from Omnilabo International (Breda, The 
Netherlands) and the microtiter orbital shaker was purchased from Dynatech (Guernsey, 
UK). The SW22 water bath was from Julabo Labortechnik (Seelbach, Germany) and 
Titertubes Micro Tube from Bio-Rad Laboratories (Hercules, CA, USA).
2.2 Buffers and solutions
Buffers and solutions were prepared as follows: phosphate-buffered saline (PBS; 154 mM 
NaCl, 5.39 mM Na2HPO4, 1.29 mM KH2PO4, pH 7.4), PBST (PBS, 0.05 % v/v Tween 20), 
glycine buffer I (27.5 mM, pH 0.5), glycine buffer II (400 mM, pH 10), MES buffer (50 mM, 
pH 5), blocking buffer (PBS, 0.1 % w/v BSA, 0.02 % v/v Tween 20, 0.05 % w/v NaN3).
2.3 Sample materials
Serum and milk samples from two animal experiments were used. In the first experiment, 
10 Holstein dairy cows of different age (1 to 7 years) were divided in two groups. After a 
2-week adaption period, 8 cows were treated every second week with 500 mg rbST in a 
slow-release formula for 8 weeks and the 2 remaining cows were treated with the slow-
release formula only. In the second animal experiment, eight 5-year-old Holstein cows (in 
groups of 4 each) were treated with rbST in slow-release formula or slow release-formula 
only in the same manner as in the first experiment. Additionally, they received another 
injection every week for two weeks directly after the first 4 injections. Both experimental 
procedures were authorized by the local ethical committees.
In both experiments, blood and milk were sampled weekly. Serum was obtained after 
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blood samples were kept for 4 hours at room temperature and centrifuged for 10 minutes 
at 3000 g. Milk was kept at -20 °C and serum at -80 °C until further use. For analysis, the 
following sampling time points were used: one week before start of treatment and 3, 6 
and 8 weeks after start of treatment.
In real practice in rbST-authorized countries, dairy cows are expected to be treated at least 
80 % of the milk production period. The remaining 20 %, which is a worst case estimate, 
consist of the time until the positive energy balance after parturition is restored, which 
can be 10 weeks. Since, in a worst case scenario, 70 – 80 % of the treated animals are 
physiologically responding to rbST treatment with antibody production, we expect more 
than 65 % of the combined milk in a tank load to originate from treated and responding 
cows. Therefore, milk mixtures for simulating tank milk testing were prepared by 
combining 10 µL each of three milk samples (randomly two from antibody-responding 
cows and one from a non-responding cow).
Pasteurized milk was obtained by preheating Micro Tubes to 72 °C in the water bath for 30 
minutes. Then, 30 µL of each milk sample (4 milk samples from time point 3 weeks after 
start of treatment, including 2 samples with a low antibody response and 2 with a high 
response) were added and kept at 72 °C in the water bath for 30, 60, 120, 300 and 600 
seconds. Immediately after, the samples were cooled on ice.
Thirty-four raw tank milk samples from different farms were used to test the applicability 
and robustness of the anti-rbST FCIA on real samples from an EU country assumed to be 
negative.
2.4 Bead coupling
Monsanto rbST coupling to seroMAP microspheres was described before [10, 11]. Brieﬂy, 
2.5 x 106 microspheres were coupled with 0.1 mg mL-1 rbST in MES buffer. Microspheres 
were stored in blocking buffer at 2-8 °C in the dark until further use.
2.5 Pretreatment of serum and milk
Serum pretreatment for removal of non-specific interference of serum proteins was 
described before [10, 11]. A similar procedure was applied to milk samples. The entire 
procedures for serum and milk sample pretreatment are summarized in Figure 1. Milk 
pretreatment includes a filtration step to remove interferences of fat micelles with the 
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microsphere detection in the ﬂow cytometer.
 
 
 
Figure 1: Sample pretreatment and direct FCIA procedure for anti-rbST detection in serum 
and milk
For comparison of responses in serum and milk, antibody titres were determined by serial 
dilution of four milk and respective serum samples (2 with high and 2 with moderate MFI 
responses) after pretreatment and subsequently following the direct FCIA protocol. The 
titre was defined as the last dilution which still yielded a response above decision limit.
2.6 Direct FCIA
Direct FCIA for measurement of anti-bST antibodies in serum was described before [10]. 
Median ﬂuorescence intensity (MFI) was measured in response to the amount of antibody 
bound to the microsphere.
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2.7 Inhibition FCIA
To prove the specificity of the induced antibodies upon rbST treatment, different 
concentrations of rbST were added to inhibit the high ﬂuorescence signal obtained in 
samples of rbST-treated animals. Therefore, 100 µL pretreated milk samples from four 
different rbST-treated cows obtained 3 weeks after start of treatment were preincubated 
for 15 minutes with 10 µL PBST or rbST standard diluted in PBST. Then, 10 µL of 
microsphere suspension were added and subsequent steps were as described in the direct 
FCIA (Figure 1).
2.8 Data analysis
Decision limit was calculated by averaging the baseline MFI values of all cow samples 
(taken one week before start of treatment) and adding two times the standard deviation, 
yielding decision limits of 230 MFI for serum and 202 MFI for milk. Only in case of the 
inhibition experiment, baseline average of all cows was subtracted and each tested sample 
from rbST-treated animals was normalized to respective B0 (rbST-treated sample without 
added rbST standard). For a clear graphical presentation of milk versus serum responses, 
reciprocal MFI values obtained for every sample are plotted in Figure 4.
3 Results & Discussion
3.1 Assay development antibody biomarker against rbST
For detection of antibodies produced in response to rbST treatment in milk, a sample 
pretreatment was necessary to remove fat micelles from the analysed sample and reduce 
non-specific binding of other milk proteins to the microspheres. Therefore, the serum 
sample pretreatment procedure was adapted and by doing this, a shorter incubation time 
of only 5 minutes could be achieved in contrast to a 60 minutes incubation time in serum 
(Figure 1). This adjustment shortens the whole assay time to 95 minutes incubation in 
comparison to 150 minutes needed in serum for a whole 96-well microtiter plate. The 
direct FCIA procedure remained identical for serum and milk. 
3.2 Applicability to milk of individual cows
Milk samples from different time points from the animal experiments were tested for 
antibody biomarker presence. RbST-induced antibody presence was indicated by MFI 
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(median ﬂuorescence intensity) signals higher than the decision limit (calculation see 
section 2.8). In samples from rbST-treated cows, MFI signals increased and declined slowly 
but remained above the decision limit throughout the course of the experiment (Figure 
2A). Ten out of twelve rbST-treated cows (83 %) showed MFIs higher than the decision 
limit in at least one of the tested milk samples, which is in accordance with literature, 
where 70-80 % of the cows showed a physiological antibody responses in blood [6, 10, 
12]. According to findings from Zwickl et al., some of the treated cows showed very 
high responses, whereas the responses in others are just above the decision limit. In 
total, 67 % of all milk samples at any time point from rbST-treated animals displayed an 
antibody response. That means, that 33 % of the milk samples from rbST-treated animals 
gave false-negative results, but this percentage includes the 20 – 30 % physiological 
non-responders indicated in literature. For five out of eight rbST-treated cows from the 
first animal experiment, antibody responses were still detectable 2 weeks after the last 
rbST treatment. MFIs of samples from untreated animals remained below the decision 
limit for all points except two, which are just above the decision limit and considered as 
false-positive results (one each in Figure 2A and 2B). In total, 94 % are correctly found as 
negative and 6 % are considered false-positive. 
To test whether anti-rbST antibodies could also be detected after heat treatment of milk, 
which is done during milk production process, milk samples from both animal experiments 
were pasteurized and antibody biomarker responses were analysed. Pasteurization 
lowered the antibody responses in all four tested milk samples, but MFIs were beyond the 
decision limit from 30 seconds until 5 minutes of heat treatment. Even after 10 minutes of 
heat treatment, three out of four samples were still found positive for antibody response. 
These results indicate that the pasteurization process does not inhibit the detectability 
of rbST-antibodies in milk completely, whereas detecting rbST itself in spiked milk was 
considered very heat-sensitive [3].
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Figure 2: Overlay of MFI responses at different time points in milk of (A) 12 rbST-treated 
cows and (B) 5 untreated cows. Dashed line indicates the absolute decision limit.
3.3 Specificity of antibodies found in milk
The specificity of the antibody biomarker found in milk was demonstrated by adding 
different concentrations of rbST standard to four exemplary milk samples from rbST-
treated cows. An rbST concentration-dependent inhibition of the MFI response is seen in 
all of the four milk samples (Figure 3). From this result we concluded that the biomarker 
measured is indeed an rbST-specific antibody. 
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Figure 3: Specificity of endogenously produced anti-rbST antibodies. B/B0 values were 
inhibited by increasing amounts of rbST in 4 independent cows.
3.4 Comparison of milk and serum levels of rbST antibody biomarkers
To be able to evaluate to which extent antibody presence in milk correlates with serum 
antibody response, the respective serum samples were analysed as well. Antibody titres 
were determined for four exemplary serum and respective milk samples and were found 
to be in average 7-times higher in serum than in milk for three of the tested samples (titres 
ranging from 18 to 576 in milk and 160 to 1280 in serum). For one tested sample from 
a pregnant cow, the titre in milk (2304) was 2-times higher than in serum (1280). It was 
shown before, that antibody titres in milk were much higher in pregnant cows and quickly 
decreased after calving [13]. Furthermore, it has to be considered that milk and serum 
matrix might have different inﬂuence on the antibody binding to the microspheres and 
results can not directly be compared. For assessment of the correlation of serum and milk 
antibody presence in all samples, MFI values were compared. In serum, all rbST-treated 
cows showed antibody presence in at least two of the tested time points, which gave an 
overall true-positive rate of 94 %, whereas the false-positive rate was the same as in milk 
(6 %). Most of the samples showed similar responses in serum and milk, but in some cases, 
a positive response in serum could not be found positive in milk (Figure 4), but in total 
more samples were found to respond truly positive in serum. Nevertheless, analysing milk 
has major advantages over serum measurements: sampling milk is a non-invasive method 
and the assay time is much shorter compared to serum analysis. Furthermore, analysing 
pooled tank milk can overcome the problem of false-negatively responding serum and milk 
samples from individual cows; see below.
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Figure 4: Anti-rbST antibody responses in milk and serum. For clear presentation, 
reciprocal MFI values of each sample are shown. Dashed lines indicate the absolute 
decision limits in milk and serum. Dots indicate samples from rbST-treated cows, crosses 
indicate samples from untreated cows.
3.5 Storage tank milk analysis
In general practice in an rbST-authorized country, it is expected that at least 65 % of the 
combined milk in a tank load originates from treated and responding cows (see section 
2.3), but the pooled tank milk obtained might still yield an overall positive assay result. 
To proof this we did a simulation experiment, where milk samples from two positively 
responding rbST-treated cows were mixed with one milk sample from a non-responding 
rbST-treated cow, i.e., simulating 33 % physiological non-responders and non-treated 
animals in the mixture. Twenty-four different mixtures were prepared, whereof 96 % 
showed responses above the assay decision limit, which complies with the <5 % false-
negative screening criterion for veterinary drugs in animal products [14]. The advantage 
of analysing tank milk also applies to the milk of stables where cows were not treated. 
The very few false-positive responses will be “diluted away” by the many correctly 
negatively responding milk samples. This was demonstrated by the analysis of 34 tank milk 
samples from different Dutch farms, of which none responded above the decision limit. 
Furthermore, analysing tank milk and obtaining an overall positive antibody response for 
milk of rbST-treated cows offers the future opportunity to develop fast, cheap and easy 
to use testing devices for on-farm use. The developed FCIA screening method features a 
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long detection window of at least two weeks after the last rbST treatment. Unfortunately, 
LC/MS confirmation methods for rbST in blood can only detect rbST for a short period 
following administration [15] and in milk, no time course studies were done in rbST-
treated animals by these authors. Because of this, high frequency blood sampling would 
be necessary to ensure confirmation of rbST abuse by this LC/MS method. Therefore, for 
future veterinary control according to Commission Decision 2002/657/EC, we suggest a 
tiered screening method, which consists of three steps: First, a fast tank milk screening 
for anti-rbST antibodies using the present FCIA. Second, in case of suspicious findings, a 
more detailed individual bovine serum biomarker profiling is envisaged, which will provide 
additional evidence, since that will be based on more biomarkers and data of individual 
cows. And third, a sufficiently sensitive instrumental method is used for final confirmation 
of rbST itself in serum samples of the individual cows. 
4 Conclusion
An FCIA screening method for anti-rbST biomarker in milk was successfully developed and 
applied to raw milk, pasteurized milk and raw milk pools (simulating tank milk analysis). 
The sample pretreatment known from serum analysis was adjusted and shortened for milk 
analysis, which facilitates the assay procedure and saves time. A preliminary validation 
of the screening method was performed by testing milk samples from untreated dairy 
cows, which allowed the calculation of an absolute decision limit. Sixty-seven percent of 
the tested milk samples from animals treated with rbST showed physiological antibody 
responses higher than the decision limit, whereas 94 % of untreated animals did not. This 
resulted in a false-positive rate of only 6 % and a false-negative rate of 33 %. The detection 
window ranged at least until two weeks after the last rbST treatment, where a positive 
antibody biomarker response still was found in 63 % of the cows. Antibody responses in 
milk were specific for rbST and similar to serum responses. Pasteurization did not fully 
obstruct the detectability of this biomarker, so even processed milk might be tested. In 
34 tested tank milk samples from Dutch farms, no single false-positive result was found. 
Moreover, more than 95 % of simulated tank milk samples from rbST-treated cows showed 
a positive assay response, which is an adequate true-positive screening rate according to 
veterinary drug screening regulations. 
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Abstract
Current contaminant and residue monitoring throughout the food chain is based on 
sampling, transport, administration and analysis in specialized control laboratories. This 
is a highly inefficient and costly process since typically more than 99 % of the samples are 
found to be compliant. On-site simplified pre-screening may provide a scenario in which 
only samples that are suspect are transported and further processed. Such a pre-screening 
can be performed using a small attachment on a cellphone. To this end, a cellphone-
based ﬂuorescence imaging platform for the detection of anti-rbST (recombinant bovine 
somatotropin) antibodies in milk extracts was developed. RbST administration to cows 
increases their milk production, but is illegal in the EU and a public health concern in the 
US. The cellphone monitors the presence of anti-rbST antibodies (rbST biomarker), which 
are endogenously produced upon administration of rbST and excreted in milk. The rbST 
biomarker present in milk extracts is captured by rbST covalently coupled to paramagnetic 
microspheres, and labeled by Quantum Dot (QD)-coupled detection antibodies. The 
emitted ﬂuorescence light from these captured QDs was then imaged using the cellphone 
camera. The ﬂuorescence micro-images were analysed using a custom-developed Android 
application running on the same cellphone. With this setup, the cellphone microsphere-
based ﬂuorescence immunoassay was successfully applied to milk sample extracts from 
rbST-treated cows. Next, the cellphone immunoassay was benchmarked against a newly 
developed planar imaging array alternative. Using cellphone-based on-site analysis in 
future residue monitoring can limit the number of samples for laboratory analysis already 
at an early stage. Therewith, the entire monitoring process can become much more 
efficient and economical.
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1 Introduction
Current contaminant and residue monitoring throughout the food chain comprises several 
steps that are standardized and require extensive administration. First, samples are taken 
either at the farm, in the food industry, in retail or even at the consumer’s home. Samples 
are then transported to specialized control laboratories, where they are registered and 
stored. Thereafter, depending on the residue to be monitored, all samples are subject to 
an initial screening procedure, which identifies suspicious samples in a high-throughput 
manner. Any identified suspicious sample undergoes the subsequent confirmation 
procedure, in which the residue is unequivocally identified and, if necessary, quantified [1]. 
Throughout the entire residue monitoring process, the number of transported, analysed 
and administrated samples is enormous, since only after screening at a specialized 
laboratory, they become narrowed down to the actual suspicious ones (Figure 1). This 
process is very inefficient and costly since typically more than 99 % of the samples are 
found to be compliant.
Figure 1: Comparison of current and proposed future residue monitoring in the food chain. 
Bar widths represent the relative number of samples processed during the respective 
monitoring step.
For future contaminant and residue monitoring, we propose a slightly different approach: 
the introduction of a simplified on-site pre-screening step that limits the number of 
samples for the following steps already at a very early stage (Figure 1). Then, only the 
suspicious samples will be transported, administrated and further analysed in specialized 
control laboratories. Furthermore, the screening procedure in the specialized laboratory 
would only remain optional. This proposed approach is much more efficient in terms of 
transportation, administration and use of equipment in highly specialized laboratories. For 
the proposed on-site pre-screening procedure, a small attachment on a cellphone may be 
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used and the administrative data together with the results can be transmitted wireless to a 
food quality and safety officer.
As a first step on the road towards future cellphone-based food analysis we adopted 
a cellphone attachment, originally designed for cell analysis [2-5], and turned it into 
a microsphere ﬂuorescence immunoassay using the analysis of recombinant bovine 
somatotropin (rbST) biomarker in milk extracts as a showcase. RbST is a proteohormone 
and increases milk production in dairy cows up to 10-20 % [6]. While rbST use is approved 
by the Food and Drug Administration in the United States, it is banned in the European 
Union [7]. To implement European regulations and have accurate ‘rbST-free’ labelling 
of milk in for example the US, field monitoring of rbST use and abuse is necessary and 
would be greatly facilitated by the use of cellphone-assisted rapid screening assays even 
at farm settings. To screen for rbST, rbST-dependent protein biomarkers can be measured 
[8]. Protein biomarkers include antibodies, which are endogenously produced by the cow 
upon treatment with rbST. These anti-rbST antibodies are not only present in serum but 
also in milk [9]. Previously, a microsphere-based ﬂow cytometric immunoassay (FCIA) 
method for the detection of anti-rbST antibody (rbST biomarker) in milk was developed 
[9]. In this previous method, rbST is covalently coupled to microspheres. After incubating 
the microspheres with a milk sample from an rbST-treated cow, the biomarker binds 
to the rbST on the surface of the microspheres. The presence of the rbST biomarker 
can then be detected by a ﬂuorescently labeled anti-bovine-IgG detection antibody. 
Finally, the ﬂuorescence on the microspheres is measured using a ﬂow cytometer (used 
as a reference method in this paper) [9]. In the present work, we redesigned that rbST 
biomarker detection assay and combined it with a cellphone-based analysis by imaging 
the total ﬂuorescence on a number of microspheres. To this end, a low-cost opto-
mechanical cellphone attachment was designed, which uses ultraviolet (UV) light emitting 
diodes (LEDs) to excite ﬂuorescent Quantum Dot (QD)-labeled anti-bovine-IgG detection 
antibodies. An optical filter and an external lens in this attachment were used to image the 
emitted light onto the cellphone camera. A custom-developed Android application, which 
we term as ‘GotMilk’, enabled image analysis to be performed on the same cellphone to 
obtain immediate results. 
The developed cellphone immunoassay platform was benchmarked against a newly 
developed transportable planar imaging array version of the original FCIA approach. 
The results of this comparison revealed that our cellphone-based approach could detect 
milk extracts from rbST-treated cows equally well. We believe that the cost-effective and 
field-portable design of our detection platform provides a good match for field testing of 
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milk samples even in farm conditions and permits remote reporting and analysis of the 
acquired test results.
2 Materials and Methods
2.1 Chemicals and instruments
Monsanto rbST standard was obtained from the National Hormone & Peptide Program of 
Dr. Parlow (Torrance, CA, USA). Posilac 500 mg single-dose syringes and syringes with only 
the slow-release formula were purchased from Monsanto company (St Louis, MO, USA) 
and Ely Lilly and Company (Indianapolis, IN, USA). Sodium chloride (NaCl), monosodium 
phosphate monohydrate (NaH2PO4xH2O), potassium dihydrogen phosphate (KH2PO4), 
Tween 20, sodium azide (NaN3) and glass microscope cover slides (rectangular: 24 x 32 
mm, thickness 1; round: Ø 10 mm, thickness 1) were obtained from VWR International 
(Amsterdam, The Netherlands) and off-the-shelf transparent nail polish was from Herome 
Cosmetics B.V. (Almere, The Netherlands). Sodium hydroxide (NaOH), disodium hydrogen 
phosphate dihydrate (Na2HPO4 x 2 H2O) and hydrochloric acid (HCl) were purchased from 
Merck (Darmstadt, Germany). Sodium dodecyl sulfate (SDS) was obtained from Serva 
(Heidelberg, Germany) and sulfo-N-Hydroxysuccinimide (sulfo-NHS) from Fluka (Buchs, 
Switzerland). N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride (EDC), 
2-(N-morpholino)ethanesulfonic acid (MES hydrate) and bovine serum albumin (BSA) 
were purchased at Sigma-Aldrich (St. Louis, MO, USA). MagPlexTM microspheres (set 
064) and the MagPixTM planar imaging array platform were from Luminex (Austin, TX, 
USA). Carboxylated paramagnetic polystyrene microspheres (diameter 8-9.9 µm) were 
obtained from Microspheres-Nanospheres (Cold Spring, NY, USA) and R-phycoerythrin 
(PE)-coupled and biotinylated goat anti-bovine immunoglobulins were both from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Protein LoBind Tubes and 1.5 mL reaction 
tubes were from Eppendorf (Hamburg, Germany). Streptavidin-coupled Quantum Dots 
(QD; semiconductor CdSe crystal core coated with a semiconductor ZnS shell, a polymer 
coating and streptavidin protein; total size 15-20 nm; emission at 625 nm) were from Life 
Technologies (Grand Island, NY, USA) and MultiScreen HTS filter plates were purchased 
from Millipore (Billerica, MA, USA). The 96-well plates were from Greiner Bio-One B.V. 
(Alphen aan de Rijn, The Netherlands), the magnetic separator was from Dexter Magnetic 
Technologies, Inc. (Elk Grove Village, IL, USA) and the orbital shaker was obtained from 
Salm en Kipp B.V. (Breukelen, The Netherlands). White light emitting diodes (3 mm) were 
from Conrad Electronic Benelux BV (Oldenzaal, The Netherlands) and the Samsung Galaxy 
SII was obtained from Amazon.com, Inc. (Seattle, WA, USA). Ultra-bright ultraviolet (380 
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nm) 5 mm LEDs were bought from Parts Express (Springboro, OH, USA) and 610 nm long 
pass filter (25 mm diameter) and aspherical lens (focal length 8 mm) were obtained from 
Thorlabs (Newton, NJ, USA). The battery compartment was obtained from DigiKey (Thief 
River Falls, MN, USA) and the 3-D printer model Dimension Elite was from Stratasys (Eden 
Prairie, MN, USA).
2.2 Sample material
Milk samples from two Bos taurus animal experiments were used, which had been 
analysed previously with the FCIA method [9]. The following milk sampling time points 
were used in the present study: one week before the rbST or placebo treatment and 36 
and 58 days after the start of the treatment. Milk samples from untreated animals were 
randomly selected to determine a decision limit, which was calculated by averaging the 
test results and adding two-times their standard deviation. Thereafter, 20 milk samples 
from rbST-treated cows with known rbST antibody responses were tested and a sample 
was considered as being suspicious for rbST treatment, when its test result was higher 
than the calculated decision limit. All tested methods, viz. cellphone, planar imaging array, 
and original FCIA, were evaluated for their capability of truly detecting rbST treatment 
samples.
2.3 Buffers and solutions
Buffers and solutions used were as follows: phosphate-buffered saline (PBS; 154 mM NaCl, 
5.39 mM Na2HPO4, 1.29 mM KH2PO4, pH 7.4), PBST (PBS, 0.05 % v/v Tween 20), activation 
buffer (100 mM NaH2PO4, pH 6.2), MES buffer (50 mM, pH 5), blocking buffer (PBS, 0.1 % 
w/v BSA, 0.02 % v/v Tween 20, 0.05 % w/v NaN3), sample diluent (PBST, 0.1 % w/v BSA, 
0.008 % w/v SDS).
2.4 Microsphere preparation 
RbST was covalently coupled to carboxylated non-coloured magnetic polystyrene 
microspheres for the cellphone platform using the two-step carbodiimide reaction as 
described previously [10]. All protocol steps were done in ProteinLobind Tubes to avoid 
protein loss. Brieﬂy, 200 µl microsphere suspension was used and microspheres were 
washed in deionized water, activated with 10 µL 50 mg mL-1 sulfo-NHS in dH2O, 10 µL 
50 mg mL-1 EDC in dH2O and 80 µL activation buffer for 18 minutes, washed twice in 
500 µL MES buffer, covalently coupled with 0.1 mg mL-1 rbST in 500 µL MES buffer for 2 
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hours, blocked in 500 µl blocking buffer for 30 minutes, washed in 500 µL blocking buffer 
twice and stored in the dark in 500 µL blocking buffer until further use at 2-8 °C. The 
same protocol was followed for coupling rbST to colour-encoded MagPlex microspheres 
(microsphere set number: 064) for the planar imaging array platform.
2.5 Preparation of milk extracts
Before conducting the assay protocol, milk samples must be extracted to lower non-
specific binding to the microspheres. The extraction procedure is summarized in Figure 
S1 of the Supplementary Information. Note that the development of a simplified on-site 
extraction method was not the objective of the present study yet. Therefore, filtration for 
removal of fat micelles was simply done by centrifugation at 3000 g for 5 minutes using 
1.2 µm pore size 96-well filter bottom plates.
2.6 Cellphone-based detection platform
2.6.1 Opto-mechanical attachment design 
The cellphone attachment was designed specifically for an Android-based Samsung Galaxy 
SII cellphone and based on the model of the previously described ﬂuorescence microscopy 
cellphone platform [2-5]. Similar attachments can also be created for other smart-phones. 
This cellphone attachment module (overall dimensions: 88 x 73 x 31.25 mm) consisted of 
several parts (Figure 2A and 2B): 
• a cellphone holder to align all optical parts with the camera, 
•  a sample tray to position the cover slides, having the microsphere suspension   
 sandwiched in between, 
•  twelve excitation light emitting diodes (wavelength 380 nm) for exciting the QDs  
 for ﬂuorescence imaging. These LEDs were arranged on three of the four sides of  
 the sample tray perpendicular to the glass cover slides, so that the glass slides   
 could serve as planar waveguides for the excitation light, 
•  two white light LEDs for darkfield imaging, 
•  an optical filter (long pass 610 nm, 25 mm diameter) was placed in the  sample   
 tray for filtering the scattered excitation light, 
•  an aspherical lens that provides 2X demagnification of the microspheres and an  
 increase of the imaging field of view, 
•  a battery compartment and  
•  a mechanical lid to protect ﬂuorescence measurements from ambient light.
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The mechanical components of this attachment unit were made from thermoplastic using 
a 3D printer. The entire attachment was aligned with the cellphone in such a way that 
the centre of the cellphone camera lens was in line with the centre of the attachment’s 
external lens. The costs of such an attachment are typically a few dollars only [3, 5].
Figure 2: Schematic overview (A, C) and a picture (B) of the cellphone attachment for the 
detection of rbST biomarker in milk extracts. (D) Excitation (dotted lines) and emission 
(solid lines) spectra of R-phycoerythrin (R-PE, green) and 625 nm emitting Quantum Dots 
(QD, red).
2.6.2 Cellphone-based assay procedures
The cellphone-based assay procedures utilize the specific binding of the cows’ endogenous 
rbST biomarker to rbST-coupled magnetic microspheres. After a washing step, a QD-
labeled anti-bovine antibody is used to detect the presence of the rbST biomarker (Figure 
3A).
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Figure 3: (A) Assay principle for rbST biomarker detection, (B) detection setup for the 
cellphone-based platform, and (C) detection setup of the planar imaging array platform 
(C).
After the milk extraction, the immunoassay (Figure S1) could be performed in transparent 
96-well plates. For all dilutions and washing steps, PBST was used and the procedure 
was performed at room temperature. While the FCIA reference method used R-PE as a 
ﬂuorescence label, 625 nm emitting QDs were used for the cellphone-based detection 
because their excitation and emission spectra allow the use of a standard long pass filter 
(Figure 2D) and QDs do not show photo-bleaching effects. The prepared sandwiched 
glass slides were slid into the cellphone attachment and a darkfield image was taken by 
using the white LEDs (Figure 3B) and the internal camera of the cellphone operated in the 
‘night mode’ for increased sensitivity. Thereafter, the white LEDs were switched off and UV 
LEDs were switched on (Figure 3B) for taking a ﬂuorescence image with the same settings 
on the cellphone. The acquired ﬂuorescence images were analysed by using a custom-
designed Android application, termed ‘GotMilk’. Using this smart application, it is possible 
to analyse images located at the internal memory of the cellphone or to capture images 
with the camera and analyse them immediately. After a region of interest was selected 
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(unless otherwise specified, by default the centre region of the image was analysed), total 
microsphere count, average ﬂuorescence intensity and its standard deviation were given 
as the result of the measurement (Figure 4). This analysis procedure was possible for both 
ﬂuorescence images and darkfield images; in the latter the number of total microspheres 
was counted, which was used for normalization in the ﬂuorescence image analysis.
 
Figure 4: Overview of the GotMilk Android application user interface for analysis of 
cellphone camera images (ﬂuorescence and darkfield).
2.7 Planar imaging array detection platform
The FCIA reference method described by Ludwig et al. [9] was slightly modified in a 
way that for all tested platforms in this work, the same sample extraction procedure 
could be applied (Figure S1). Next, the assay principle of the FCIA reference method was 
transferred to a newly developed transportable planar imaging array. For this, colour-
encoded MagPlex microspheres (microsphere set number: 064) were coupled with 
rbST as described in Section 2.4, milk samples were extracted as detailed in Section 
2.5 and the samples were prepared following the procedures shown in Figure S1. Since 
colour-encoded microspheres and the photo-labile ﬂuorophore R-PE were used for this 
platform, all the assay procedures were performed in the dark. The readily prepared 
microspheres in the 96-well plate were put into the planar imaging array instrument for 
detection (Figure 3C). The colour code of the microspheres was identified after excitation 
with a red LED (621 nm) and the signal was detected with a CCD camera and two optical 
filters. The amount of ﬂuorescence (i.e., the signal) for each microsphere was quantified 
after excitation with a green LED (511 nm) and detected with the CCD camera and an 
optical filter (590 nm). The quantified ﬂuorescence signal was reported as the median 
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ﬂuorescence intensity (MFI) of the particles. A decision limit was calculated as described in 
Section 2.2.
3 Results
3.1 Cellphone-based detection
In this work, a cellphone-based analysis method for the detection of anti-rbST antibodies 
(rbST biomarker) was developed, following the capture of rbST biomarker by rbST-coupled 
magnetic microspheres. The binding event was detected using a Quantum Dot (QD)-
labeled detection antibody together with the specific imaging design of the cellphone 
attachment.
3.1.1 Cellphone-based ﬂuorescence and darkfield imaging
The developed cellphone attachment for visualizing the presence of rbST biomarker is a 
light-weight and low-cost device, which can easily be attached to and detached from the 
cellphone. Its compactness, light weight and low-power consumption makes it a versatile 
tool, suitable for laboratory and field use. It can be adapted to any available cellphone 
that has a camera module by simply modifying the dimensions of the cellphone holder 
and 3D-printing another one accordingly. Our specific attachment was designed for the 
excitation and emission light spectrum of the 625 nm-emitting QDs (Figure 2D), which 
were used as a label in the rbST biomarker assay. Therefore, UV LEDs (at 380 nm) were 
used for excitation of these QDs and a 610 nm long pass filter was used for filtering the 
emission light. Furthermore, an external aspherical lens was used for demagnification of 
the microspheres such that a large field of view of 80 mm2 was imaged by the cellphone 
camera. White light LEDs were also used in the same design for capturing darkfield images 
of the microspheres such that the total microsphere count could be determined. Since 
the long pass filter was not removed for darkfield imaging, the microspheres in darkfield 
images appeared also in red colour. The cellphone holder and the sample tray positioned 
all the optical parts correctly and aligned the external and camera lenses for imaging. 
Using this cellphone attachment setup, darkfield (Figure 5A.1 and 5B.1) and ﬂuorescence 
(Figure 5A.2 and 5B.2) images were captured, where a custom-designed application 
(GotMilk) was used to process these images to count the number of microspheres and 
determine their mean ﬂuorescence intensity. 
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Figure 5: Sample images obtained using the presented cellphone-based ﬂuorescence 
immunoassay platform. Darkfield (1) and ﬂuorescence images (2) are shown for a milk 
extract from (A) an rbST-treated animal and (B) a milk extract from an untreated animal. 
Note that the darkfield images also appear in red colour due to the long pass filter present 
in the optical path.
3.1.2 Cellphone image data analysis
To be able to discriminate samples deriving from rbST-treated and untreated animals, 
two different image analysis approaches, namely the intensity analysis approach and 
the microsphere count-based approach were tested for reproducibility and linearity. For 
reproducibility, the same milk extract was analysed repeatedly and for linearity, samples 
with no, low and high rbST biomarker levels were correlated to the results of the FCIA 
reference method. Note that it is not possible to measure absolute rbST biomarker 
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concentrations due to a lack of a suitable standard protein. In the intensity analysis 
approach, the average intensity values of the detected microspheres and the standard 
deviations calculated by the GotMilk application were used. This approach was expected 
to deliver similar results as the planar imaging array platform (Section 2.7 and 3.2), in 
which also median ﬂuorescence intensities (MFIs) are obtained. However, this approach 
was found less useful in our cellphone platform: first, the dynamic range of the obtained 
intensities varied between 0.09 and 0.22 on a scale from 0 to 1.00 (Figure 6A.1). Second, 
the standard deviation of the microspheres from the same sample was approximately 25 % 
of the total intensity, which is high and makes the discrimination between milk samples 
from rbST-treated and untreated animals difficult. Third, there was no obvious biomarker-
dependent increase in signal observed (see for example Figure 6A.1 and 6A.2).
 
 
Figure 6: The signal intensity obtained using the cellphone platform with (A) the intensity 
analysis approach, and (B) the microsphere count ratio obtained with the microsphere 
count-based approach. Reproducibility and linearity (A.1 and B.1) and individual results 
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for milk sample extracts from rbST-treated (squares and triangles) and untreated (circles) 
animals (A.2 and B.2). (C) Correlation of MFI results obtained using the planar imaging 
array detection approach compared to the reference FCIA method. The decision limit, 
above which a sample was considered as ‘suspicious for rbST treatment’ is marked as red 
dotted line. The decision limit of the ﬂow cytometer reference method is marked with a 
black dotted line. MFI: median ﬂuorescence intensity. 
As an alternative method, a microsphere count-based approach was tested, in which 
the total microsphere count of the ﬂuorescence image was normalized against the total 
microsphere count of the darkfield image and this ratio was used for analysis. Using this 
approach, an increased dynamic range (0.01 to 0.88 on a scale from 0 to 1.00) and an 
improved reproducibility could be obtained as illustrated in Figure 6B.1. Furthermore, this 
microsphere count ratio correlated quite well with the biomarker presence in the milk 
extracts. Therefore, this approach was selected to analyse 20 milk sample extracts deriving 
from rbST-treated cows.
3.1.3 Results of milk sample extracts analysed with the cellphone-based 
immunoassay platform
For evaluation of the developed cellphone-based rbST biomarker detection platform, 20 
milk sample extracts from untreated cows were tested for decision limit calculation and 
thereafter, 20 further milk extracts from rbST-treated cows, having anti-rbST antibody 
response according to FCIA, In both cases the microsphere count-based approach as 
detailed in the previous sub-section was applied. Examples of darkfield and ﬂuorescence 
images of milk samples taken from rbST-treated and untreated cows can be seen in Figure 
5. In the darkfield images (Figure 5A.1 and 5B.1), microspheres are well visible as red 
dots. In the ﬂuorescence image of the sample from an rbST-treated animal (Figure 5A.2), 
the majority of microspheres shows a ﬂuorescence signal, whereas in the sample from an 
untreated animal, only a few ﬂuorescence signals are visible (Figure 5B.2). The decision 
limit was determined by averaging the microsphere count ratios of 20 milk extracts from 
untreated cows and adding two-times their standard deviation (Section 2.2) and was 
found to be at a microsphere count ratio of 0.261. Based on this decision limit, our tests 
revealed that fifteen out of the 20 tested milk extracts (75 %) from rbST-treated animals 
were found suspicious for rbST treatment. Of course, the 75 % truly positive screening rate 
of the cellphone is not good enough for official testing yet; on the other hand, it is quite 
remarkable that such a simple low-cost device demonstrates such a rate already now.
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The laboratory-based FCIA reference method was used to test the same 20 milk samples 
from untreated animals for decision limit calculation (211.9 MFI; calculated according 
to Section 2.2); followed by the 20 milk samples from rbST-treated animals, whereof 19 
were found to exceed the decision limit, meaning that 95 % of the samples were found 
suspicious for rbST treatment using the lab-based FCIA method.
3.2 Planar imaging array assay
3.2.1 Development of the planar imaging array assay
For the planar imaging array-based detection method, the same sample preparation 
protocol of the cellphone-based approach (with a single step of sample dilution) was used. 
The assay procedure were adopted from the FCIA reference method (Figure 3C, S1 and 
Section 2.7).
3.2.2 Results of milk sample extracts analysed with the planar imaging array 
instrument
When the 20 milk samples from untreated animals were analysed using the planar imaging 
array instrument, a decision limit of 26.72 MFI was calculated as described in Section 2.2. 
Furthermore, the variability in between the negative samples was quite low (4.3 % CV). 
Of the 20 analysed milk sample extracts from rbST-treated animals, sixteen (80 %) were 
correctly identified as being suspicious for rbST treatment with the planar imaging array 
platform. Note that this achievement is hardly better than the cellphone results. The 
individual results of each milk sample are depicted in Figure 6C in correlation to the results 
of the reference ﬂow cytometer method.
4 Discussion
We presented the development and initial real-life applicability testing of a field-portable 
cellphone-based analysis platform for the detection of rbST biomarker in milk extracts. 
Other cellphone-based detection platforms were developed before for several different 
applications [2-5, 11-23]. The here presented platform, however, combines for the first 
time immunoﬂuorescence detection of single molecules from a sample extract using a 
cellphone for ﬂuorescence and dark field imaging.
When testing 20 milk extracts derived from rbST-treated cows, our cellphone-based 
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detection platform performed similar to the planar imaging array (Table 1). Currently, the 
assay time is substantial and therefore, future studies should focus on simplified on-site 
sample preparation and shorter incubation times. For example, as a first step, in-field 
sample extraction could be performed by simply diluting the milk sample and remove fat 
micelles by quick syringe-filtration. Second, the QD detection antibody may be prepared 
as a single reagent thereby omitting the 30 minutes incubation step for streptavidin-QD in 
Figure S1. Third, co-incubating all assay reagents simultaneously may reduce the several 
individual incubation steps down to only one. Fourth, the employment of a microﬂuidic 
chip comprising all assay reagents prepared would facilitate the entire assay procedure. 
One should be aware that with the cellphone-based approach the results can be obtained 
at the site where the sample was taken, i.e., transporting the samples to a specialized 
laboratory is no longer required. When a suspicious sample is identified during the on-site 
screening process, further samples, for instance blood samples, can also be taken for 
subsequent laboratory-based analysis (Figure 1). In that case, the multiple serum protein 
biomarker screening test previously developed [8] and direct confirmatory analysis of rbST 
itself using LC-MS/MS [24] can be applied.
When benchmarking the anti-rbST platforms available so far, the cellphone-based 
detection device is the only option for on-farm analysis of tank milk by inspection services 
(or truck milk at the dairy gate). The planar imaging array platform is, compared to the 
ﬂow cytometer instrument, transportable, but its dimensions (16.5 x 60 x 43 cm) and its 
weight of 17.5 kg (the necessary operating computer not included) do not favour in-field 
use. Note that, as highly desired, the cellphone immunoassay platform combines not only 
a camera and image analysis tool, but it also allows data storage and wireless transmission 
via a mobile network to food quality and safety officers, central inspection agencies, 
control laboratories or industrial QA/QC decision makers.
Multiplexing can be easily achieved by the planar imaging array platform and the 
ﬂow cytometer reference method, which are designed especially for colour-encoded 
microsphere ligand binding assays. For the cellphone-based detection device, multiplexing 
may be achieved easily by using either different ﬂuorescent labels for additional analytes 
or different colour-encoded or size-encoded microspheres in the microsphere counting 
process. In both cases, the cellphone attachment needs LEDs of different wavelengths and 
exchangeable optical filters as demonstrated recently by Zhu et al. [5]. Alternatively, using 
microspheres of a different size would only require adjustments in the GotMilk application 
in order to discriminate bigger and smaller particles in the ﬂuorescence and darkfield 
images.
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Table 1: Performance of the cellphone assay for rbST biomarker detection in cows’ milk 
versus alternative approaches
Cellphone detection Planar imaging array 
platform
Flow cytometer 
reference method
Amount of samples 
found suspicious for 
rbST treatment
75 % 80 % 95 %
Reading time 5 minutes per sample 1 minute per sample 1 minute per sample
Portability Portable Transportable Not transportable
In-field applicability No external power 
supply needed
Operation requires 
external power supply
Not applicable in field
Multiplexing capability Requires inter-
changeable filters 
Multiplex ready Multiplex ready
Wireless Connectivity Yes No No
In conclusion, we demonstrated the development and real-life applicability of a novel 
cellphone-based assay platform for the analysis of rbST biomarker in milk as a pre-
screening method for the detection of rbST abuse in dairy cattle. Applying this cellphone-
based on-site pre-screening in future contaminant and residue monitoring can limit 
the number of samples to be processed already at an early stage. Therewith, the 
administration and transport of an extensive number of compliant samples can be avoided 
and the entire monitoring process can become much more efficient and economical 
(Figure 1). The cellphone platform’s small dimensions, light weight and cost-effectiveness 
make it highly desirable for field testing even in farm settings.
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Figure S1: Sample preparation procedures for the three platforms that are used in this 
work and the ﬂow cytometer reference method.
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Abstract 
On-site testing has a broad significance for food safety, environment and health monitoring 
and simultaneous analysis of multiple analytes (contaminants or biomarkers) saves 
analysis time, money and sample volume. Here we present the scientific concept of a 
protein microarray-based platform for multiple biomarker detection on a cellphone. We 
selected the detection of recombinant bovine somatotropin (rbST) abuse based on altered 
biomarker profiles of IGF-1 and anti-rbST antibodies in milk extracts as a showcase. A 
multiplex immunoassay having built-in positive and negative controls was designed on 
a microarray chip. The 48 microspots were labelled with Quantum Dots depending on 
the biomarker levels in the sample. Fluorescence was detected by the cellphone camera 
under UV light excitation from LEDs embedded in a simple 3D-printed opto-mechanical 
attachment on the cellphone and images were analysed by custom software. RbST-treated 
and untreated cows clearly showed a treatment-dependent biomarker profile in milk. 
Broad application and adoption of this concept is envisaged.
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On-site testing platforms have a broad significance for food safety, environment and 
health monitoring as they allow the analysis of samples on the spot and the initiation 
of immediate measures depending on the outcome of the test. In food safety controls, 
on-site testing platforms can be used to detect the presence of antibiotics, contaminants 
or veterinary drugs for instance in milk directly on farm. In environmental monitoring, 
toxins, heavy metals or endocrine disrupting chemicals can be analysed directly at the 
sampling site. And in health care, disease biomarkers can be monitored using an on-site 
testing platform as a point-of-care (POC) device. In recent years, several on-site testing 
platforms have been developed, for instance for food allergen testing [1], monitoring of 
polycyclic aromatic hydrocarbon (PAH) presence in river water [2], detection of mercury 
contamination in water [3] and red and white blood cell analysis [4, 5]. Topol summarized 
that “the 2010s will probably be known as the era of digital medical devices” [6], but these 
recent developments demonstrate a broader significance of on-site testing platforms 
beyond disease diagnosis. Another trend within the area of on-site monitoring is the 
use of standard cellphones, which are equipped with simple attachments for analysis 
[4, 5, 7]. These attachments usually house simple optical components to enable imaging 
and analysis of the sample using the built-in camera module of the cellphone. For all 
applications, the simultaneous analysis of multiple analytes, such as contaminants, 
chemicals or biomarkers, is advantageous, because it saves analysis time, money and 
sample volume. To meet the demands of multiple analyte detection using an on-site 
platform, we present here a protein microarray for biomarker detection on a standard 
cellphone as a scientific concept. Design features are 48 array spots thus allowing replicate 
measurements of multiple biomarkers and built-in positive and negative quality controls. 
We chose the biomarker-based detection of recombinant bovine somatotropin (rbST) 
abuse in milk sample extracts from dairy cows as a challenge. RbST is a proteohormone 
that can be used to increase milk production but its administration is illegal in EU [8] 
and of consumer’s concern in the USA. To detect rbST abuse, it has been shown that 
rbST-dependent protein biomarkers in serum and milk of dairy cows can be monitored, 
but levels are typically low (10 ng mL-1 range) [9-11]. Here, we analyse the biomarkers 
anti-rbST antibodies and insulin-like growth factor-1 (IGF-1) in milk sample extracts by 
a ﬂuorescence immunoassay microarray. The array was conveniently imaged using a 
cellphone equipped with a 3D-printed opto-mechanical attachment originally designed as 
a ﬂuorescent microscope for e.g., particle analysis (Figure 1A) [12].
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Figure 1: Cellphone with ﬂuorescent microscope attachment, detection setup and 
microarray image. (A) Photograph of the 3D-printed microscopic imaging attachment on 
the cellphone, which was used for analysis. (B) Setup of the cellphone biomarker detection 
platform. A detailed description of the microarray immunoassay setup can be found in the 
Supplementary Material. (C) Exemplary microarray image obtained using the cellphone 
ﬂuorescent microscope.
The microarray for rbST biomarkers comprised four different proteins spotted on a single 
functionalized glass slide: rbST for anti-rbST antibody analysis, anti-IGF-1 antibody for IGF-
1 analysis, ovalbumin as negative control and sheep IgG as positive control. The positive 
control was used to monitor whether the assay was performed properly and provided 
reference points for image analysis and for normalization of all the other protein spots 
(further details can be found in the Materials and Methods section, Figure S1 and Figure 
S2A in the Supplementary Material). The microarray chip was successively incubated with 
milk sample extract, secondary antibodies and Quantum Dots, whereupon the microarray 
spots were ﬂuorescently labelled depending on the amount of biomarker present in 
the sample extract. The microarray chip was subsequently imaged using the low-cost 
cellphone attachment housing UV LEDs for ﬂuorescence excitation, an external lens for an 
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increased field of view and an optical filter (Figure 1A and Figure 1B) [12]. An exemplary 
microarray image as it was taken by the cellphone camera is shown in Figure 1C. The 
luminance of each single protein spot in the microarray images was automatically analysed 
using a custom-written MATLAB software code, which detected all protein microspot 
locations (Figure S2C) and reported median luminance values per protein spot. The 
luminance data of respective protein spots were averaged, the background signal (negative 
control) was subtracted and the background-corrected luminance was normalized against 
the positive control on the same microarray chip. 
As a first step for evaluating the applicability of the developed protein microarray, an 
IGF-1 standard addition curve was measured, which was prepared in milk extracts from 
an untreated cow. The best results were obtained with 100 µg mL-1 anti-IGF-1 antibody 
spotted onto the microarray chip. Despite the relatively small increase in ﬂuorescence 
signal, a concentration-dependent trend was clearly obtained (Figure 2), demonstrating 
that the low IGF-1 levels in milk extracts can be analysed in the relevant physiological 
range using a cellphone-based ﬂuorescent microarray platform. Note that no standard 
curve can be obtained for the anti-rbST antibodies because of the lack of a pure standard 
of that biomarker. Then, milk sample extracts from rbST-treated and untreated cows were 
tested to investigate whether these can be discriminated on the basis of their biomarker 
responses. In milk sample extracts from rbST-treated cows increased IGF-1 levels and anti-
rbST antibodies were detected (Figure 3A and Figure 3B). These results are in agreement 
with previously found increased IGF-1 levels and anti-rbST antibody presence in serum and 
milk after rbST treatment [9-11]. Furthermore, similar as with more sophisticated lab-
based methods, in this protein microarray approach anti-rbST antibodies also appear to be 
more discriminative than IGF-1 [9, 10]. Anti-rbST antibodies form a very specific biomarker 
and are only induced after rbST treatment and not present in serum or milk otherwise [9, 
10], whereas IGF-1 is always present in serum and milk at certain background levels.
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Figure 2: IGF-1 standard addition curve. The curve was prepared in milk from an untreated 
cow.
Compared to the particle-based cellphone concepts [12, 13], the presented microarray 
format shows several advantages. First, no white LED is required in the microarray format. 
Previously, a white LED was used to locate and count the total number of particles in the 
darkfield image. In the multiplexed microarray format presented in this work, the positions 
of the positive control spots determine the location of the other protein spots, which can 
then be easily analysed using the automatic image analysis. Second, in our previous work, 
a particle count ratio between the ﬂuorescence and darkfield images was calculated, 
which correlated with the biomarker level in the sample. Therefore, two individual images 
had to be taken and analysed in our previous work. In the current format, however, the 
luminance of each protein spot is determined from a single image in the ﬂuorescence 
mode. And third, using the multiplexed microarray format, the simultaneous detection 
of multiple replicates of several different biomarkers is possible and even positive and 
negative controls can be incorporated. The fixed location of each individual spot in the 
array allows the discrimination of multiple biomarkers by using the same Quantum Dot 
label for all markers analysed.
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Figure 3: Biomarker responses of rbST-treated and untreated cows. (A) Normalized 
luminance units of the biomarker anti-rbST antibodies in milk extracts from untreated 
(1, 2; white bars) and rbST-treated (3, 4; grey bars) cows. (B) Normalized luminance units 
for the biomarker IGF-1 in the same milk extracts from the same untreated (1, 2; white 
bars) and rbST-treated (3, 4; grey bars) cows. Corresponding selected individual microspot 
images obtained with the cellphone-based ﬂuorescent microscope for the biomarkers (C) 
anti-rbST antibodies and (D) IGF-1.
In order to validate the developed cellphone-based biomarker microarray approach 
for rbST abuse detection during official on-farm dairy controls, higher numbers of milk 
samples from rbST-treated and untreated cows need to be tested. The same is necessary 
to account for physiological ﬂuctuations in biomarker levels, which are expected to occur 
in milk as well as in serum [10]. The continuous ﬂow microspotter used for production of 
the microarray chips allows spotting 48 different protein spots at the same time (Figure 
S2), therewith providing the opportunity to detect more distinct biomarkers on the same 
chip and/or to perform replicate analysis. Note that the number of spots may be easily 
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increased using a microcontact printing technique. For applicability of the developed 
cellphone-based microarray platform in resource-limited environments, the assay 
protocol and its incubation times need to be improved. For rbST abuse detection, such an 
improvement could include a co-incubation step of the different assay components. For a 
general microarray approach using a cellphone, the incorporation of a microﬂuidic device 
having all assay components included [14] could minimize the required manual handling 
steps. Moreover, the use of a membrane filter microarray format, in which the sample and 
the bioreagents are ﬂowing through a membrane filter, would overcome diffusion-limited 
binding assay kinetics and thereby reduce the required incubation time to a minimum [15]. 
This cellphone-based protein microarray approach clearly demonstrates that it is possible 
to monitor several biomarkers simultaneously for food safety monitoring. Since the 
microarray format is broadly applicable, multiple contaminants and/or biomarkers may 
be analysed in a similar manner for environmental monitoring and health care. The latter 
includes POC applications, home-diagnostics, mobile-health, or telemedicine analysis. 
The showcase assay presented here only required a few drops of milk and therefore this 
platform is very well suited for assaying small volumes, such as blood, saliva and urine. 
The hardware costs for such a cellphone attachment are significantly reduced compared to 
conventional ﬂuorescent microscopes [13, 16]; the housing dimensions of the attachment 
can be easily adapted to the rapidly changing cellphone market by simply 3D-printing a 
new housing; the microarray assay kit may be eventually purchased through the internet. 
A cellphone-based device offers the opportunity to instantly analyse the images using the 
internal computing power of the phone and transmit the results to food safety authorities, 
environmental monitoring centres or medical specialist doctors via wireless network 
connection. Therewith, immediate measures can be initiated on the spot depending on the 
outcome of the test. We envisage that in all these application areas, cloud-based cellphone 
analysis networks may be established to create patio-temporal maps of contaminant or 
disease occurrence and spreading, also providing an important tool for e.g., epidemiology.
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Supplementary Material
Materials and Methods
Reagents 
Monsanto rbST standard was obtained from the National Hormone & Peptide Program 
of Dr. Parlow (Torrance, CA, USA). Posilac 500 mg single-dose syringes and syringes with 
only the slow-release formula were purchased from Monsanto Company (St Louis, MO, 
USA) and Ely Lilly and Company (Indianapolis, IN, USA). Rabbit anti-IGF-1 antibody (H-70), 
biotinylated donkey anti-sheep antibody and biotinylated goat anti-bovine antibody were 
bought from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Sheep IgG was obtained 
from Jackson Immunoresearch Europe Ltd (Suffolk, UK) and albumin from chicken egg 
white (ovalbumin), N-hydroxysuccinimide (NHS), 2-(N-morpholino) ethane sulfonic 
acid (MES), (w/v) 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid (EDC), ethanolamine 
hydrochloride and tris(hydroxymethyl)-aminomethan (Tris) were bought from Sigma-
Aldrich (St. Louis, MO, USA). MultiScreen HTS filter plates (pore size 1.2 µm) and Amicon 
Ultra 0.5 mL 30 K centrifugal filter units were purchased from Millipore (Billerica, MA, 
USA). Polycarboxylate hydrogel-coated borosilicate glass chips (24.9 x 24 x 0.13 - 0.16 mm) 
were from XanTec bioanalytics GmbH (Düsseldorf, Germany). Biotinylated rabbit anti-IGF-1 
antibody was obtained from R&D Systems (Minneapolis, MN, USA) and Streptavidin-
conjugated Quantum Dots (QD) were from Life Technologies (Grand Island, NY, USA). 
Prot G HP SpinTrap columns and 30000 MWCO VivaSpin500 units were obtained from 
GE Healthcare Europe GmbH (Diegem, Belgium). Sodium chloride (NaCl), monosodium 
phosphate monohydrate (NaH2PO4 x H2O), potassium dihydrogen phosphate (KH2PO4), 
Tween 20 and glass microscope cover slides (rectangular: 24 x 32 mm, thickness 1) 
were obtained from VWR International (Amsterdam, The Netherlands) and glycine was 
from Duchefa (Haarlem, The Netherlands). Sodium hydroxide (NaOH), sodium hydrogen 
carbonate (NaHCO3), disodium hydrogen phosphate dihydrate (Na2HPO4 x 2H2O), acetic 
acid and hydrochloric acid (HCl) were purchased from Merck (Darmstadt, Germany). 
Sodium dodecyl sulfate (SDS) was obtained from Serva (Heidelberg, Germany). 
Buffers and solutions
Antibody purification: binding buffer (20 mM NaH2PO4, pH 7.0), elution buffer (0.1 M 
glycine-HCl, pH 2.7), neutralizing buffer (1 M Tris-HCl, pH 9.0); microarray spotting: elution 
buffer (1 M NaCl, 0.1 M NaHCO3, pH 10.0), activation buffer (0.1 M (NHS), 0.1 M MES, 
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0.5 % (w/v) EDC) washing buffer (5 mM acetic acid), coupling buffer (50 mM MES, pH 5.0), 
quenching buffer (0.5 M ethanolamine hydrochloride, pH 8.5); sample preparation: glycine 
solution I (GS I; 27.5 mM glycine, pH 0.5 adjusted with HCl); glycine solution II mixture 
(GS II; 230 mM glycine, 250 ng mL-1 IGF-2, 0.015 % SDS (w/v), pH 10 adjusted with NaOH); 
microarray procedure: phosphate-buffered saline with Tween (PBST; 154 mM NaCl, 5.39 
mM Na2HPO4, 1.29 mM KH2PO4, 0.05 % v/v Tween20, pH 7.4)
Instruments
The NanoDrop instrument was obtained from Isogen LifeScience (De Meern, The 
Netherlands).The continuous ﬂow microspotter was from Wasatch Microﬂuidics (Salt Lake 
City, UT, USA) and the Samsung Galaxy SII cellphone was obtained from Amazon.com, Inc. 
(Seattle, WA, USA). The cellphone ﬂuorescent microscope attachment was constructed as 
described in [12]. In short, the mechanical components, such as the cellphone holder, the 
sample tray and the lid were made from thermoplastic using a 3D printer from Stratasys 
(Eden Prairie, MN, USA). For ﬂuorescence excitation, twelve 380 nm UV LEDs, obtained 
from Parts Express (Springboro, OH, USA), were positioned around the sample tray. A 
610 nm long pass filter (25 mm diameter) and an aspherical lens (focal length 8 mm), both 
were obtained from Thorlabs (Newton, NJ, USA), were used to filter the ﬂuorescence light 
and improve the imaging field of view, respectively.
Sample material
Milk samples were collected from Bos taurus controlled animal treatment experiments 
as described before [9]. For both studies, permissions were obtained from the respective 
local ethical committees. 
Antibody purification
Rabbit anti-IGF-1 antibodies (H-70) had to be purified from their storage solution to avoid 
interference with stabilizing proteins during protein spotting. For purification, Prot G HP 
SpinTrap columns were used according to the protocol of the manufacturer followed by 
membrane ultrafiltration using 30kDa MWCO centrifugal filter units. Protein concentration 
was determined with the NanoDrop.
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Microarray chip spotting
Before protein spotting, polycarboxylate hydrogel-coated borosilicate glass chips were 
activated. Therefore, they were kept in elution buffer for 5 minutes, were washed three 
times in Milli Q water, activated in activation buffer for 15 minutes, washed three times 
in washing buffer and dried in a sharp stream of nitrogen gas. Then, they were mounted 
in the continuous ﬂow microspotter and spotted with the protein solutions. Protein 
concentrations were 100 µg mL-1 rbST, ovalbumin, IGF-1 antibody and sheep IgG and 
250 µg mL-1 for IGF-1 antibody in coupling buffer. RbST and each of the IGF-1 antibody 
concentrations were spotted in replicates of 6 each. The remaining spots were allocated 
with 15 replicates each of positive and negative control. The spotting instrument settings 
were as follows: location 3, air gap 5 µL, ﬂow time 30 minutes and rinse 2 minutes. After 
spotting, the remaining binding sites were quenched for 30 minutes in quenching buffer 
and washed three times in Milli Q water. Readily spotted chips were kept in PBST at 4 °C 
until use. 
Milk extraction
For the protein microarray procedure, milk samples had to be extracted. Therefore, 250 µL 
milk sample (just a few drops) was mixed with 250 µL glycine solution I while vortexting 
and kept at room temperature for 60 minutes. Thereafter, 500 µL glycine solution II 
mixture was added while vortexing and samples were filtered via a 1.2 µm pore size filter.
Microarray procedure
The spotted microarray chip was washed with PBST and 1 mL milk extract was pipetted 
onto the chip and incubated for 60 minutes (Figure S1). The chip was washed again and 
500 µL antibody mixture was pipetted onto the chip surface (1:10,000 biotinylated donkey 
anti-sheep antibody, 1:10,000 biotinylated goat anti-bovine antibody, 1:125 biotinylated 
anti-IGF-1 antibody in PBST) and incubated for 60 minutes. After washing the microarray 
chip, 500 µL 20 nM QD solution was pipetted onto the chip and incubated for 30 minutes. 
After a final washing step, the microarray chip was covered with a cover slide to keep the 
ﬂuorescence label in an aqueous environment and for easier handling. The microarray chip 
was then positioned into the cellphone microscope attachment and was imaged using the 
ultraviolet LED-based excitation in the cellphone attachment. The phone was set to ‘night 
mode’ for increased sensitivity.
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Image analysis 
In order to analyse the spots automatically, the MATLAB® Image Processing ToolboxTM was 
used (MATLAB 8.1, The MathWorks Inc., Natick, MA, 2013). The aim of the image analysis 
is to determine the luminance in every spot systematically and calculate luminance values 
of the spot area in a standardized way. Since all images showed spatial aberrations (see 
e.g., Figure S2B), it was necessary to transform each image to a standardized image from 
which the luminance values could be calculated. In a first step, the positive control spots 
were detected automatically by finding connected illuminating areas of a certain minimum 
size. Since the positive control spots were always at the same location, their centroid was 
used to perform a first transformation (i.e., cubic polynomial transformation) to distinct 
locations (Figure S2C to S2D). Therewith, shearing was removed and curving was reduced. 
Next, the image was cut to the area containing only the spots and omitting the remaining 
surrounding area. In a second cubic polynomial transformation, the slightly curved image 
was uniformly sized and therewith, the spots were positioned on specific locations (Figure 
S2D to S2E). After these image transformation steps, a standardized grid of centroids was 
used to determine luminance of each spot by taking all pixels within a defined ellipse 
into account (Figure S2E). The median luminance of each spot was reported. Then, the 
luminance data of respective protein spots were averaged, the background signal (negative 
control) was subtracted and background-corrected luminance was normalized against the 
positive control on the same microarray chip.
 
Figure S1: Protein microarray immunoassay principle. Recombinant bovine somatotropin 
(rbST), rabbit anti-insulin-like growth factor-1 (IGF-1), sheep IgG and ovalbumin were 
covalently coupled to polycarboxylate hydrogel-coated borosilicate glass chips (spot 
size: 400 µm x 600 µm). During the milk incubation step, anti-rbST antibodies and IGF-1 
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bound to their respective binding partners and during the antibody mix incubation step, 
biotinylated goat anti-bovine, rabbit anti-IGF-1 and donkey anti-sheep bound to their 
respective binding partners. In the final Quantum Dot incubation step, streptavidin-
coupled Quantum Dots labelled the biotinylated antibodies present on the microarray 
chip.
Figure S2: Microarray images. (A) Microarray layout for spotting of the four different 
proteins recombinant bovine somatotropin (rbST) for detection of the biomarker anti-rbST 
antibody (α-rbST, blue), anti-insulin-like growth factor-1 (IGF-1) antibody (spotted in two 
concentrations: 100 µg mL-1 and 250 µg mL-1) for detection of the biomarker IGF-1 (IGF-1 
Chapter 8
196
100, yellow; IGF-1 250, orange), ovalbumin as a negative control (N, grey) and sheep IgG as 
positive control (P, green). (B)-(E) Image analysis workﬂow showing the original cellphone 
camera image (B), transformation points (red to green) for (C) correcting aberrations in a 
first transformation step and (D) size correction in a second transformation step. (E) Final 
image with elliptic spots, from which the median luminance is obtained. Luminance data 
of respective protein spots were averaged, the background signal (negative control) was 
subtracted, background-corrected luminance was normalized against the positive control 
on the same microarray chip and normalized values were plotted in Figure 2A and Figure 
2B.
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1 A protein biomarker-based screening tool for rbST abuse 
detection
As reported by the Spanish newspaper La Voz de Galicia in April 2012, an illegal storage 
of hundreds of rbST syringes was uncovered and it turned out that rbST had been used 
on more than 300 Spanish farms [1]. This shows that even after rbST has been banned 
since 2000, the topic of illegal rbST use in milk production remains ongoing. Most likely, 
milk producers continuously use the hormone, because of its economic benefits and so 
far, there is no analytical method implemented EU-wide to control for this abuse. The 
development of proper methodology to directly detect the hormone itself in the cow’s 
body ﬂuids is facing several challenges: First, the molecular structure of the recombinant 
proteohormone is more than 99 % identical with its endogenous form; the 22 kDa 
proteins differ by only 60 Da, which is due to an N-terminal amino acid exchange from 
alanine to methionine [2]. Second, there are strong natural ﬂuctuations in somatotropin 
concentrations in blood circulation. And third, expected rbST concentrations are very low: 
in serum they are less than 30 ng mL-1 and in milk less than 1 ng mL-1 [3, 4]. 
The approach followed in this thesis therefore focussed on the detection of rbST-
dependent biomarkers. This is an indirect approach, meaning that the rbST molecule 
itself is not measured. Instead, rbST-dependent proteins, which are specifically up- or 
downregulated by physiological rbST actions, give an indication whether the hormone was 
used. This approach is advantageous since it is not affected by low rbST or ﬂuctuating bST 
concentrations and molecular similarities of the recombinant and endogenous hormone. 
Furthermore, biomarkers remain altered for a prolonged period of time and offer 
therewith an extended time window for detection of rbST abuse.
1.1 Biomarker screening in serum
Analysed serum protein biomarkers were IGF-1 and IGFBP2, which are members of the 
GH-IGF-axis, and anti-rbST antibodies, which are produced by the cow as an immunological 
response towards rbST (Chapter 3) [5]. This triplex assay was complemented with the 
biomarker osteocalcin, a marker of bone turnover (Chapter 4) [6]. All four biomarkers 
were simultaneously analysed in serum of rbST-treated and untreated cows using the FCIA 
technology. The individual biomarker results were combined using the statistical model 
k-nearest neighbours (kNN) and true-positive rates were calculated and plotted over 
time (Figure 3 in Chapter 3 and Figure 5 in Chapter 4). According to European legislation 
(Commission Decision 2002/657/EC), screening methods should be capable of at least 
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detecting 95 % of the samples from treated animals as being non-compliant [7]. Both, the 
triplex and the fourplex FCIA formats did not differ too much in their performances: both 
detected 4 out of 11 time points during rbST-treatment above the 95 % target (Table 1). 
And also during the wash-out phase for both FCIA formats, 3 out of 5 time points were 
above the 95 % target. The false-positive rates for the entire animal study period were only 
2.3 % for the triplex FCIA and 5.5 % for the fourplex FCIA. Even if both FCIA formats seem 
to show similar performances in correctly identifying rbST-treated and untreated cows, 
there is a major difference: For the statistical model of the triplex FCIA, the very same 
data were used as training and test set data. Therefore, this model and data outcome is 
over-optimistic. In the fourplex FCIA model, however, two different data sets were used 
for model building and testing: data from one group of cows were used to build the model 
(training set) and data from an independent group of cows were used to test the model 
(test set). This means that the outcome is more realistic than in the triplex format and that 
the performance results are statistically spoken more robust than the triplex results.
Table 1: Time points above the 95 % true-positive target during treatment and wash-out 
phases and overall false-positive rates of triplex, fourplex and reduced duplex FCIAs for 
rbST abuse detection in rbST-treated and untreated dairy cows.
Time points above the 95 % target False-positive rate
Assay Chapter Treatment phase Wash-out phase Overall 
Triplex FCIA 3 4/11 3/5 2.3 %
Fourplex FCIA 4 4/11 3/5 5.5 %
Reduced duplex FCIA 4 7/11 3/5 11.8 %
 
A next step was to assess and evaluate which of the 11 possible biomarker combinations 
was most indicative for rbST abuse and it appeared that the combination osteocalcin 
and anti-rbST antibodies showed the most time points above the 95 % target during the 
treatment phase (Chapter 4 and Table 1). The biomarkers IGF-1 and IGFBP2 did not remain 
in the final reduced duplex FICA format. IGF-1 is a biomarker, which rapidly reacts upon 
rbST presence with a transient increase in serum concentration. Already before the next 
rbST injection, IGF-1 concentrations were back to baseline levels (Figure 2A.1 Chapter 4). 
These ﬂuctuating IGF-1 levels are difficult to use as robust and reliable predictors for rbST 
abuse detection. IGFBP2 levels also showed a ﬂuctuating pattern and furthermore, inter-
individual differences were high (Figure 2B.1 Chapter 4). Hence, kNN models including 
IGFBP2 as a biomarker, performed less than others (Figure 5 Chapter 4).
For all presented formats, there were time points for which the 95 % true-positive target 
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was not reached. The most difficult time points for rbST abuse detection are short after 
beginning of the treatment, when there is a delayed biomarker response, and during the 
wash-out phase, when altered biomarker levels return to baseline. If rbST is administered 
according to manufacturer’s suggestions, the wash-out phase is at the same time as the 
dry period, which usually lasts for 50 days (approximately 7 weeks). In the animal studies 
performed for this thesis, the wash-out phase lasted only 4 weeks, meaning that not 
the entire dry period was covered. Moreover, the triplex, fourplex and reduced duplex 
formats were all capable of only detecting rbST administration up to 2 weeks after the last 
administration. This means that the biomarker-based approach is so far not good enough 
for all time points and needs to be improved to cover the entire treatment phase and a 
large period of the wash-out phase.
The animal studies performed for obtaining the data of this thesis comprised of four or 
six rbST injection time points respectively. In reality, cows are treated for 25-30 weeks, 
which results in 13-15 rbST injections per lactation period. No data are available how 
well the here presented FCIA formats perform in long-term treated cows. Especially 
when looking at the declining immunological response after a few rbST administrations 
(Figure 2C.1 in Chapter 4), the performance of the anti-rbST antibodies as a biomarker 
needs to be assessed in long-term rbST-treated cows. Also Zwickl et al. [8] saw a declining 
immunological response in long-term treated cows after 3 months of rbST treatment. 
Furthermore, they did not see an immunological memory effect with boosted antibody 
titres in cows, which were treated in two subsequent years. In both years however, they 
found that approximately 83 % of the rbST-treated cows produced anti-rbST antibodies. 
For long-term and repeatedly treated cows, the fourplex FCIA should be tested and all 
biomarkers should be evaluated individually and in combination for their capability of 
detecting rbST abuse.
To improve the detection capabilities of the FCIA, additional protein biomarkers can 
be included. Potential biomarkers are for instance myostatin, N-terminal propeptide of 
procollagen III (PIIINP) and C-terminal cross-linked telopeptide of collagen I (CTx). For all 
these potential biomarkers, commercially available immunoassays were obtained to test 
the feasibility of the biomarkers in serum samples from rbST-treated and untreated cows. 
Even though these commercial assays were initially developed for analysis of human 
samples, amino acid sequence homology of the target proteins has been verified or these 
assay kits have been shown to be applicable to bovine samples in other studies [9-11].  
Myostatin levels measured with an enzyme-linked immunosorbent assay (ELISA) kit 
remained unaffected by rbST treatment (Figure 1A). 
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An increase in PIIINP levels was observed in rbST-treated cows using a radio immunoassay 
(Figure 1B). PIIINP concentrations of untreated cows were similar except one cow showed 
a very high PIIINP concentration already before treatment (cow E). Note that cows A-D 
were all approximately 4.5 years old whereas cow E was only two years old and PIIINP 
levels are known to be age-dependent [12]. 
CTx concentrations were found to be very different between individual cows (Figure 1C). 
Baseline values before rbST treatment differed a lot and these differences were not age-
dependent (data not shown), even though an age-dependent decline in CTx levels was 
observed in children and young adults [13]. CTx levels have been shown to vary during 
the day and these circadian ﬂuctuations can be lowered by using samples that were taken 
after a 24 hour fasting period [14], which is not realistic for the analysis of samples from 
dairy cows. Also the responses upon rbST treatment were different: some cows (e.g., cows 
J and K) did not show any response, some showed increasing CTx concentrations over time 
(e.g., cows B, E and I) and some showed the highest CTx concentration after 3 weeks of 
rbST treatment (e.g., cows C, D and F).
Figure 1: (A) Myostatin, (B) PIIINP and (C) CTx levels in serum of rbST-treated and 
untreated animals. Cow labels do not correspond between individual graphs.
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In conclusion, based on these preliminary results, PIIINP can be considered a candidate 
biomarker but needs to be further investigated and validated on serum samples from 
more rbST-treated and untreated dairy cows. Successful FCIA assay development for 
PIIINP and inclusion in the existing fourplex FCIA was hindered by the lack of a suitable 
PIIINP standard protein.For additional serum biomarkers, biomarker discovery studies as 
outlined in Chapter 2 can be performed. Similar studies have been performed for equine 
somatotropin (eST) detection in horses and hGH abuse detection in humans and revealed 
a high number of candidate biomarkers. Also in cattle and race horses for detection of 
steroid and other anabolic agent treatments, biomarker discovery studies have been 
performed and candidate biomarkers, such as reticuloalbin, apolipoprotein A1 and 
clusterin, were identified (Chapter 2) [15-17].
1.2 Biomarker screening in milk
Another important part of this thesis is the targeted analysis of protein biomarkers in milk, 
such as anti-rbST antibodies, which can be found in more than 62 % of the milk samples 
from the rbST treatment animal studies. They were detectable starting from the second 
rbST administration and showed the maximum response around 20 days in treatment. 
Thereafter, the response declined, but remained above the decision limit for two to three 
more weeks during the wash-out phase (Figure 2 in Chapter 6). For the untreated cows, a 
false-positive rate of 7 % was found. Obviously, the true-positive rate of 62 % (equivalent 
to false-compliant rate of 38 %) is not sufficient according to Commission Decision 
2002/657/EC for screening methods [7]. But note that in real practice, tank milk will be 
analysed and therefore, milk from high-, low- and no-responders will be mixed, leading to 
a detectable antibody response as shown in Chapter 6 [18]. 
Similarly to the FCIA formats for multiple biomarker analysis in serum, several different 
rbST-dependent biomarkers can be added to the existing milk FCIA. For preparing the 
cellphone-based protein microarray analysis of milk samples (Chapter 8), a duplex FCIA 
was tested for the simultaneous detection of anti-rbST antibodies and IGF-1. In this duplex 
FCIA, increased IGF-1 levels and increased anti-rbST response were detectable after rbST 
treatment (Figure 2A and 2B). The expected levels of IGF-1 in milk typically range from 1 
ng mL-1 to 50 ng mL-1 and can further increase after rbST treatment [19, 20]. The standard 
addition curve of the duplex FCIA (Figure 2C) has its linear range from approximately 10 
ng mL-1 to 50 ng mL-1. Taking into account that there is IGF-1 present in the milk used for 
the standard addition curve, this method is not accurate for milk samples with a very low 
IGF-1 concentration. 
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Figure 2: (A) IGF-1 concentrations and (B) anti-rbST antibody response in milk samples 
from untreated and rbST-treated cows. (C) IGF-1 standard addition curve in milk from an 
untreated cow (MFI – median ﬂuorescence intensity).
According to serum biomarker discovery studies (Chapter 2), milk biomarkers for detecting 
rbST abuse can also be discovered in an untargeted manner using mass spectrometry 
techniques. Biomarkers for rbST treatment in milk could be growth factors, similarly to 
IGF-1 (insulin-like growth factor-1). Growth factors belong to the low-abundant proteins 
in milk and discovery of low-abundant proteins poses challenges as already described in 
Chapter 2. One possibility to facilitate the detection of low-abundant proteins is the use 
of suitable depletion methods for removal of high-abundant proteins. Unfortunately, the 
majority of existing depletion methods is optimized for serum or plasma use. Caseins 
and β-lactoglobulin, the two major bovine milk protein fractions, are both not present in 
serum or plasma [21, 22]. Therefore, they are not sufficiently removed by serum-specific 
depletion methods. Another possibility for the detection of low-abundant proteins is 
the use of selective enrichment strategies to enrich the low-abundant protein fraction 
from the complex milk matrix. Boehmer et al., however found serum-optimized selective 
enrichment tools not suitable for bovine milk samples because of their limited capability in 
removing high-abundant proteins, such as caseins and β-lactoglobulin [23]. Milk proteins 
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can also be analysed after removing a major fraction of the caseins by ultracentrifugation 
of the raw milk sample. Using this approach, Hettinga et al. detected 269 milk proteins 
in bovine milk using a qualitative setup; only a limited amount of these proteins was 
subsequently also quantified [24]. For untargeted milk biomarker discovery studies, there 
is a lot of future research needed on suitable sample preparation strategies.
1.3 Biomarker screening in other matrices
For the detection of certain substances in sports doping and veterinary control, urine 
is used for analysis. The detected substances are for example steroids, which are also 
excreted via the renal route. In the recent years, the urinary proteome was studied and 
it was also used for protein biomarker discovery in clinical studies [25, 26]. In a protein 
biomarker discovery study for hGH-dependent biomarkers in serum, α1-antitrypsin has 
been identified as a candidate biomarker (Chapter 2) and this protein has also been 
found in the human urinary proteome [25, 27]. Similarly to many serum proteins, urinary 
protein concentrations underlie inter- and intra-individual differences and therefore, 
characterization of the normal ﬂuctuations is required [25]. In conclusion, it might be 
possible to detect protein biomarkers for rbST abuse in urine of cows.
2 Biomarker panels for discrimination of different substance 
classes 
In Chapter 5 in this thesis it is shown that a biomarker panel originally developed for 
detection of rbST abuse can also be used to indicate steroid hormone administration. 
Likewise, in Chapter 2 it is described that similar protein biomarkers, such as IGF-
1, leucine-rich α-2-glycoprotein or PIIINP, were indicative for more than one specific 
treatment. The reason for this is that partly the same physiological machinery is used 
as a response upon different growth promoter treatments. This finding highlights the 
significance of biomarker-based approaches. It is conceivable that in the future, multiplex 
assays comprising a full range of different biomarkers are used to indicate a class of 
substances, where the abused substance belongs to. With this knowledge, subsequent 
targeted instrumental analysis can be performed for confirmation of the abused 
substance. 
Even though biomarker profiling for an entire range of different substances offers great 
advantages, the issue of confounding factors has to be carefully considered. Confounding 
factors are for instance age, gender, nutrition, exercise, injuries, medication or co-
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administration of other drugs. In general, the more a biomarker is inﬂuenced by other 
factors or treatments, the more extensive validation procedures are required. This 
extensive validation is particularly essential for biomarkers, which are indicative for more 
than one administered substance.
3 Multiple-analyte assays: extensive development procedure
When multiple biomarkers are measured, multiple-analyte, also called multiplex assays, 
have major advantages over single-analyte assays. First, the required sample material is 
kept at a minimum volume, because all biomarkers are simultaneously analysed in one 
sample aliquot. Second, sample preparation and assay time is minimized, because all steps 
are performed only once. And third, material, bioreagents and chemicals are saved for the 
same reasons [28].
Although the conduction of a multiplex assay is time-saving, because several assays are 
combined in one, the development of such a multiplex assay is more laborious compared 
to the development of a single-analyte assay. Several additional experiments are required 
to ensure that no unwanted cross-reactions occur during an assay for combined detection 
of several analytes. Moreover, these experiments have to be performed again if an existing 
multiplex analyte panel is extended by additional analytes. In general, the higher the 
number of different antibodies and standard analytes in one well, the higher the chance 
of unwanted cross-reactions of the antibodies with each other, of antibodies with non-
specific analytes and analytes with each other [28, 29].
By decreasing the total number of different assay components (antibodies and protein 
standards), possible unwanted cross-reactions can be avoided. Figure 3 shows three 
exemplary immunoassay formats with decreasing number of assay components. Whereas 
in the classical sandwich format, typically four assay components are required, in the 
inhibition format only three and in the direct inhibition format only two are required. 
Despite the fact that less assay components show a lower chance of unwanted cross-
reactivity, additional detection antibodies can amplify the final signal and can therefore 
lead to more sensitive assays.
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Figure 3: Three exemplary microsphere-based immunoassay formats suitable for 
multiplexing. In the sandwich format and direct inhibition format, capture antibodies are 
immobilized on the surface of colour-encoded microspheres, whereas in the inhibition 
format, a protein standard is immobilized. Depending on the assay format, different 
bioreagents, such as analytes and detection antibodies (either labelled or unlabelled) are 
present in solution.
Another important item in the development of a multiplex immunoassay is the sample 
that shall be measured. To account for sample matrix effects, standard curves should be 
performed in the final sample matrix. Moreover, all standard curves are to be measured 
with all assay components simultaneously to keep the assay conditions as similar as 
possible between the standards and samples. When exogenous analytes are analysed, 
which are normally not present in a sample, the analyte can be simply spiked in blank 
samples to create a standard curve. However, when endogenous analytes are analysed, 
which are always present in a sample at a certain concentration, the choice of matrix 
for a standard curve is more difficult. On one hand, blank samples can be created by 
depleting the sample from the target analyte. But when multiple analytes are intended to 
be measured and therefore, multiple analytes are depleted, the character of the standard 
sample matrix becomes more and more different from the real sample matrix. On the 
other hand, matrix-matched buffers can be prepared as an alternative for a blank sample. 
For the development of the serum biomarker FCIA in this thesis, 80 mg mL-1 bovine 
serum albumin in phosphate-buffered saline was used as a serum-matched buffer, which 
resembled the total protein concentration in a serum sample. Then, according to the 
analysis of exogenous analytes, the analytes were spiked into the serum-matched buffer 
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for the standard curve. One has to be aware that both, analyte depletion and the use of 
matrix-matched buffers do not necessarily completely reﬂect the character of the final 
sample, but might be fit-for-purpose.
When combining several single-analyte assays into one multiple analyte method, the 
different target analyte concentrations in the sample and the sensitivities achieved 
using the different assays have to be considered. If a developed multiplex assay requires 
different sample preparations, this method might detect several analytes at the same time 
but not in the very same sample [30, 31]. One can only make use of all advantages of a 
multiplex method if the target concentrations of all the analytes in the sample fit into their 
respective standard curve at the same sample dilution.
4 On the search for treatment-specific biomarkers: Anti-rbST 
antibodies
Even if protein biomarkers are usually endogenously produced and are therewith 
inﬂuenced by many different factors, some can be specific for one treatment and only 
present after that treatment. One example is the biomarker anti-rbST antibodies, 
which are endogenously produced by the cow after administration of rbST (Chapters 
3-8). There can be several different reasons for the occurrence of anti-rbST antibodies 
after rbST administration: First, the body might detect the administered rbST as an 
exogenous protein because of its altered N-terminus and respond via the T-cell-dependent 
immunological pathway [32]. During this pathway, high titres of IgG are produced and 
memory cells are generated for rapid and high antibody production in case of a second 
administration. Considering that there were generally no high IgG titres and no memory 
effect observed upon a second administration period in the following year [8, 33], the 
activation of the T-cell-dependent pathway upon rbST administration seems unlikely [34]. 
Second, antibody production against biopharmaceuticals is a known phenomenon in the 
clinical environment and is attributed to many factors, such as product-related factors, 
patient-related factors and treatment-related factors [32]. Product-related factors 
are for instance protein aggregation, which often occurs in recombinantly produced 
biopharmaceutical formulas, and impurities from the recombinant protein production 
process, which both can trigger immunological reactions [35]. RbST is known to aggregate 
through hydrophobic interactions and these aggregates might therefore be responsible 
for the observed immunological response [36]. Moreover, since rbST is produced using 
E.coli, there might be impurities deriving from the host, which further inﬂuence the 
immunogenicity of the administered drug [32].
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Since antibody production is a frequent phenomenon after treatment with protein 
biopharmaceuticals, the presence of these antibodies can be used as an indicator for 
protein hormone abuse, such as human growth hormone or erythropoietin, in human and 
animal sports doping analysis as well [37]. Compared to the other protein biomarkers used 
to indicate drug abuse, anti-drug antibodies are very specific for the particular treatment 
and therefore offer a great potential to complement current biomarker-based detection 
strategies (Chapter 2) [37-39].
For screening, anti-rbST antibodies can be incorporated into a biomarker panel and be 
measured using a multiplex FCIA for instance, but they can also be monitored using a quick 
on-site test platform, such as a lateral ﬂow device or dip stick. A general consideration 
for analysing antibodies in cows’ serum or milk is that there are many other different 
bovine antibodies present, which might affect the sensitivity of the test for the specific 
antibodies. Two different dipstick formats for the detection of anti-rbST antibodies were 
developed and tested during this thesis. In the first format (format A), anti-rbST antibodies 
are sandwiched in between rbST on the nitrocellulose membrane and rbST on coloured 
latex particles (Figure 4A). In this format, no secondary anti-bovine IgG detection antibody 
is required and therewith, unwanted cross-interactions with the other present milk 
antibodies can be avoided. In a second format (format B), the anti-rbST antibodies bound 
to rbST on the nitrocellulose membrane and were detected by a colloid carbon-labelled 
anti-bovine antibody (Figure 4B). Here, the result might be affected by other bovine 
antibodies present in the same sample, which may be bound by the anti-bovine detection 
antibodies. For both tests, the presence of anti-rbST antibodies resulted in appearance of a 
test line (Figures 5A.1 and 5A.2). 
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Figure 4: Dip stick formats tested for this thesis. In format A, the anti-rbST antibody 
interconnects rbST on the nitrocellulose membrane and rbST on coloured latex particles 
using its two antigenic binding sites. In format B, a labelled secondary antibody detects the 
presence of the anti-rbST antibody bound to rbST on the nitrocellulose membrane.
Figure 5: Examples of dipstick results in using (A) format A dipsticks and (B) format B 
dipsticks with milk samples from (1) rbST-treated and (2) control cows. Arrows indicate the 
presence of the test line.
To assess the performance of the developed dipsticks, 20 milk samples from rbST-treated 
and 20 milk samples from untreated cows were tested. These samples were selected 
based on their responses shown in FCIA experiments. Samples from rbST-treated cows 
previously found positive and samples from untreated cows previously found negative 
were selected. For both formats, different assay protocols were used since the biotinylated 
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antibody and neutravidin-carbon-conjugate required a pre-incubation step. Using the 
format A dipstick, 50 % of the milk samples from rbST-treated animals were detected 
(examples in Figure 5A.1), whereas with format B, 65 % of the milk samples from rbST-
treated animals were detected (examples in Figure 5B.1). The false-positive rate obtained 
by analysis of milk samples from untreated animals was comparable between the two 
formats (examples see Figure 5A.2 and Figure 5B.2; Table 2).
Table 2: True-positive results obtained by testing 20 milk samples from rbST-treated cows 
and false-positive results from 20 milk samples from control animals by using format A and 
format B dipsticks.
Cows Format A Format B
rbST-treated 50 % (10/20) 65 % (13/20)
untreated 5 % (1/20) 10 % (2/20)
These results indicate that both dipsticks yield anti-rbST antibody-specific signals, but are 
not sensitive enough to detect sufficient rbST-positive samples according to Commission 
Decision 2002/657/EC, which requires that 95 % of the treated samples are detected as 
non-compliant [7]. To improve the sensitivity of the dipstick, additional secondary labelled 
antibodies can be used to amplify the signal on the test line.
5 Effect-based screening methods in the view of current 
European legislation
5.1 Validation requirements for effect-based screening methods
Classically, screening methods are defined by Commission Decision 2002/657/EC as 
“methods that are used to detect the presence of a substance or class of substances at 
the level of interest.”, whereby substance is defined as “matter of particular or definite 
chemical constitution and its metabolites.” [7]. Thus, these definitions and the specified 
validation requirements for the detection of substances in this legal paper relate to the 
detection of a substance itself or its metabolites. But effect-based screening strategies, 
which only indirectly indicate that a substance is or was present, are not covered by the 
Commission Decision. Effect-based strategies comprise for instance bioassays, steroid 
profiling and biomarker methods. Bioassays monitor the effect of a bioactive substance, 
e.g.  the specific binding to a receptor using a transcription activation assay [40]. Steroid 
profiling can be used to monitor the effect of different administered substances on 
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steroidogenesis [41]. And protein biomarker levels can also be changed as an effect 
upon substance administration (Chapters 2-5). Even though in certain bioassays, a dose-
response relation can be made and therewith the classical validation procedures according 
to Commission Decision 2002/657/EC can be followed, the other effect-based screening 
methods may not show a dose-response relation because of the complex physiological 
machinery behind the response. It is therefore advisable that these effect-based methods 
follow a different validation procedure before they can be used as a screening method. 
The aim of validating an effect-based screening method is the definition of a background 
response, background level or a reference profile in an untreated population and the 
determination of a threshold beyond which the sample is considered suspect. This can 
be achieved by the assessment of variation in an untreated population and statistical 
determination of the threshold value, e.g., addition of 2.33-times the standard deviation of 
the population data to its mean. In this case, only 1 % of the untreated population will be 
classified as false-positive using the assessed screening method. Additionally, the response 
of a treated population and the variation therein has to be assessed to determine the 
false-negative rate, which should be less than 5 % for a screening method according to 
Commission Decision 2002/657/EC [7]. Since the effect-based methods are expected to 
identify suspect samples in a time-dependent manner after treatment, time course studies 
can be performed to determine in which time window the assessed effect can be observed 
with the required confidence (Chapter 4). This procedure is obviously more extensive 
and laborious compared to the classical validation described in Commission Decision 
2002/657/EC and “Guidelines for the validation of screening methods for residues of 
veterinary medicines” [7, 42] and the extent is dependent on the variation observed in the 
treated and untreated populations. This means, the more confounding factors are exerting 
effects on the background response or response upon treatment, the higher the number 
of samples that are required for validation. Method validation by assessing untreated 
and treated populations including numerous confounding factors has been performed for 
sports doping analysis [39]. 
Despite successful effect-based method development, method validation can be hindered 
by strong inter-individual differences, which cannot be linked to general confounding 
factors. Then, the monitoring of individual profiles over time as done with the athlete’s 
biological passport may be performed to see changes in protein biomarker or steroid 
profiles compared to previous profiles of the same athlete (Chapter 2). Abnormal intra-
individual changes can then be related to substance administration. Animal passports 
are unfortunately not feasible due to the high number of individual animals in food 
production. But farm passports, combining samples from one farm, are conceivable if it is 
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proven that intra-farm variations are lower than inter-farm variations and that a combined 
biomarker or steroid profile can be indicative for substance administration.
5.2 Screening and subsequent confirmatory process
Traditionally when screening for a specific substance, a suspicious result can be obtained. 
The time window for finding a suspicious result is determined by the half-life time of the 
substance in the sample. Subsequent confirmatory analysis can then either confirm the 
previous finding, the sample is then considered non-compliant, or it can deliver a negative 
result, which in turn means that the screening result was a false-positive. The reasons for a 
false-positive screening result can be a specific (e.g., a related compound was detected by 
a similar epitope with the antibody used in screening) or an unspecific interference (e.g., 
an unexpected matrix effect) during screening or a substance level in the sample below the 
limit of detection of the instrument used for confirmatory analysis (Table 3).
Table 3: Screening and subsequent confirmatory process overview for the classical 
substance detection approach and the effect-based detection approaches.
Screening Confirmatory positive (true-positive 
screening result)
Confirmatory negative (false-
positive screening result)
Substance screening Substance identity confirmed
Substance level above threshold
Substance level below LOD
Screening result was specific or 
non-specific interference
Effect-based 
screening
Substance identity confirmed
Substance level above threshold
Substance-effect relation
Substance level below LOD
Screening result was specific 
(unknown active substance) or 
non-specific interference
If effect-based methods, such as bioassays, steroid profiles or biomarkers, are used for 
screening, the presumed time windows for detecting a suspicious sample are diverging. 
Since a bioassay is detecting the effect of a substance present, the time window for 
observing a specific signal is depending on the substance presence. Steroid profiles, 
which are the result of a specific endogenous enzyme activity, however, are presumed to 
be altered for a longer period of time. And biomarkers or biomarker profiles, which are 
usually the result of a changed protein synthesis in the animal’s body, are presumed to be 
changed for the longest period and offer therewith the longest time window for detecting 
a suspicious sample.
If a suspicious sample has been identified using one of the abovementioned effect-based 
screening methods, the result has to be confirmed by a subsequent confirmatory method. 
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The confirmatory method can then confirm the presence of the substance, which caused 
the observed effect during screening, and therewith establish a direct substance-effect 
relation. But the confirmatory analysis can also give a negative result, thus a false-positive 
screening result. In the case of effect- or biomarker-based screening, false-positive 
screening results can also be caused by different reasons. First, the substance level in the 
sample can be below the limit of detection of the method used for confirmatory analysis. 
This can be because the effect of the substance can be detected longer than the substance 
itself or the substance level is in general too low for detection. Second, an unknown 
other substance caused the same effect during screening, which resulted in a specific 
interference. And third, an unspecific interference caused the false-positive result.
Note that there is one fundamental difference in reasons for false-positive screening 
results between the two approaches, the classical substance screening and the effect-
based screening. During effect-based screening, a treatment-specific effect might be 
observed, which cannot be confirmed, because the substance itself is below the limit 
of detection in the sample. By the strict definition of EU regulation, this would mean a 
false-positive screening result. In view of the advantages of biomarker-based strategies, 
namely a prolonged time window for detection, this strict definition cuts back this valuable 
advantage. In this case, it might be a possibility to adopt the regulations used in sports 
and horse racing doping control where solely a specific biomarker profile can indicate 
the hormone abuse (Chapter 2). Then, the confirmatory method would not play such an 
important role anymore.
Another important point to discuss is the example of IGF-1, which is being used as a 
biomarker in different assays [39] (Chapters 3, 4 and 8), but can also be the abused 
substance itself [43, 44]. In this case it is advisable to follow both approaches, the classical 
approach detecting IGF-1 itself in blood, as IGF-1 levels are strongly increased after IGF-1 
treatment [43], and the biomarker-based approach detecting IGF-1-dependent biomarkers 
[44]. Both approaches can then be compared in respect of false-negative and false-positive 
results during an entire treatment and washout period in an IGF-1 treatment study. 
Depending on which of the approaches gives the better outcome, either a single approach 
can be chosen for the following thorough validation, or both approaches can be used 
complimentary to increase the chances of a positive screening result. In the veterinary 
field, subsequent confirmatory analysis will focus on the direct detection of IGF-1 in the 
sample by instrumental analysis.
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5.3 Towards a new veterinary drug monitoring approach
As described in the general introduction (Chapter 1), the Netherlands developed a multi-
level surveillance system for food safety control. Within this system, the different levels 
are usually followed in a certain order depending on the extent of the occurring food 
safety problem. After a general suspicion is raised by for instance the discovery of injection 
preparations during general inspections, a surveillance program is run to estimate the 
extent of the use of the veterinary drug or contaminant. During the surveillance program, 
up to a few hundred of samples are measured using a simple screening method. In case 
of the rbST abuse detection, the surveillance step is reached, which means that screening 
methods have been developed (Chapters 4 and 6) and samples are being analysed on 
small-scale in a reference or specific laboratory. If suspicious samples are identified during 
screening, then a confirmatory method is required to detect the rbST molecule itself. An 
immunoaffinity enrichment on monolithic micro-column approach for rbST purification 
from serum prior to instrumental analysis is currently being developed and will be adopted 
for milk analysis as well [45]. Using this approach, the general problem of a very limited 
window of detection can be solved, because of its superior sensitivity performance 
compared to previously described confirmatory analysis attempts [2, 3, 46]. If screening 
and confirmation reveal that rbST is widely used in the dairy sector, rbST detection will be 
incorporated in the yearly national residue monitoring plan using the developed methods. 
Then, rbST use will be systematically analysed in official laboratories and the results are 
reported to the EU. At this stage, it is advisable to limit the amount of samples, which 
need to be transported to and analysed in specialized laboratories, for cost reasons. As 
discussed in Chapter 7, a quick on-farm pre-screening method can identify suspicious 
samples. Compliant samples, which are usually the majority of the tested samples, do 
not need to be administrated, transported and analysed using expensive and time-
consuming methodology. As an effect of this, money and time can be saved, which in turn 
can be reinvested in further rbST pre-screening or sample analysis for other high priority 
substances.
6 Future outlook on biomarker profiling
The benefits of protein biomarker profiling have extensively been discussed in Chapter 
2. They are not only widespread used in disease diagnosis but are also applied in sports 
doping control and biomarker-based methods are ready to be used in future veterinary 
control. For the latter, there are still a number of fields where biomarker-based screening 
methods can be beneficial especially in view of the expanded time window for detection. 
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Protein biomarkers can then serve as indicators even when the abused substance itself is 
not present anymore. Therefore, biomarker methods are imaginable for general hormone 
abuse detection (Chapter 5) [10, 30, 31, 47-49], contaminant pollution assessment [50] or 
heavy metal exposure analysis [51]. Also in environmental analysis, contaminant pollution 
and heavy metal exposure are important issues. Therefore, the same biomarkers as in 
veterinary control for food production can be indicative for the presence of trace levels of 
these substances.
When biomarker profiles or biomarkers for several different substance exposures are to 
be measured, the use of a multiplex method, such as the FCIA (Chapters 3, 4 and 5) is 
advisable. But, as discussed earlier, such a multiplex method is only beneficial if there are 
no cross-interactions between the single assays and if the same sample preparation can 
be applied for all the single assays. For instance, it can be assessed whether the multiple 
protein biomarker methods used in sports doping control, which are currently performed 
with single analyte methods (ELISAs), can also be performed using a multiplex method.
In addition to protein biomarkers, other biomarkers can be monitored as well, such as 
transcriptomic or metabolomic biomarkers [41, 52-54]. Using proteomic, transcriptomic 
and metabolomic technologies, combined biomarker profiles can be measured with 
enhanced statistical significance. Biomarker profiles that are altered after drug treatment 
can be indicative for a specific abused substance or group of substances. Therefore, 
expanded biomarker profiling can be used as a general drug abuse monitoring tool and 
point to samples, which need further targeted investigation.
7 Future outlook on technical developments
As described in Chapter 8, the use of an on-site test for multiplex analysis of several 
substances, which can be analysed with the help of the ligand-binding principle, enables 
the simultaneous detection of several food safety-related substances. Therewith, 
the opportunity arises to measure all targets of interest by only using one test. As an 
example, a single milk sample could be analysed for hormones, allergens, antibiotics, 
contaminants and other substances, all at the same time, provided they can be detected 
through the ligand-binding principle and no occurrence of unwanted cross interactions. 
A cellphone-based multiplex analysis platform can even automatically analyse all the 
data obtained, show a final report about the sample and send it to central food quality 
and safety databases. Such a device would not only be beneficial for the food quality and 
safety sectors but also for any situation, where an on-site test is desired, such as medical 
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diagnosis and environmental monitoring.
In general for on-site analysis, miniaturisation and automation of the applied assays is 
envisaged in order to minimize manual handling steps. Therefore, for cellphone-based 
microarray or microsphere analyses, the fabrication of a microﬂuidic device including all 
required assay reagents is advisable. Then, only the sample needs to be added, which will 
subsequently be diluted and extracted and which follows the assay procedure in a single-
step or by passing through consecutive microchambers [55]. The readout and analysis of 
the result can then be easily performed by the cellphone equipped with an attachment in 
which the microﬂuidic device fits exactly. 
Using a microarray format for the detection of abused substances in veterinary control, 
also offers the opportunity to couple the screening step directly to a confirmatory step. 
A dual read-out microarray approach combining ﬂuorescence detection and subsequent 
matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometer (MALDI-TOF) 
has been published [56]. Using this approach, several substances such as residues of 
veterinary drugs, antibiotics and contaminants present in food samples can be captured 
on the surface of a microarray chip covered with specific capture antibodies. Then, a quick 
ﬂuorescence read-out can be performed as screening and in case of a suspicious result, 
the very same microarray chip can be subsequently used to truly identify the captured 
substances by MALDI-TOF as confirmatory analysis. Following this approach only one 
sample aliquot is needed for the entire analysis and time needed for sample preparation is 
limited because of the combined direct consecutive analysis.
8 Societal impact of research in this thesis
The developed methods for rbST abuse detection, which are presented in this thesis, 
are envisaged to be used in surveillance and national residue plan analysis in the EU. 
Moreover, independent control organizations (e.g., consumer associations) that are 
concerned about hormone use in food production can easily apply the testing. This is not 
only important for the EU, but also for the countries where rbST use is legal and so far, 
dairies, vendors, retailers and consumers can only trust the ‘rbST-free’ labelling. With the 
use of rbST detection methods, this labelling can be controlled and therewith, the value of 
the label and the trust in the label can be increased. 
The consequences of the possibility to monitor rbST abuse are manifold. First, the EU 
regulation concerning the ban of rbST administration [57] can be enforced, which has 
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not been possible so far. Second, animal welfare will improve when rbST administration 
is stopped, because rbST administration increased incidences of mastitis, foot and leg 
disorders. Third, the use of veterinary drugs, such as antibiotics, which are used to restore 
animal health in case of an infection, will therewith decrease as well. Therefore, the overall 
use of antibiotics can decrease, which is highly appreciated since antibiotics use is a wide 
problem in food production. Therewith, also the occurrence of antibiotic-resistant bacteria 
will decrease. Fourth, consumer trust can be maintained that milk is produced without 
the use of administered hormones. This would permit fair consumer choices on what 
they want to buy, eat and drink. And fifth, border inspection controls would be enabled 
to control whether the imported dairy products have been produced according to EU 
regulations.
In conclusion, this thesis presents the development of protein biomarker-based screening 
methods for rbST abuse detection in serum and milk of dairy cows. Using the different 
developed testing platforms, on-site testing and laboratory-based analyses are possible. 
The future implementation of these testing platforms for rbST abuse detection is a major 
leap forward concerning the enforcement of the rbST ban in the EU and concerning the 
value of protein biomarker-based approaches in veterinary control.
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Recombinant bovine somatotropin (rbST) is a 22 kDa proteohormone, which can be used 
to increase milk production in dairy cows. It has been marketed since 1994 and while its 
use in food production is approved in several countries, such as the US, it is banned in the 
EU since 2000. To enforce the ban on rbST in the EU and to control for ‘rbST-free’ –labelling 
in the US, detection methods are required that identify whether rbST has been used. 
Existing rbST detection methods focus on the detection of rbST itself in bovine serum. The 
recombinant form of the hormone has one amino acid exchanged at the N-terminus of the 
protein. RbST can therefore be potentially discriminated from the endogenous bST by mass 
spectrometric methods. Other methods employ sandwich enzyme-linked immunosorbent 
assays (ELISAs) with antibodies having a higher affinity to rbST than bST. These methods, 
however mainly lack sensitivity, reproducibility or selectivity for rbST and are therefore not 
widely applied. Hence, no method has been implemented so far to monitor rbST abuse in 
dairy farming. Screening methods developed for veterinary drug residue control in the EU 
have to perform according to Commission Decision 2002/657/EC and have to identify at 
least 95 % of the treated animals.
An alternative approach for rbST abuse detection is the analysis of rbST-dependent 
biomarkers. A biomarker is defined as an indicator of normal physiological processes, 
pathogenic processes, or pharmacological responses to a therapeutic intervention. 
Therefore, the levels of rbST-dependent protein biomarkers are either up- or down-
regulated after administration of rbST and rbST-specific biomarker profiles can be used 
to detect its abuse. RbST exerts similar physiological actions in the cow’s body as the 
endogenous bST. Therefore, proteins involved in the regulatory circuit of bST have been 
chosen as candidate biomarkers, such as insulin-like growth factor-1 (IGF-1), IGF binding 
protein 2 (IGFBP2) and osteocalcin. Additionally to that, the administration of rbST 
induces anti-rbST antibodies in the cow’s body, which can be detected as biomarkers. 
This approach is according to the growth hormone (GH) abuse detection in sports doping 
control, where solely protein biomarker profiles are used to identify the abuse.
Chapter 2 introduces protein biomarkers and how biomarkers can be used in sports 
doping and veterinary control to detect the abuse of illegal substances. The advantages 
of using biomarkers are that the biological effect of a substance usually lasts longer than 
the substance itself can be detected and therewith, the window of detection is expanded. 
Moreover, since different substances exert similar effects on physiological machineries 
for growth or production enhancement, biomarker-based-detection methods have the 
potential to detect a whole class of substances. Furthermore, low-dose mixtures of 
different banned substances, which might escape from direct detection of each individual 
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substance used, could be still detected by the combined effect they exert. In this chapter, 
protein biomarker-based detection strategies are discussed against generic challenges in 
biomarker discovery and method development. 
Part I of the thesis concerns biomarker analysis in serum and plasma samples from 
cattle, which are analysed using laboratory-based equipment.A triplex ﬂow cytometric 
immunoassay (FCIA), which combines the detection of three rbST-dependent biomarkers, 
viz. IGF-1, IGFBP2 and anti-rbST antibodies is demonstrated in Chapter 3. Serum samples 
from treated and untreated dairy cows from a single animal study were analysed using 
this triplex FCIA. Characteristic treatment-dependent responses for all three individual 
biomarkers were shown. These results were combined using the statistical model k-nearest 
neighbours (kNN). This model discriminated rbST-treated from untreated cows with a true-
positive rate of 89.1 % and a true-negative rate of 97.7 %. 
This triplex FCIA was further extended with the biomarker osteocalcin and the resulting 
fourplex FCIA was used for biomarker profiling in serum samples from rbST-treated and 
untreated cows from two independent rbST treatment studies. In Chapter 4, different 
data analysis approaches were tested with the aim to detect the highest possible number 
of true-positive samples. The statistical model kNN was used on all 11 possible biomarker 
combinations and the combination of the biomarkers osteocalcin and endogenously 
produced antibodies against rbST proved to be very reliable and correctly predicted 95 % 
of the samples of treated cows starting from the second rbST injection until the end of the 
treatment period and even thereafter. With the same biomarker combination, only 12 % 
of the samples of untreated animals appeared false-positive. This reliability meets the 
requirements of Commission Decision 2002/657/EC for screening methods in veterinary 
control.  
It can be expected that rbST-dependent biomarkers also show a response upon other 
treatments. Therefore in Chapter 5, the fourplex FCIA for rbST abuse detection was applied 
to bovines treated with steroids, such as estradiol, dexamethasone and prednisolone. Each 
treatment resulted in a specific plasma biomarker profile for IGF-1, IGFBP2, osteocalcin 
and anti-rbST antibodies, which could be distinguished from the profile of untreated 
animals. Therefore, the fourplex biomarker FCIA is, apart from rbST, also capable of 
detecting treatment with other growth-promoting agents and clearly shows the potential 
of biomarker profiling as a screening method in veterinary control.
Part II of the thesis focusses on protein biomarker analysis in milk samples and the change 
from laboratory-based to on-site analysis.  
In Chapter 6, the detection of anti-rbST antibodies in raw milk samples was demonstrated, 
which discriminated rbST-treated from untreated cows with a 67 % true-positive and 94 % 
true-negative rate. The laboratory-based assay was also applied to simulated tank milk and 
pasteurized milk samples. Using milk as a sample matrix for detection has the advantages 
of non-invasive sampling, and for tank milk analysis at the farm only one milk sample is 
needed to screen the whole farm for rbST (ab)use. 
As a next step in Chapter 7, this assay was translated to an on-site pre-screening platform 
including a cellphone. Using this on-site platform, samples can be tested at the point 
where they were taken. Only samples that are suspect are transported to an laboratory 
for further analysis. To this end, a cellphone-based ﬂuorescence imaging platform for 
the detection of anti-rbST antibodies in milk extracts was developed, which is based on 
a microsphere ﬂuorescence immunoassay. After performing the assay, the ﬂuorescence 
is excited by UV LEDs embedded in a dedicated cellphone attachment and the emitted 
ﬂuorescence light is imaged by the cellphone camera. The ﬂuorescence micro-images were 
analysed using a custom-developed Android application running on the same cellphone 
and milk samples from rbST-treated and untreated cows were discriminated.  
Also in milk samples, the simultaneous detection of several biomarkers is advantageous 
as they can increase the confidence of a positive finding. Therefore in Chapter 8, a 
protein microarray-based platform for multiple rbST biomarker detection on a cellphone 
is presented, which detects anti-rbST antibodies and IGF-1 in milk samples. The 48 
microspots on the microarray were labelled with Quantum Dots depending on the 
biomarker levels in the sample. Quantum Dot ﬂuorescence was detected by the cellphone 
camera and the same opto-mechanical attachment as in Chapter 7 and images were 
analysed by custom software. RbST-treated clearly showed a treatment-dependent 
biomarker profile in milk that could be discriminated from the profile of untreated cows.
Future research should focus on the simultaneous detection of different targets of 
interest in milk samples, such as hormones, allergens, antibiotics, contaminants and 
other substances, all at the same time using the microarray platform on the cellphone. 
Moreover, sample handling can be facilitated by the use of pre-fabricated microﬂuidic 
devices including all required assay reagents. 
With the work presented in this thesis, screening for rbST abuse in serum and milk 
becomes possible: in the laboratory and on-site. The future implementation of these 
testing platforms for rbST abuse detection is a major leap forward concerning the 
enforcement of the rbST ban in the EU and concerning the value of protein biomarker-
based approaches in veterinary control.
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Recombinant bovien somatotropine (rbST) is een 22 kDa peptide hormoon, dat in koeien 
melkproductie verhogend werkt. In 1994 is het middel op de markt gebracht en sindsdien 
is het gebruik in veel landen goedgekeurd. In de EU is het gebruik van rbST echter sinds 
2000 verboden. Om het verbod in de EU te handhaven, maar ook om etikettering met 
‘rbST-vrij’ in de VS te kunnen controleren, zijn detectiemethoden die rbST-gebruik 
aantonen nodig. Bestaande detectiemethoden focussen op het identificeren van rbST in 
het serum van de koe. Zo is het mogelijk om met massaspectrometrie onderscheidt te 
maken tussen rbST en endogeen geproduceerd bST doordat deze 1 aminozuur verschillen 
aan de N-terminus. Andere methoden, zoals sandwich enzyme-linked immunosorbent 
assays (ELISAs), maken gebruik van antilichamen die een hogere affiniteit voor rbST dan 
voor bST hebben. Deze methoden worden echter niet breed toegepast doordat ze niet 
gevoelig genoeg zijn en het ontbreekt aan herhaalbaarheid en specificiteit voor rbST. 
Screeningsmethoden ontwikkeld voor controle op residuen van diergeneesmiddelen 
moeten voldoen aan de eisen van richtlijn 2002/657/EG van de Europeese Commissie. 
Dit houdt in dat behandeling bij minimaal 95 % van de behandelde dieren aangetoond 
moet kunnen worden. Tot nu toe is er echter nog geen methode beschikbaar die gebruikt 
kan worden voor controle op rbST-misbruik in de zuivelproductie, en voldoet aan richtlijn 
2002/657/EG.
Een alternatieve aanpak om misbruik van rbST aan te tonen is de detectie van rbST-
afhankelijke biomarkers. Een biomarker is gedefinieerd als een stof die wordt gebruikt als 
indicator van een bepaalde biologische toestand. Na rbST toediening zijn de concentraties 
van rbST-afhankelijke biomarkers verhoogd of verlaagd. Dit levert rbST-specifieke 
biomarkerprofielen op, die vervolgens gebruikt kunnen worden voor de identificatie van 
rbST-misbruik. De effecten van rbST en het endogeen geproduceerde bST op het lichaam 
van een koe zijn gelijk. De eiwitten, die door bST gereguleerd worden zoals insulin-like 
growth factor-1 (IGF-1), IGF binding protein 2 (IGFBP2) en osteocalcine zijn daarom 
als kandidaat-biomarker gekozen. Daarnaast vindt na toediening van rbST, antilichaam 
productie tegen rbST plaats, welke als biomarker gebruikt kunnen worden. Deze aanpak 
is grotendeels gelijk aan de detectiemethode die in de sport gebruikt wordt voor het 
aantonen van groeihormoon-misbruik. 
In hoofdstuk 2 wordt de toepassing van eiwit-biomarkers voor sport-doping controles en 
bij veterinaire inspecties toegelicht. Een voordeel van het gebruik van biomarkers is dat 
het biologische effect, veroorzaakt door de gebruikte stof, langer aantoonbaar is dan de 
gebruikte stof zelf. Een ander voordeel is dat verschillende stoffen voor zowel groei-, als 
productieverhoging hetzelfde fysiologische mechanisme gebruiken. Detectiemethoden 
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gebaseerd op biomarkers hebben hierdoor het potentieel gehele stofklassen aan te 
tonen. Daarnaast kunnen mengsels van laag gedoseerde illegale stoffen, die afzonderlijk 
niet opgespoord kunnen worden, op basis van hun gecombineerde effect op het 
biomarkerprofiel aangetoond worden. In dit hoofdstuk worden op biomarker gebaseerde 
detectiemethoden, de bijbehorende algemene uitdagingen van biomarker-identificatie en 
methode ontwikkeling beschreven.
Deel I van dit proefschrift beschrijft op laboratorium apparatuur gebaseerde biomarker 
analyses in koeienserum en plasma. 
In hoofdstuk 3 wordt een drievoudige ﬂowcytometrische immunoassay beschreven, die 
de detectie van drie rbST-afhankelijke biomarkers, namelijk IGF-1, IGFBP2 en anti-rbST 
antilichamen combineert. Serummonsters van behandelde en onbehandelde melkkoeien 
zijn met deze drievoudige ﬂowcytometrische immunoassay gemeten. De drie biomarkers 
hebben allen specifiek op de behandeling gereageerd. De resultaten zijn vervolgens met 
behulp van het statistische k-nearest neighbours (kNN) model gecombineerd. Dit model 
maakt het mogelijk een onderscheid te maken tussen rbST-behandelde en onbehandelde 
koeien met een juist-positief percentage van 89,1 % en een juist-negatief percentage van 
97,7 %.  
Deze drievoudige ﬂowcytometrische immunoassay is uitgebreid met de biomarker 
osteocalcine, resulterend in een viervoudige ﬂowcytometrische immunoassay. Deze 
immunoassay is gebruikt voor de analyse van serummonsters van behandelde en 
onbehandelde koeien. In hoofdstuk 4 worden, met de verkregen resultaten, verschillende 
data analyse methoden getest om te bepalen hoe het maximaal aantal juist-positieve 
resultaten behaald kan worden. Met 4 biomarkers is het mogelijk 11 verschillende 
combinaties te maken. Het statistische kNN model is vervolgens gebruikt om alle 11 
mogelijke combinaties van biomarkers te testen. Bij de biomarker combinatie, osteocalcine 
en anti-rbST antilichamen worden, vanaf de tweede injectie tot het na het einde van 
de behandelingsperiode, 95 % van de serummonsters van rbST-behandelde koeien juist 
geïdentificeerd. Daarnaast worden met deze combinatie van biomarkers maar 12 % van de 
monsters afkomstig van onbehandelde koeien foutief geïdentificeerd. Deze resultaten zijn 
in overeenstemming met de eisen voor screeningsmethoden voor veterinaire inspectie, 
zoals beschreven in richtlijn 2002/657/EG. 
Het vermoeden bestaat dat biomarkers geselecteerd om rbST-misbruik aan te tonen 
ook na behandelingen met andere stoffen een reactie laten zien. Daarom wordt in 
hoofdstuk 5 een onderzoek gepresenteerd waarbij de viervoudige ﬂowcytometrische 
immunoassay voor detectie van rbST-misbruik is gebruikt om serum van koeien behandeld 
met estradiol, dexamethason en prednisolon te testen. Iedere behandeling leverde 
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behandelings-specifieke biomarkerprofielen op die afwijkend waren van het profiel van 
onbehandelde koeien. De viervoudige biomarker immunoassay kan daarom naast rbST 
ook behandelingen met andere groeibevorderaars aantonen en demonstreert daarmee 
duidelijk het potentieel van biomarkerprofilering als een screeningsmethode in de 
veterinaire inspectie. 
Deel II van dit proefschrift beschrijft de transitie van lab-gebaseerde methoden voor eiwit-
biomarker analyses in melkmonsters naar veldtesten. 
In hoofdstuk 6 wordt de detectie van anti-rbST antilichamen in rauwe melkmonsters 
besproken, waarmee 67 % van rbST behandelde koeien en 94 % van onbehandelde koeien 
juist geïdentificeerd worden. Deze lab-gebaseerde methode is gebruikt om anti-rbST 
antilichamen in een op het lab nagebootste tankmelk en gepasteuriseerde melk te meten. 
Melk als monstermateriaal heeft als voordeel dat de monsters niet-invasief afgenomen 
hoeven worden. Daarnaast geeft het analyseren van tankmelk de mogelijkheid om met 
één enkel monster een heel melkveebedrijf op rbST-misbruik te controleren. 
Deze lab-gebaseerde assay is vervolgens omgezet naar een methode die ter plaatse 
uitgevoerd kan worden; een pre-screening gebaseerd op een mobiele telefoon 
(hoofdstuk 7). Hiervoor is een houder voor op de mobiele telefoon ontwikkeld, waarmee 
de aanwezigheid van anti-rbST antilichamen in melk door middel van ﬂuorescentie 
aangetoond kan worden. Hiervoor zijn UV LEDs op de mobiele telefoonhouder geplaatst. 
Deze zorgen voor excitatie van de ﬂuorescente Quantum Dots gekoppeld aan de anti-rbST 
antilichamen. Door met de camera van de mobiele telefoon een foto te maken is deze 
ﬂuorescentie als afbeelding vast te leggen. Met behulp van een speciaal ontwikkelde 
Android-app kunnen de ﬂuorescentie afbeeldingen aanwezig op de telefoon geanalyseerd 
worden. Melkmonsters van rbST-behandelde en onbehandelde koeien kunnen op deze 
manier onderscheiden worden, en kunnen monsters direct na afname gemeten worden. 
Uitsluitend verdachte monsters worden vervolgens naar een laboratorium getransporteerd 
voor aanvullende analyses.  
Ook voor melkmonsters geldt dat de betrouwbaarheid van een positieve vondst verhoogd 
wordt wanneer meerdere biomarkers tegelijkertijd gemeten worden. In + wordt een 
eiwit-microarray geïntroduceerd welke compatibel is met de mobiele telefoon. Deze 
microarray kan meerdere rbST-afhankelijke biomarkers in melkmonsters meten, namelijk 
anti-rbST antilichamen en IGF-1. Aan de 48 spots op de microarray worden, afhankelijk van 
de aanwezige concentratie van de biomarker in het monster, Quantum Dots gebonden. 
De ﬂuorescentie van de Quantum Dots wordt vervolgens op dezelfde manier, en met 
dezelfde mobiele telefoonhouder als gebruikt in hoofdstuk 7, gemeten. De verkregen 
afbeeldingen worden vervolgens met speciaal ontwikkelde software geanalyseerd. De 
Samenvatting
231
biomarkerprofielen in melkmonsters van rbST-behandelde koeien zijn specifiek, en 
duidelijk te onderscheiden van het profiel in melk van onbehandelde koeien. 
In toekomstige studies kan gelijktijdige detectie van verschillende stofklassen, zoals 
hormonen, allergenen, antibiotica en verontreinigingen, in melk onderzocht worden 
met de microarray methode op de mobiele telefoon. De monstervoorbewerking kan 
vereenvoudigd worden door geprefabriceerde microﬂuidische modules te gebruiken 
die alle nodige assay-reagentia bevatten. Met de resultaten van dit proefschrift wordt 
aangetoond dat het mogelijk is serum en melkmonsters in het laboratorium of in het 
veld op rbST-misbruik te testen. De toekomstige introductie van deze testmethoden voor 
het aantonen van rbST-misbruik is een grote stap vooruit om het verbod op rbST-gebruik 
binnen de EU te kunnen handhaven. Daarnaast verduidelijken de verkregen resultaten de 
waarde van biomarker-gebaseerde methoden voor de veterinaire inspectie.

Zusammenfassung
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Rekombinantes bovines Somatotropin (rbST) ist ein 22 kDa großes Proteinhormon, das zur 
Steigerung der Milchproduktion in Milchkühen eingesetzt werden kann. Seit 1994 wird es 
kommerziell vermarktet und seine Verwendung ist in vielen nicht-europäischen Ländern 
zugelassen. In der Europäischen Union (EU) hingegen ist es aus tiergesundheitlichen 
Gründen seit dem Jahr 2000 verboten. Um das Verbot in der EU durchzusetzen und 
die „rbST-frei“-Kennzeichnung von Lebensmitteln in den USA zu kontrollieren, sind 
Nachweismethoden erforderlich, die die rbST-Anwendung aufzeigen. Bisher bestehende 
Nachweismethoden konzentrieren sich auf die Identifizierung des rbST-Proteins im 
Blutserum von Kühen. Die rekombinante Form des Hormons hat eine andere N-terminale 
Aminosäure als das endogen produzierten bST. Deswegen kann rbST potenziell mittels 
massenspektrometrischen Methoden identifiziert werden. Andere Methoden, wie der 
sandwich enzyme-linked immunosorbent assay (ELISA), nutzen Antikörper mit einer 
größeren Affinität zu rbST als bST. Allerdings sind diese Methoden oftmals nicht sensitiv 
genug, die Ergenisse sind nicht reproduzierbar oder die Antikörper sind nicht selektiv 
gegen rbST gerichtet. Deshalb sind diese Methoden nicht weit verbreitet. Demzufolge 
gibt es bisher keine Methode, die offiziell zur Überwachung von möglichem rbST-
Missbrauch in der Milchwirtschaft eingeführt ist. Allgemein sollte beachtet werden, dass 
Screeningmethoden, die in der EU zur Überwachung von Tierarzneimittelrückständen 
entwickelt werden, die Richtlinie 2002/657/EG der Kommission der Europäischen 
Gemeinschaften erfüllen müssen und demnach mindestens 95 % der behandelten Tiere als 
solche identifizieren müssen.
Eine Alternative zum Nachweis von rbST-Missbrauch ist die Analyse von rbST-abhängigen 
Biomarkern. Per Definition ist ein Biomarker ein Indikator von physiologischen oder 
krankheitserregenden Prozessen oder pharmakologischen Reaktionen auf einen 
therapeutischen Eingriff. Demzufolge ist es zu erwarten, dass die Spiegel von rbST-
abhängigen Biomarkern nach rbST-Behandlung erhöht oder abgesenkt sind. Dadurch 
können rbST-spezifische Biomarkerprofile zur Identifizierung von rbST-Missbrauch 
herangezogen werden. RbST hat ähnliche Effekte auf den Körper des Rindes wie das 
endogen produzierte bST. Deswegen wurden Proteine, die im hormonellen Regelkreis 
von bST involviert sind, als Biomarker-Kandidaten ausgewählt. Dazu zählen Insulin-like 
growth factor-1 (IGF-1), IGF binding protein 2 (IGFBP2) und Osteocalcin. Außerdem 
induziert die rbST-Behandlung die Antikörperproduktion gegen rbST in der Kuh, welche 
auch als Biomarker nachgewiesen werden können. Diese Herangehensweise ist analog zur 
Nachweismethode von Wachstumshormonmissbrauch, die in der Dopingkontrolle im Sport 
angewendet wird. Hierbei werden auch ausschließlich Biomarkerprofile zum Nachweis von 
Missbrauch genutzt. 
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Kapitel 2 befasst sich mit Protein-Biomarkern und deren Potenzial, illegal 
verwendete Substanzen nachweisen zu können und somit bei Dopingkontrollen und 
Veterinärkontrollen zum Einsatz zu kommen. Die Vorteile der Verwendung von Biomarkern 
liegen in der verlängerten Nachweisbarkeit der zugeführten Substanz. Der biologische 
Effekt der angewendeten Substanz hält meist länger als die Substanz selbst nachgewiesen 
werden kann. Desweiteren besitzen biomarkerbasierte Nachweismethoden das Potenzial 
ganze Substanzklassen aufzuspüren, da ähnliche physiologische Mechanismen zur 
Wachstums- und Produktionssteigerung von unterschiedlichen Stoffen angesprochen 
werden. Weiterhin können niedrigdosierte Mixturen mehrerer verbotener Substanzen, 
die einzeln durch ihre niedrige Konzentration nicht nachweisbar sind, auf Basis ihres 
kombinierten Effekts auf das Biomarkerprofil nachgewiesen werden. In diesem Kapitel 
werden biomarkerbasierte Nachweisstrategien vor dem Hintergrund allgemeiner 
Herausforderungen der Biomarkeridentifizierung und Methodenentwicklung diskutiert.
Teil I dieser Doktorarbeit beschäftigt sich mit Biomarkeranalyse in Rinderserum und  
–plasma, die mit Hilfe von Laborgeräten untersucht wurden. 
In Kapitel 3 wird ein dreifacher durchﬂusszytometrischer Immunassay dargestellt, der den 
Nachweis von drei rbST-abhängigen Biomarkern, IGF-1, IGFBP2 und Anti-rbST-Antikörpern, 
kombiniert. Mit diesem dreifach durchﬂusszytometrischen Immunassay wurden 
Serumproben von behandelten und unbehandelten Milchkühen eines Tierexperiments 
analysiert. Alle drei Biomarker zeigten charakteristische behandlungsabhängige 
Reaktionen. Die Ergebnisse wurden mittels des statistischen Modells k-nearest neighbours 
kombiniert. Dieses Modell konnte zwischen rbST-behandelten und unbehandelten 
Kühen mit einer Echt-Positiv-Rate von 89,1 % und einer Echt-Negativ-Rate von 97,7 % 
unterscheiden.  
Dieser dreifache Immunassay wurde mit dem Biomarker Osteocalcin erweitert und der 
resultierende vierfache Immunassay zur Analyse von Serumproben rbST-behandelter 
und unbehandelter Kühe aus zwei unabhängigen Tierexperimenten genutzt. In Kapitel 
4 wurden verschiedene Datenanalyseverfahren getestet um die höchstmögliche Anzahl 
echt-positiver Proben zu erhalten. Das statistische k-nearest neighbours-Modell wurde auf 
alle 11 möglichen Biomarkerkombinationen angewendet. Die statistische Kombination der 
Biomarker Osteocalcin und Anti-rbST-Antikörper identifizierte zuverlässig 95 % der Proben 
von rbST-behandelten Kühen im Zeitraum beginnend von der zweiten rbST-Anwendung 
bis zum Ende des Behandlungszeitraumes sowie darüber hinaus. Mit derselben 
Biomarkerkombination traten nur 12 % der Proben von unbehandelten Kühen als Falsch-
Positive auf. Diese Ergebnisse sind im Einklang mit den von der oben genannten Richtlinie 
2002/657/EG geforderten Bedingungen für Screeningmethoden in der Veterinärkontrolle. 
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Es wird angenommen, dass rbST-abhängige Biomarker auch nach anderen Behandlungen 
Reaktionen zeigen. Deswegen wird in Kapitel 5 eine Studie vorgestellt, in der der vierfach 
durchﬂusszytometrische Immunassay für den rbST-Missbrauchsnachweis verwendet 
wurde. Ziel der Analyse war die Untersuchung von Kühen, die mit den Steroiden Östradiol, 
Dexamethason und Prednisolon behandelt wurden. Das Resultat jeder einzelnen 
Behandlung war ein behandlungsspezifisches Biomarkerprofil für die vier Biomarker IGF-1, 
IGFBP2, Osteocalcin und Anti-rbST-Antikörper, die jeweils vom Profil unbehandelter Tiere 
unterschieden werden konnten. Deswegen kann der vierfache Biomarker-Immunassay, 
neben rbST, auch Behandlungen mit anderen wachstumsfördernden Substanzen 
nachweisen und zeigt damit deutlich das Potenzial von Biomarkerprofiling als eine 
Screeningmethode in der Veterinärkontrolle.
Teil II dieser Doktorarbeit behandelt die Protein-Biomarkeranalyse in Milchproben und den 
Übergang von Labor- zu Vor-Ort-Analysen. 
In Kapitel 6 wird der Nachweis von Anti-rbST-Antikörpern in Rohmilchproben dargelegt, 
mit Hilfe derer 67 % der Proben von rbST-behandelten Kühen und 94 % der Proben von 
unbehandelten Kühen identifiziert werden konnten. Diese laborbasierte Methode wurde 
auch bei simulierten Kühltankmilchproben und pasteurisierten Milchproben angewendet. 
Der Vorteil ist hier, dass Milchproben im Gegensatz zu Serumproben nichtinvasiv 
genommen werden und bei der Untersuchung von Kühltankmilchproben ist eine einzige 
Probe ausreichend um einen gesamten Milchviehbetrieb auf möglichen rbST-Missbrauch 
zu kontrollieren. 
In einem nächsten Schritt wurde dieser Assay in eine Handy-basierte Vor-Ort-
Vorscreeningmethode umgewandelt, die in Kapitel 7 näher beschrieben ist. Mittels 
dieser Vor-Ort-Methode können die Proben direkt dort untersucht werden, wo sie 
genommen wurden. Ausschließlich die auffälligen Proben würden anschließend zu einem 
Labor für weitere Analysen transportiert werden. Zu diesem Zweck wurde ein Handy-
basiertes Fluoreszenz-bildgebendes System zum Nachweis von Anti-rbST-Antikörpern 
in Milchextrakten entwickelt, dem ein Fluoreszenzimmunassay auf der Oberﬂäche von 
Mikrokugeln zugrunde liegt. Nach der Assaydurchführung wurde die Fluoreszenz durch 
ultraviolette Leuchtdioden, die in einer zugehörigen Handyhalterung eingebettet waren, 
angeregt. Das abgegebene Fluoreszenzlicht wurde mittels der Handykamera abgebildet. 
Die Auswertung der Fluoreszenzbilder erfolgte mit einer speziell entwickelten Android-
App, die auf demselben Handy ausgeführt wurde.Damit konnten Milchproben von rbST-
behandelten und unbehandelten Kühen voneinander unterschieden werden.  
Auch bei der Untersuchung von Milchproben hat es Vorteile mehrere Biomarker 
gleichzeitig zu analysieren, da dies die Zuverlässigkeit eines positiven Ergebnisses erhöht. 
Zusammenfassung
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In Kapitel 8 wird ein Proteinmikroarray vorgestellt, mit dem mehrere rbST-abhängige 
Biomarker, Anti-rbST-Antikörper und IGF-1, in Milchproben mittels eines Handys 
nachgewiesen werden können. Die 48 Protein-Mikropunkte auf dem Mikroarray wurden 
in Abhängigkeit von den Biomarkerspiegeln in der Probe mit ﬂuoreszenten Quantum 
Dots markiert. Die Fluoreszenz der Quantum Dots konnte mittels der Handykamera und 
derselben opto-mechanischen Handyhalterung wie in Kapitel 7 detektiert werden. Die 
Bildasuwertung erfolgte mit speziell entwickelter Software. Behandlungs-spezifische 
Biomarkerprofile wurden in Milchproben von rbST-behandelten Kühen nachgewiesen, das 
deutlich von dem unbehandelter Kühe zu unterscheiden war.
Zukünftige Forschungstätigkeiten können sich auf den gleichzeitigen Nachweis 
verschiedener Stoffgruppen in Milch (zum Beispiel Hormone, Allergene, Antibiotika 
und Schadstoffe) ausrichten und dabei die Proteinmikroarraymethode auf dem 
Handy anwenden. Desweiteren kann die Probenbearbeitung durch den Gebrauch von 
vorgefertigten mikroﬂuidischen Elementen vereinfacht werden. Letzere beinhalten 
bereits alle nötigen Assayreagenzien. Die in dieser Doktorarbeit dargelegten Ergebnisse 
ermöglichen das Screening von Serum- und Milchproben auf möglichen rbST-Missbrauch 
sowohl im Labor und vor Ort. Die Einführung dieser Testmethoden wäre ein großer 
Meilenstein für die Durchsetzung des rbST-Verbots in der EU . Des Weiteren unterstreichen 
die Ergebnisse die Relevanz von biomarkerbasierten Methoden in der Veterinärkontrolle.
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